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Heart disease (HD) is the leading cause of mortality worldwide. Currently, diagnosis is based 
on clinical features, imaging, and circulating cardiac biomarkers. Cardiac imaging 
technologies, such as echocardiography and cardiac magnetic resonance imaging (cMRI), 
enable the non-invasive detection of changes in heart function. Although these modalities can 
detect changes in structure and anatomy, it is usually at later stages, where prevention may not 
be possible. In conjunction with imaging, circulating biomarkers of heart failure (HF), notably 
B-type natriuretic peptide (BNP) and cardiac troponin I and T, can be detected with increased 
levels in the blood. These biomarkers are associated with other comorbidities and may not be 
specific to cardiac tissue. Thus, there is a critical need to develop imaging agents to detect the 
biochemical and molecular changes that precede gross structural changes in HD. There is 
evidence that the growth hormone secretagogue receptor (GHSR) and its ligand ghrelin, could 
be a potential molecular imaging target where expression is increased in HF. The purpose of 
my work was to characterize GHSR as a biomarker for the underlying biological mechanisms 
involved in heart disease and heart.  
To characterize GHSR in end stage HF and valvular HD in humans, I used quantitative 
fluorescence microscopy with a custom far-red ghrelin analog to evaluate changes in the 
ghrelin-GHSR system and its downstream signalling. In this way, the ghrelin-GHSR system 
was elevated in HF and showed specific regional changes in HD. The ghrelin-GHSR system 
was correlated to heart function through left ventricular ejection fraction in HF while this 
system correlates regionally in only the left atrium in HD and no correlations are present in 
healthy tissue. Therefore, the ghrelin-GHSR system shows scalability from healthy to HD to 
HF.     
After characterization of ghrelin-GHSR in the human heart, I evaluated this system using in 
vivo imaging techniques to track the heart after a myocardial infarction in canines. A novel 
molecular imaging agent demonstrated a unique binding pattern in the heart before and after a 
myocardial infarction. This binding pattern did not simply reflect cardiac perfusion showing 




sensitivity. Therefore, I identified a novel in vivo imaging agent to bind specifically and 
selectively in the canine heart.  
In summary, my thesis describes the characterization of the changes in the myocardial ghrelin-
GHSR system using novel imaging agents in situ and in vivo. These findings have important 
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Summary for Lay Audience 
Heart disease is the leading cause of death worldwide. It is defined by any condition that 
negatively affects the structure or function of the heart. Heart disease may eventually develop 
into heart failure, which is defined by a weakened or damaged heart muscle that cannot pump 
blood throughout the body sufficiently. It is a difficult problem as there is no way to predict 
who will proceed to heart failure, or who will respond to therapies. Currently, heart disease is 
diagnosed using imaging methods, mainly ultrasound, that detect changes in the heart’s 
anatomy and function. However, these changes are associated with late stages of the disease 
when prevention may not be possible. In addition to imaging, other signs, or markers, of heart 
failure can be measured in the blood, although they are not necessarily specific to cardiac 
tissue. Thus, there is a need to detect heart disease at earlier stages with markers specific to 
cardiac tissue using non-invasive imaging methods. I have used one such marker, called the 
growth hormone secretagogue receptor (GHSR), as a tool to develop new methods of imaging 
the heart. GHSR is known to be beneficial to heart health, as it helps to strengthen the heart 
muscle and prevents heart tissue from dying. Changes in GHSR levels may indicate early 
stages of heart disease. The purpose of my work was to identify how GHSR changes in heart 
disease and heart failure, and to design new imaging methods that target GHSR in the heart. I 
used advanced microscope techniques to show that GHSR increases in advanced heart failure, 
and changes to a much smaller extent in mild heart disease. I then developed a non-invasive 
radioactive imaging method to measure changes in GHSR in dogs before and up to 1 year after 
a heart attack. I found that GHSR levels decreased in the area of the heart injured in the heart 
attack, and increased specifically in the area surrounding the injured area immediately after the 
heart attack, and these changes were sustained for a period of one year. Therefore, I developed 
a new non-invasive imaging method that can evaluate specific changes in GHSR in the heart. 
In summary, my thesis describes the changes in GHSR in the heart in human heart disease, and 
the development of a specific imaging tool to detect these changes in GHSR non-invasively. 
This is important as alterations in GHSR can indicate early stages of heart disease and therefore 
will lead to improvements in early detection, which may lead to improved treatments and 
management of heart disease, thus decreasing the likelihood of progression to heart failure.   
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Chapter 1  
 
1 Introduction 
According to the Heart and Stroke Foundation report (2019) there are currently 2.4 million 
Canadians living with heart disease (HD)1. HD includes impairment and damage to heart 
muscles or structures that refer to cardiomyopathies including heart wall thickening, severe 
inflammation, cardiac muscle rigidity, and conductivity derangements. If HD becomes 
severe, heart function progressively worsens, leading to the clinical syndrome of heart 
failure (HF). Of the 2.4 million people with HD, over 600,000 are living with HF2. HF 
occurs when the heart cannot pump enough blood to provide sufficient oxygen to the rest 
of the body, often caused by systolic heart failure where the heart muscle is too weak to 
pump blood sufficiently1. HF places a significant burden on both the patient and the global 
health care system’s limited resources as 40% of people admitted to the hospital are 
readmitted for adverse cardiac events. Significant advancements in diagnosing and treating 
patients with HF, specifically caused by myocardial infarction, have reduced the incidence 
of death but have also led to increased risk of future cardiac events1,2.  
 
1.1 Heart Failure Progression  
The heart is one of the most efficient organs which contains the contractile force to pump 
blood throughout the body. The wall of the heart is composed of three distinct layers; 
epicardium (outermost layer of the wall), endocardium (inner most layer), and the 
myocardium (intermediate and most prominent layer of the heart). The heart contains 4 
distinct chambers; the left and right atria, which are small, thin-walled chambers, and the 
left and right ventricles, the large thick-walled chambers where most of the work is 
performed. The right atrium (RA) receives blood from the venous system where 
contraction results in ejection of blood to the right ventricle (RV). The RV pumps blood to 
2 
 
the lungs for oxygenation and is pumped back into the left atrium (LA). The blood is 
ejected into the left ventricle (LV) which facilitates blood flow throughout the body. 
Impairment in this process causes cardiac dysfunction; when impairment becomes chronic, 
it can lead to HF. HF is a clinical syndrome characterized by impaired cardiac output and/or 
volume overload resulting in the inability to meet the metabolic demands of the body. HF 
is also commonly associated with structural abnormalities. The two most common forms 
of HF are: 1) systolic HF where reduced ejection fraction is caused by weakening of the 
ventricular wall and decreased contractile force; and 2) diastolic HF with preserved 
ejection fraction and stiffened ventricular walls that are unable to fully relax and fill the 
chamber with enough blood to pump to the rest of the body3. HF can originate from 
different causes: 1) directly from the heart including congenital heart defects in the valves 
or chambers of the heart; cardiomyopathies resulting from infection or pressure overload; 
vasculopathies typically from coronary artery disease and myocardial infarction; and 
arrythmias caused by electrical failure in the heart, and 2) whole body effects, such as 
hypertension, lung disease, diabetes complications and drug misuse. In advanced stages of 
HF, perfusion becomes severely limited, leading to fluid retention in the lungs and 
peripheral tissues potentially resulting in renal failure. The body compensates through 
cardio-protective events such as increasing heart rate, sympathetic activation, and up-
regulation of hormonal blood pressure through the renin-angiotensin-aldosterone system 
(RAAS). However, once HF is established in an individual, the functional and structural 
changes may respond to conventional treatments that manage patient symptoms until the 
heart deteriorates to the point where advanced therapies/ interventions are needed4. 
Predicting which patients proceed to HF after initial symptoms or trauma remains difficult.  
There are many risk factors that are associated with the onset of HF. These include diabetes, 
smoking, high cholesterol (specifically high low-density lipoprotein levels), high blood 
pressure, physical inactivity, obesity, age, and previous cardiac conditions5. Thus, reduced 
and preserved ejection fraction (HFrEF and HFpEF, respectively) present with these risk 
factors which contribute to the progression of HF3. HFrEF is usually characterized by an 
enlarged LV that results in global decreased cardiac output while HFpEF is usually 




HF has become a global health problem where prevalence is on the rise with enormous 
health care expenditures. In industrialized countries, roughly 0.4-2.2% of the population 
suffer from HF and rates increasing with age with 9.2 fold increases in prevalence in 
individuals over 65 years of age7. In overall HF incidence, the elderly population accounts 
for 80% of HF-related hospitalizations and 90% of HF-related deaths7. HF presence is 
increasing in the population largely due to the aging population coupled with the 
advancements in treatments and diagnostic technology that lead to improved outcomes for 
patients. Therefore advancements in how HF is diagnosed and treated are necessary8. In 
Sub-Sarharan Africa, cardiovascular disease is progressively taking over infectious disease 
as the leading cause of mortality with mortality rates range variably from 60 days at 9.5% 
up to 3 years with 67.1% mortality9. With worldwide HF prevalence increasing there is a 
larger economic burden placed on health care systems both directly and indirectly. 
Globally, the economic burden of HF is roughly $108 billion7 with the cost of Canada’s 
health care system being $2.8 billion annually2. According to one study that evaluated the 
readmission rates of Canadians after primary diagnosis of HF in 2015, 18.2% were 
readmitted within 30 days where older patients were readmitted more frequently than 
younger patients. Patients who were readmitted had high comorbidity burdens, more 
hospitalizations in 6-months prior to HF diagnosis, and a longer length of stay at the 
hospital10. With an increasing aging population, there is an expected increase of HF patients 
with comorbid conditions which could ultimately increase HF mortality. HF rates may also 
increase due to common trends including increases in physical inactivity, obesity, poor 
eating habits, and diabetes11. Therefore, there is a need for more compelling and innovative 
strategies to counter the effects of HF on the health care system. 
 
1.1.1 Heart Failure Pathophysiology 
Heart failure is a complex clinical syndrome that has a diverse path of progression. When 
the heart starts to fail, many compensatory mechanisms are initiated, which eventually 
contribute to the pathophysiology of HF12. Compensation occurs as the heart strives to 
maintain overall cardiac output (CO) as declining mean atrial and ventricular pressures 
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decrease cardiac perfusion. This increases the left ventricular (LV) end-diastolic pressure 
with stretching of the myocardial wall and restoration of the CO13 through mechanisms of 
sympathetic activation, neurohormonal regulation and cardiac remodeling, along with 
alterations in biochemical signalling pathways13. The main signalling pathways used to 
compensate for HF include calcium regulation for contractility, cellular death/ survival 
pathways, and myocardial energy metabolism.  
Cardiac output (CO) represents the amount of blood pumped out of the heart as a product 
of heart rate and stroke volume. CO is also affected by ventricular contraction, chamber 
wall integrity, and valvular competence12. Left ventricular (LV) dysfunction is commonly 
associated with left atrial (LA) pressure and pulmonary congestion. Right ventricular 
failure occurs with LV failure and similarly, alterations in right atrial pressures. When the 
CO along with total peripheral resistance (TPR) decreases, the mean atrial pressure (MAP) 
and, in turn, tissue perfusion, decrease. The body compensates for decreased CO by 
increasing the heart rate with subsequent increases in neurohormone secretion12 and 
increasing stroke volume via either LV dilation (muscle stretching and thinning) or LV 
hypertrophy (muscle thickening). Chronically, this process becomes detrimental ultimately 
resulting in impaired contractility, increases in cell death, a switch in metabolic substrates, 
initiation of inflammation, all of which lead to further cardiac damage.    
Another component of the compensatory mechanism is cardiomyocyte hypertrophy. Since 
cardiomyocytes lack the ability to divide, cardiomyocyte hypertrophy is a compensatory 
mechanism to trauma where cells increase in size and mass to normalize wall stress and 
allow normal function of the heart at rest14. This increased size and mass are accompanied 
by biochemical and molecular mechanism changes to help with cardiomyocyte 
compensation including contractility, cell survival/ death, and cardiomyocyte metabolism.  
The regulation of calcium (Ca2+) homeostasis within cardiomyocytes plays an important 
role in contractile function (excitation-contraction coupling) in the cardiomyocytes. 
Contractile function encompasses both contraction (systole) and relaxation (diastole). In 
contraction, the cell membrane is depolarized through action potentials from neighboring 
cells allowing for Ca2+ to enter the cardiomyocyte through the L-type calcium channel 
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(LTCC) on the cell membrane. This Ca2+ binds to the ryanodine 2 receptor (RyR2) on the 
sarcoplasmic reticulum (SR) membrane causing an efflux of Ca2+ from the SR to the 
cytosol. The excess of Ca2+ in the cell causes contractile proteins to activate. Upon 
relaxation, the cytosolic Ca2+ is pumped back into the SR using SR ATPase pump 
SERCA2a, and the remaining Ca2+ is removed from the cell using the sodium-calcium 
exchanger (NCX) on the cell membrane3,15. In HF, this process is disrupted through either 
accumulation of excess Ca2+ in the cytosol or decreased Ca2+ in the SR during the 
contraction and relaxation processes. Excess amounts of Ca2+ can be the result of defects 
in the LTCC causing too much Ca2+ to enter the cell or NCX where Ca2+ cannot fully exit 
the cell15. A dysfunction in the RyR2 can cause Ca2+ to leak from the SR and accumulate 
in the cytosol3 while dysfunction in SERCA2a pump can cause reduced uptake into the SR 
causing systolic dysfunction. SERCA2a dysfunction can also reduce the speed and quantity 
of Ca2+ transport out of the cytoplasm, thus inhibiting relaxation and causing diastolic 
dysfunction3,15,16. Therefore, Ca2+ flux in the cardiomyocytes, specifically in the SR, is 
highly regulated and can provide therapeutic targets for LV dysfunction.    
HF is commonly characterized by increased rates of cell death, commonly through 
apoptosis, necrosis, or autophagy, ultimately leading to excessive depletion of 
cardiomyocytes and HF. In the normal functioning heart, cycles of apoptosis and 
autophagy occur at low basal levels during the process of cardiomyocyte turnover17. When 
these processes become overactive and new cells cannot replace old cells at such rates, the 
heart starts to fail.  
Apoptosis is a highly regulated process of programmed cell death that occurs through 
extrinsic and intrinsic pathways, characterized by blebbing of the cell membrane, cell 
shrinkage and formation of apoptotic bodies. In the intrinsic pathway, hypoxia, 
ischemia/reperfusion, or oxidative stress induce the opening of the mitochondrial 
permeability transition pore (MPTP) on the mitochondrial membrane. This leads to a 
release of proteins from inside the mitochondria (cytochrome C, endonuclease G, and 
apoptosis-inducing factor) to form apoptosomes containing caspase-9, which activate 
caspase-3 to initiate DNA fragmentation and cell death18. This is the most prominent 
apoptotic process in cell death. The extrinsic pathway involves the “death receptors” Fas 
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and tumor necrosis factor (TNF) receptors, which are upregulated during myocardial 
ischemia and HF. When these receptors are bound and activated by their ligands, they form 
signalling complexes that recruit caspase-8, leading to activation of caspase-3 for cell 
death. It is still questionable today if apoptosis is the most prominent form of cell death in 
common types of HF (ischemic and dilated cardiomyopathy)19.  
Cell death in the form of necrosis occurs when there is trauma or damage to the 
cardiomyocytes usually by nutrient shortage, or exposure to harsh environments. In early 
stages of necrosis, there is organelle/ cytoplasmic swelling and disrupted cellular functions, 
eventually leading to rupture of the cell membrane that releases all cellular contents. This 
is not a form of programmed cell death as there is no formation of apoptotic cell bodies20. 
Necrosis is commonly associated with myocardial infarction, cardiac ischemia/ reperfusion 
and HF with a prolonged period of restricted blood flow resulting in a lack of nutrients for 
cellular function21.  
Autophagy is the process of intracellular organelle and protein enzymatic degradation that 
alters nutrient homeostasis in the cell. Cellular stress triggers degradation of excess 
organelles and proteins, which would otherwise lead to pressure overload-induced 
hypertrophy, oxidative stress, and myocardial ischemia which can all lead to HF20. In 
autophagy, deficiency in the lysosomal-activated membrane protein-2 (LAMP-2) causes 
increased autophagosomes in cardiomyocytes. In a model of Danon’s disease (a lysosomal 
glycogen storage disease) heart dysfunction and HF are common characteristics where 
defects in autophagy caused by LAMP-2 deficiency in the myocardium causes cardiac 
dysfunction22. The entire process of autophagy is not fully understood although there are 
known activators, including phosphatidylinositol-3 kinase and Beclin-1, and suppression 
of these activators causes disruption in the maintenance of metabolic requirements in the 
cell. Treatments for HF have been developed to target the AMPK/ Akt/ mTOR pathway 
where autophagic defects are restored and cardiac function is improved23–25.  
Cardiac energy metabolism in the healthy heart encompasses primarily fatty-acid (FA) 
oxidation used by mitochondria while glucose metabolism is responsible for minimal 
energy production. FAs oxidation accounts for 60-90% of adenosine triphosphate (ATP) 
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production in the healthy heart. FAs in the cytoplasm are converted to FA-acyl-coenzyme 
A (FA-acyl-CoA) by fatty acyl-CoA synthase which gets esterified before entering the 
mitochondria. Once in the mitochondria, it gets converted back to FA-acyl-CoA for beta-
oxidation. This process produces ATP but consumes oxygen in the process26. To produce 
ATP, glucose enters the cell through glucose transporters on cell membranes and proceeds 
through glycolysis, which uses less oxygen compared to FA oxidation. The products from 
the glycolysis pathway are transferred to the mitochondria to continue with energy 
production27. This ability to utilize energy substrates based on availability allows the heart 
some metabolic flexibility through complex regulatory mechanisms.  
HF is accompanied by derangements in all aspects of energy metabolism including 
substrate uptake, utilization, and oxidative phosphorylation which ultimately decreases the 
rate of ATP synthesis, resulting in LV dysfunction28. Substrate uptake and utilization 
switches from primarily FA to glucose utilization, likely because FA oxidation uses 10-
12% more oxygen when compared to glucose metabolism to generate the same amount of 
ATP. Therefore, FA usage in HF can waste oxygen and increase damage to the heart26. In 
contrast, in advanced HF and in ischemia/reperfusion, there is decreased FA and glucose 
metabolism which may be explained by decreased activity of mitochondrial enzymes for 
FA oxidation and mitochondrial dysfunction27. It is not fully known whether the altered 
substrate metabolism in HF is a cause or a consequence of LV dysfunction. It is suggested 
that the accumulation of FA in the cytosol can lead to toxic lipid species that may contribute 
to HF, meanwhile, the switch to glucose metabolism is an adaptive process to minimize 
damage in the failing heart28. More research needs to be conducted to evaluate the cause-
and-effect relationship with energy metabolism and HF.  
In summary, there are many complex and highly regulated signaling processes that function 
in cardiac homeostasis. In the progression of HF, these processes become dysregulated and 
can worsen the already present damage to the heart. Overall cardiac output is maintained 
through regulation of both sympathetic and neurohormonal activation along with LV 
remodeling and many biochemical signalling pathways (contractility/ calcium 
homeostasis, cell death, and energy metabolism). Prolonged derangements in these 




1.1.2 Management of Heart Failure  
Management of HF remains difficult as disease progression and response to therapy are 
highly variable between patients, and diagnosis is usually made in the later stages of the 
disease. HF with reduced ejection fraction (HFrEF) has been the largely studied and 
historically is the most the predominant form of HF. Thus, the management and treatment 
of HFrEF has improved substantially. HF with preserved ejection fraction (HFpEF) has 
only recently been studied extensively for its pathophysiology and treatment stradegies29.  
Three classes of drugs have been identified to aid in treatment: angiotensin converting 
enzyme (ACE) inhibitors/angiotensin II receptor blockers (ARB), aldosterone antagonists/ 
diuretics, and beta-adrenergic blockers3. ACE inhibitors/ARBs prevent the conversion of 
angiotensin I to angiotensin II and block the actions of angiotensin II to inhibit hypertrophy 
in vascular tissues and narrowing of coronary vessels leading to decreases in cardiac 
pressure and workload30. ACE inhibitors/ ARB drugs have been shown to improve 
mortality and reduce hospitalizations, and thus are the first-line drugs for most patients 
with HF.  
Aldosterone antagonists, or diuretics, function to inhibit the production of aldosterone, 
ultimately preventing aldosterone-induced sodium and water retention and potassium 
secretion. Subsequent reduction in fluid retention improves kidney function, reduces 
swelling and bloating, and lowers blood pressure to enhance cardiac function31.  
Beta-adrenergic blockers are usually used in combination with ACE inhibitors/ARB drugs. 
Beta-adrenergic blockers inhibit the binding of epinephrine to the adrenergic receptors in 
the heart to reduce heart rate and blood pressure, and relaxes blood vessels to improve 
blood flow. Beta-blockers have proven to reduce mortality and help regulate heart rate by 
reduction of sympathetic nervous system activity32. ACE inhibitors/ARB and beta blockers 
are often used together as a first line of HF therapy for all individuals, and aldosterone 
antagonists/diuretics are used in patients with symptoms of congestion32.  
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Some novel and emerging therapies for HFrEF include angiotensin receptor-neprilysin 
inhibitors (ARNI) and sodium‐glucose cotransporter‐2 (SGLT2) inhibitors. ARNI are a 
new class of medications that incorporate blocking of the angiotensin receptors and it 
inhibits the enzyme neprilysin which degrades protective vasoactive peptides (natriuretic 
peptides and bradykinin). Entresto is an example of this type of medication which has 
shown to decrease cardiovascular death and first hospitalization compared to conventional 
drugs (eg. Enalapril)33. SGLT2 inhibitors are approved for the management of type 2 
diabetes mellitus and recently have been explored for their use in prevention and treatment 
of diabetic cardiomyopathy. In diabetic patients with atherosclerosis, prevention with 
SGLT2 inhibitors have shown to reduce future cases of HF where these results were 
independent of glucose levels and renal function34. Treatment with SGLT2 inhibitors in 
later stages of HF remain to be fully elucidated. In contrast to these evaluated drug therapies 
for HFrEF, there is a lack of evidence-based medications for HFpEF and treatment is reliant 
on the management of comorbidities and symptoms.  
If drug therapy is not sufficient for maintaining optimal cardiac function, implantable 
cardiac devices or extensive surgery may be required. Patients with coronary artery disease 
(the most common form of HD) that have significant reduction in cardiac output and 
reduced left ventricular ejection fraction (LVEF) <35%, require cardiac revascularization 
surgery using a coronary artery bypass graft35. This procedure is used to redirect blood 
flow past blocked arteries and restore normal blood flow to cardiac tissue. Coronary artery 
bypass graft used in combination with drug therapies lowers mortality rate 2 years after 
surgery and decreases subsequent myocardial infarctions36. Another treatment used is the 
implantable left ventricular assist device (LVAD) that improves overall heart function by 
assisting the LV to contract properly and pump sufficient blood across the body. These 
devices help reduce LV mass and size, reduce levels of renin, angiotensin II, and 
aldosterone, and improve contractility and subsequently calcium regulation3. LVAD 
implementation has proven to decrease mortality rates and some individuals may even be 
weaned off the device as the heart strengthens; others may be on the device permanently37. 
In severe cases of end-stage HF, when there are no other options for cardiac improvement, 
cardiac transplantation may be needed. The limitation with this procedure is the short 
supply of donor hearts. Upon transplantation, there is a significant improvement in 
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survival, exercise capacity, and quality of life4. In contrast to patients with HFrEF, patients 
with HFpEF have no current approved device-based therapy for treatment29.  
Novel treatments are emerging that offer new approaches for patients with HF. One 
promising new technology is gene therapy. This therapy uses viral vectors to target a 
specific gene that is either over or under expressed. Gene phenotyping can be used to 
determine any abnormalities in the presence or regulation of genes in the heart29. Once 
phenotyping has been established and a target of interest has been identified, the use of 
targeted gene therapy could be used38. There are many viral delivery methods being 
evaluated including coronary artery infusion, direct myocardial injection, and injection into 
pericardial space. A variety of targets have been identified as possible opportunities for 
treatment including beta-adrenergic receptors, calcium regulation proteins, and G-protein 
receptor kinases3. Additionally, stem cell therapy has been examined for its role in cardiac 
regeneration. The past decades researchers have examined various cell types and  
mesenchymal stem cells have shown the most promise39. These cells have been tested in 
animal models and clinical trials to revitalize cardiac stem cells or revascularize the arteries 
and veins in the heart40. Although the idea of this technology is promising, there are major 
issues including inefficient cell delivery to the target site and low cell retention with 
minimal effectiveness of the stem cells that do implant in the target area41. There are 
ongoing developments to improve the regenerative capacity of the cells and enhancement 
of delivery techniques for the target area. Although the idea of gene therapy and cardiac 
stem-cell regeneration are exciting novel ideas, the technology remains to be optimized to 
allow for accurate and targeted treatment of HF. 
 
1.2 Diagnosis of Heart Disease and Heart Failure  
1.2.1 Clinical Diagnosis of HF 
Diagnosis of HF is a very complex process including clinical examination, imaging 
technology, and the measurement of an array of cardiac biomarkers. Clinical diagnosis of 
heart failure is commonly initiated with the physical examination which is limited to non-
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specific symptoms (age, sex, obesity, smoking and drinking habits, along with other 
comorbidities), laboratory tests with varying sensitivities, and characteristics not 
necessarily associated directly with the heart.  
The two most common diagnostic methods to evaluate the stage of HF are the New York 
Heart Association (NYHA)42 classification and the American College of Cardiology 
Foundation and American Heart Association (ACC/AHA)43.  
The NYHA classification is based on clinical severity and prognosis with an emphasis on 
exercise capacity and clinical symptoms. The classification ranges from functional class I 
(not severe) to IV (most severe). Functional class I includes no limitations to physical 
activity and no overt symptoms of HF. Functional class II has some limitations of physical 
activity where ordinary physical activity leads to HF symptoms. Functional class III occurs 
when less than ordinary activity causes symptoms of HF. Functional class IV refers to 
patients who are unable to perform physical activity without severe HF symptoms and 
possible HF symptoms while at rest43. One study evaluated the accuracy of this 
classification method where it correlated with mid- to long-term mortality rates in patients 
and thus, is a good method for HF classification42.  
The ACC/AHA classification method emphasizes the development and progression of HF 
and can provide complementary information on diagnosis when combined with NYHA 
classification. The ACC/AHA classification system recognizes both risk factors and 
cardiac structure abnormalities associated with HF. Stages range from A, at risk for HF but 
no structural abnormalities or symptoms of HF; B, structural defects in the heart but no HF 
symptoms; C, structural HF and prior or current symptoms; D, refractory HF that requires 
special interventions. Once a patient progresses to the next stage it is not possible to regress 
and increasing stages is associated with reduced 5-year survival43. In 2017, an update to 
the ACC/AHA guidelines was published to aid in clinical diagnosis along with treatment, 
medications, and therapies based on a combination of stage and clinical symptoms 
present44. These new guidelines are aimed at diagnosing structural changes at earlier stages 
(B or C) and targeting treatment to prevent progression of HF and ultimately reduce the 
morbidity and mortality linked to HF. Although these guidelines have been developed to 
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aid in early diagnosis, it remains based on patients to identify HF symptoms and a physician 
to detect based on patient history. In addition, these diagnoses rely on structural and 
physical changes of the heart which usually occur in the later stages of HF, while early 
stages of HF progression remain difficult to detect.      
 
1.2.2 Echocardiography in Clinical HD 
Echocardiography (Echo) is a commonly used diagnostic tool for cardiac imaging. Echo 
uses a transducer to send sound waves and generate moving images showing the structure 
and movement of the heart43. It is widely used for its availability to quickly measure the 
left ventricular size and dysfunction as well as to identify valvular abnormalities non-
invasively. Echo is a low-cost technique that is widely available for clinicians to evaluate 
gross changes in LVEF, cardiac hypertrophy, and valve dysfunction of any patient that 
presents in the clinic with HD signs and symptoms. There are many forms of 
echocardiography used in clinic, each with their own advantages and optimal target 
quantifications (Table 1.1). 
Transthoracic Echo is the most common form of Echo used in the clinic for its wide 
availability and basic cardiac evaluation. Transthoracic Echo uses an ultrasound system 
transducer to evaluate cardiac structure and function. It can evaluate gross structural 
abnormalities, valvular disease and any abnormal blood flow through the heart46. Doppler 
Echo is a specialized technique (still using a transducer) that can acquire myocardial 
velocities and can obtain quantitative information about myocardial motion during the 
cardiac cycle. Colour M-mode Doppler can also provide spatiotemporal distribution of the 
velocities across a vertical line for more accurate assessment47. Doppler Echo has shown 
promise in the evaluation of blood flow and cardiac structure in valvular stenosis, valvular 
regurgitation, blood flow, intracardiac pressures, and intracardiac shunts48. This technique 
is limited due to underestimating the severity of aortic stenosis if the sound beam is not 
positioned precisely and may not provide accurate diagnosis post-surgery if velocities are 
abnormally high.  
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Stress Echo is 2D Echo with stress-induced changes in blood flow to determine severity of 
coronary artery disease such as in  ischemic heart disease and any abnormalities in cardiac 
blood flow49. Stress Echo uses a stressing agent, either through physical exertion/ exercise 
or a chemical agent (such as dobutamine) to show the function of the heart under these 
conditions. Echo measurements will be gathered prior to the stress agent and then once 
again after full stress to the heart is induced. This will allow for clinicians to evaluate the 
change in blood flow and potential coronary artery disease or ischemic regions in the 
heart50. There are some limitations with this technique that have not yet been fully 
evaluated including tissue characterization of the myocardial structure, myocardial 
perfusion with contrast, and regional wall motion quantification with new technologies. 
New advancements have focused on targeting these limitations to match the data acquired 
with PET perfusion imaging50.  
One emerging technique that is changing the use of Echo is 3D Echo which measures the 
geometry and size/ volume of the LV along with valve assessment and functional 
parameters of the heart. Researchers have evaluated various reconstruction techniques 
where sequential 2D sliced through the heart have been reconstructed into 3D images to 
assess better measurements of the heart. Real-time 3D Echo has also been developed to 
incorporate these reconstructions in real time to more efficiently generate quantitative 
data50. 3D Echo is proposed to generate LV wall thickness and volume measurements 
comparable to that of cardiac magnetic resonance imaging (cMRI)51. New advancements 
and improvements with clinical studies will help to broaden the applicability of this 
modality in a variety of cardiovascular diseases. The main limitations with this technique 
are the user dependence, the extra expense of the probe and software, and the lack of 











Most common form of echo; measures basic cardiac 
structure and function 
DOPPLER 
ECHOCARDIOGRAPHY 
Used to measure blood flow in the chambers and valves; 
Can detect abnormal blood flow indicating problems with 
valves or walls 
STRESS 
ECHOCARDIOGRAPHY 
 Measures stress induced changes to blood flow and 
determine severity of CAD; stress agent can be physical 
exertion or chemically induced 
3D ECHOCARDIOGRAPHY Helpful for identifying problems with heart valves, 
replacement valves, and the LV; new additional ways to 
use 3-D echo are being developed 
 
Therefore, echocardiography provides a wide variety of initial measurements for LV size 
and overall blood flow. After a patient is initially screened with Echo, they may go on to 
be scanned with cardiac magnetic resonance imaging (cMRI) or cardiac computed 




1.2.3 Cardiac CT and MRI 
Computed tomography (CT) is a technique that allows high-resolution detection of 
structure and anatomy, thereby enhancing the diagnosis of gross structural changes. CT 
involves the use of narrow x-ray beams aimed at the target which are quickly rotated to 
create a combination of cross-sectional planes to generate a 3D image of the specific target 
of interest52. CT provides excellent spatial resolution (0.5-0.625 mm) to evaluate 3D 
morphological changes in the heart including dimensions and overall heart function. 
Temporal resolution of CT is limited and poses a challenge with the beating heart53. To 
acquire optimal images using CT, images should be captured between heart beats when 
movement is lowest. A contrast agent, iodine, can be used to help visualize the difference 
between adipose and soft muscle tissue as non-contrast CT cannot distinguish between 
these tissue types. Contrast CT can evaluate the extent of cardiac lesions, myocardial 
perfusion, and tissue viability54. One important consideration with CT imaging is its use 
with implant devices. CT can be used to image the heart even with implanted devices 
present although devices near the heart may show an irregular artifact. Although CT 
imaging uses small doses of radiation, there is no evidence that the radiation disrupts the 
implanted devices55.   
CT perfusion (CTP) has been shown to improve the specificity and overall accuracy of 
cardiac CT to detect cardiac blood flow. In CTP, the iodine contrast agent is injected 
followed by rest and stress scans to evaluate the artery plaque/lesion presence and blood 
flow56. Scans are performed immediately after contrast injection as either static single 
image scans, or a dynamic set of sequential scans to better visualize perfusion over time57. 
Rest scans are performed with low resting heart rates, <65 beats per minute, where lesions 
can be detected in the heart. Stress scans are initiated with vasodilator stress agents 
including adenosine, dipyridamole, or regadenoson followed immediately by a CT scan to 
enhance defects in perfusion58. Rest and stress scans are compared for changes in perfusion 
which can provide specific information on cardiac defects: 1) hypoperfusion with the same 
intensity in both stress and rest images indicate regional necrosis; 2) hypoperfusion in stress 
but normal in rest indicate ischemia; 3) hypoperfusion in stress which decreases in rest 
show peri-necrosis ischemia; 4) normal perfusion in both rest and stress58. Myocardial 
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blood flow using CTP has been evaluated in porcine hearts before and after a myocardial 
infarction where decreased perfusion was present specifically in the infarcted region and 
not in the remote myocardium59. CTP imaging is advantageous for cases of suspected 
coronary artery disease where both blood flow and cardiac anatomy can be examined in 
one set of images60. Further research is needed to evaluate the potential clinical advantages 
in patient care, treatment costs, and patient outcomes when compared to the current gold 
standard cardiac PET perfusion imaging.   
Cardiac magnetic resonance imaging (cMRI) is an emerging technique that allows for 
highly reproducible assessment of cardiac dimensions, function, flow, and perfusion. cMRI 
can recover early structural changes in the heart that comprise many different 
cardiomyopathies61. MRI uses strong magnetic fields to orient protons in the body, then a 
radiofrequency is applied to detect the location of these protons and can differentiate based 
on the type of tissue present. MRI provides spatial resolution of 1-2 mm, with temporal 
resolution of 20-50 milliseconds, and excellent soft-tissue contrast53. Due to enhanced 
resolution of cMRI, sequences have been developed to determine cardiac function, edema, 
iron deposition, and perfusion62. In addition, a gadolinium contrast agent can be used to 
visualize the morphological changes in the heart and determine cardiomyocyte viability 
with fibrosis deposition, typically after cardiac ischemia. However, this contrast agent is 
only able to discern concentrated fibrotic areas and not diffuse regions of fibrosis which is 
common in some ischemic cardiomyopathies63. Therefore, T1 mapping (anatomical 
images) can be gathered before and after contrast images to accurately determine total 
fibrotic deposition in the heart. One of the main limitations with cMRI is that patients with 
magnetic devices or implants near the heart cannot be imaged. Magnetic devices are 
attracted to the high-powered magnets resulting in damage to the patient and the machine. 
Additionally, implants near the heart can cause image artifacts and skew images. cMRI 
provides comprehensive evaluation of HD and is the current gold standard in evaluating 
ventricular volumes, wall motion and dimensions, and systolic and diastolic function. With 
the many techniques that encompass cMRI, it detects physical cardiac changes in many 
forms of HD including: myocardial infarction, dilated and hypertrophic cardiomyopathy, 
myocarditis, sarcoidosis, and pulmonary hypertension64. Overall, cMRI is a robust tool to 
comprehensively evaluate HD through cardiac anatomy, function, and wall motion.  
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Hyperpolarized MRI is an emerging technique using 13C to track changes in cardiac 
metabolism. Hyperpolarized MRI uses a combination of low temperatures and high 
magnetic fields to allow for high polarization (nearly all electrons are aligned in the same 
direction). 13C uses this technique to enhance MRI signals65. Natural 13C abundance is 
extremely low in the body (~1.1%) and therefore the use of 13C-tracers have been 
developed to temporarily enhance the abundance and cause an increase in signal where 
these tracers are located in the tissue65. The most commonly used tracer is 13C-pyruvate 
where it can measure cellular metabolism through many metabolic processes from energy 
production to the formation of lactate, alanine and CO2
66. A shift in myocardial energy 
metabolism from primarily fatty acid metabolism to more glucose metabolism is expected 
to contribute to the development of HF67. 13C-pyruvate can be measured through the 
activity of the pyruvate dehydrogenase complex where increases in its activity show a 
preference for glucose metabolism. 13C-pyruvate flux through this complex is reduced in 
the hyperthyroid heart, diabetic heart, and dilated cardiomyopathy while the flux increased 
in hypertrophic cardiomyopathy65. This technology in the heart has only recently been 
explored and the clinical translatability in heart disease requires further evaluation.  
When deciding which imaging tool to use between cMRI or CT, it is important to evaluate 
each case individually to determine the best one for the patient. cMRI is the gold-standard 
cardiac imaging technique, however not all patients can safely be imaged (i.e. any patient 
with metal implants) along with longer scan times as multiple sequences may be used. In 
evaluation of HD, it is imperative to use accurate and reproducible imaging methods with 
high temporal, spatial, and contrast resolution68. cMRI fulfills all these components in the 
evaluation of LV function. Recently, new techniques in CT have been developed that 
approach the function of cMRI by enhancing the temporal resolution. One study evaluated 
a new dual-source CT technique where temporal resolution (83 milliseconds) results in 
minimal differences when compared  to cMRI69. Another study used dual-energy 
equilibrium contrast-enhanced CT which uses two different x-ray potentials 
simultaneously to detect both blood and myocardium together in addition to iodine contrast 
agents measuring fibrosis70. The emergence of new cardiac CT imaging techniques can 
allow for more options when evaluating patients who need diagnostic imaging. Even with 
many CT techniques being developed to target each aspect of myocardial imaging, cMRI 
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still remains the gold standard for HD diagnosis. It is important to note that these modalities 
are used primarily for diagnosis of gross structural changes once HD is already established, 
and not for the prediction of the onset of HD, prior to overt symptoms. It is imperative to 
discern changes to the myocardium to be able to facilitate targeted interventions to prevent 
the progression to HF. One clinical molecular imaging modality that can be used to 
elucidate the biochemical changes early in HD pathogenesis is positron emission 
tomography (PET).  
 
1.2.4 Cardiac PET Imaging 
Positron Emission Tomography (PET) is a powerful imaging technique that detects 
molecular and biochemical changes in the body. PET encompasses quantitative non-
invasive in vivo imaging using positron-emitting radioisotopes (such as 11C, 13N, 15O, 18F, 
68Ga, 82Rb) incorporated into biological compounds/ molecules targeted to a specific 
biological process. Positrons are positively-charged electrons that travel short distances 
and interact with an electron, causing an annihilation producing two 511 keV gamma rays 
moving 180° from each other. PET ring detector arrays can detect these gamma rays and 
determine the original location of the positron which results in sequential high-quality 
corrected images71. PET systems have good temporal resolution and spatial resolution of 
4-7 mm which is decreased slightly by movement during image acquisition. Using tracer 
kinetic modelling with motion and respiratory correction results in high-precision 
quantitative imaging of targeted biological processes72. The main limitation of this 
technology lies in the limited availability of both PET scanners and a cyclotron facility 
used to generate the radionuclide compounds for tracers. PET compounds can be useful 
with drug development, disease diagnosis and monitoring of treatment response based on 
a specific target. Sensitivity with PET imaging is exceptional as low concentrations of 
radionucleotide tracers (10-11 – 10-12 M) are needed to generate precise images73. Many 
tracers have been developed to target overall perfusion and known biological pathways of 
metabolic processes including fatty acid transport, oxygen consumption, and glucose.   
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Single photon emission tomography (SPECT) imaging uses radiopharmaceuticals injected 
into the body where gamma-rays are emitted and detected by collimated radiation 
detectors. The most common radiopharmaceutical used with SPECT is 99technetium (99Tc) 
as it has a relatively short half-life of 6 hours. 99Tc-sestamibi (99Tc-MIBI) is a common 
perfusion tracer that enters cardiomyocytes through passive diffusion and accumulates in 
the mitochondria. Increased uptake of 99Tc-MIBI demonstrate areas of adequate blood flow 
while decreased uptake show a loss in perfusion74. Evaluation of 99Tc-MIBI in patients 
with confirmed coronary artery disease showed a diagnostic sensitivity of 90% to evaluate 
myocardial blood flow and tissue viability75. 99Tc-MIBI has shown a demonstrated 
prognostic value of future acute MI or cardiac death with abnormalities in perfusion 
imaging76,77. Therefore, 99Tc-MIBI may be a useful diagnostic and predictive tool for 
patients with suspected blood flow abnormalities.  
PET imaging shows promise over other radionucleotide imaging techniques, such as single 
photon emission computer tomography (SPECT), with its superior sensitivity compared to 
echocardiography/ cMRI, standardized correction of attenuation, and quantitative 
measurements of tracer uptake78. Therefore, PET has begun to be recognized as a useful 
tool to evaluate biochemical changes throughout the body, including in the heart. In clinical 
imaging of HD, PET is used primarily to evaluate cardiac perfusion/ tissue viability 
(ischemia), inflammation, and neuronal activity71. Using PET to identify changes in these 
processes remains an important diagnostic and prognostic tool for evaluation of many 
forms of HD and HF in patients. Myocardial perfusion tracers (13N-ammonia, 15O-water, 
82Rubidium) detect reduced blood flow within the heart and vasculature to determine 
subclinical coronary stenosis and the severity of both coronary artery disease and ischemia. 
Inflammation is common in many forms of HD where PET tracers (18F-
fluorodeoxyglucose) can measure significant increases of regional inflammation associated 
with diseases such as endocarditis, sarcoidosis, atherosclerosis, and acute tissue injuries 
including myocardial ischemia. Neuronal imaging (11C-meta-hydroxyephedrine) assesses 
the severity of HF and post-transplant reinnervation along with arrhythmias in the heart79. 
Therefore, PET is an exciting in vivo molecular imaging technique that allows for diagnosis 
of biochemical processes altered in the severity and type of HD and HF. 
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1.2.5 Cardiac Perfusion PET Tracers 
Myocardial perfusion is an important assessment of coronary artery disease and cardiac 
ischemia where there is a marked regional reduction in blood flow. PET imaging has 
emerged as the gold standard for non-invasive myocardial perfusion measurement. The 
commonly used PET tracers are 13N-NH3, 
15OH2, and 
82Rb, which all have their own 
strengths and weaknesses (outlined in table 1.2)80. All tracers have relatively short half-
lives, ranging from 75 seconds to 10 minutes. Although all of these tracers detect perfusion, 
their mechanisms of action differ. 13N-NH3 passively enters the cardiomyocytes and is 
incorporated into glutamine through the glutamate synthesis pathway, thereby getting 
metabolically trapped in the cell. When cardiomyocytes are damaged and the cellular 
membranes are weakened, 13N-NH3 cannot enter the cells to access myocardial blood flow. 
Similarly, 82Rb is a potassium analog and enters cardiomyocytes through the 
sodium/potassium ATP transporter in the cell membrane where it accumulates and gets 
retained. In cells that are dead or damaged, 82Rb is not taken up and does not accumulate 
therefore no signal is generated. In contrast, 15OH2 is a metabolically inert tracer that freely 
diffuses across the cell membrane and creates an equilibrium between blood and tissue 
without significant accumulation in the myocardium. This tends to result in lower count 
density and overall lower quality images for quantification with this tracer80,81.  
 
Table 1.2 Common Cardiac Perfusion Tracer for PET Imaging80. 
 13N-NH3 15OH2 82RB 
GENERATION Cyclotron Cyclotron Generator 
HALF-LIFE ~10 min ~125 sec ~75 sec 




All these tracers have been evaluated in the forms of HD that are characterized by 
decreased cardiac perfusion in the myocardium and vasculature. In particular, decreased 
perfusion reported by 13N-NH3 PET is a strong predictor of adverse cardiac outcomes in 
HD82. Lee et al. was able to show that quantitative 13N-NH3 imaging of myocardial blood 
flow improved detection of coronary artery stenosis and suggested that this in vivo imaging 
method be used to accurately determine disease severity prior to invasive coronary 
angiography surgery83. 13N-NH3 has also been used to detect tissue viability in cardiac 
ischemia with rest/ stress induced imaging to discern ischemic myocardium from viable 
tissue84. 82Rb has similarly been used in studies evaluating cardiac perfusion where reduced 
blood flow was an indicator of short-term cardiac events85,86. Zampella et al. was able to 
show that 82Rb can detect the extent of calcification and blockage in coronary artery disease 
patients86. 15OH2 has also assessed the extent of coronary artery disease
87,88 and detect 
blood flow in ischemic patients89. Taken together, these tracers have been shown to non-
invasively correctly identify and diagnose reduced regional blood flow and disease severity 
in various forms of HD. 
 
1.2.6 Inflammation in the Heart with 18F-FDG PET 
Inflammation is commonly associated with HD and HF, and excessive proinflammatory 
processes may be a predictor of future adverse cardiac events. Inflammation is a common 
process in the body used to remove dead and damaged cells followed by specific repair 
mechanisms. Initially after cardiac injury, or reduced cardiac perfusion, an immune 
response is activated where inflammatory cells including neutrophils, monocytes, and 
macrophages target the area of interest. This process removes the dead and damaged cells 
from the area. The immune reaction induces pro-inflammatory cytokine activation 
including tumor necrosis factor-alpha (TNF-α), interlukin-6 (IL-6), and interlukin-1 (IL-
1)90. After the pro-inflammatory phase subsides, the anti-inflammatory phase initiates 
fibroblasts and matrix metalloproteins to deposit fibrotic (scar) tissue in place of the dead/ 
damaged cells. However, fibrosis deposition may also occur in the presence of chronically 
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active pro-inflammatory markers where both the pro- and anti-inflammatory phases are 
active simultaneously91. When these pro-inflammatory markers are significantly elevated 
for prolonged periods of time, they can be a sign of chronic inflammation and can 
contribute to the progression of HF92. A commonly used tracer for inflammation and tissue 
viability is 18F-fluorodeoxyglucose (18F-FDG). 18F-FDG is a glucose analog that is taken 
up by viable cardiomyocytes through glucose transporters and promptly gets trapped in the 
cell as 18F-glucose-6-phosphate via hexokinase. Proinflammatory macrophages have a 
significant overexpression of glucose transporters which results in increased 18F-FDG 
uptake93. One important thing to note when using 18F-FDG in studies of cardiac 
inflammation is that normal myocardial glucose uptake should be suppressed to minimize 
normal tissue uptake. This is usually done with an Intralipid™ infusion in animal studies. 
Human subjects are required to fast or consume a high fat meal prior to imaging to reduce 
the extent of myocardial glucose uptake and increase the lipid metabolism in the normal 
myocardium94. One example of imaging cardiac inflammation is the case of cardiac 
sarcoidosis, an inflammatory disease where granulomas (white blood cells) form in the 
heart muscle and disrupt normal function. 18F-FDG has been shown to accurately detect it 
in its early stages where perfusion defects may not yet be present95. In patients with 
suspected unstable angina, 18F-FDG was able to detect angina more sensitively than 
myocardial perfusion imaging (85.7% vs 52.4% respectively). Therefore, increases in 18F-
FDG in angina may indicate angina as an inflammatory condition where 18F-FDG clearly 
demonstrates the accuracy and sensitivity of non-invasive PET imaging96. 18F-FDG PET 
can also assess the severity of  inflammation associated with coronary artery disease (CAD) 
and atherosclerosis97,98. Upon plaque build-up from low-density lipoprotein in the arteries, 
monocytes, leukocytes, and T-cells are recruited to the plaque area, where monocytes 
mature into macrophages, the target for 18F-FDG99. Therefore, 18F-FDG is a specific 
clinically relevant tracer to examine the extent of inflammation associated with HD.  
18F-FDG is the current clinical gold standard for determination of viable tissue in patients 
after myocardial infarction and in cardiac dysfunction with accurate assessment of scar 
presence75,100. In addition, 18F-FDG can be used to measure the efficacy of treatments by 
comparing scans before and after treatment. One study used 18F-FDG to evaluate alcohol 
septal ablation treatment in patients with hypertropic obstructive cardiomyopathy where 
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clear reduction of tracer uptake, and associated inflammation, was seen after treatment101. 
Ultimately 18F-FDG is an important non-invasive imaging tool to detect inflammatory heart 
disease and assess disease severity. 
 
1.2.7 Neuronal Cardiac PET Imaging 
Cardiac neuronal imaging is an important tool to evaluate arrythmias associated with HF. 
In congestive heart failure there are abnormalities in the autonomic nervous system with 
altered sympathetic traffic (blood pressure) to peripheral vascular areas; however, how this 
process functions remains largely unknown. 11C-meta-hydroxyephedrine (11C-HED) is a 
norepinephrine (NE) analogue that targets the NE transporter on nerve endings in the 
sympathetic nervous system, therefore determining NE transporter activity and density102. 
In HF and in arrythmias there are NE transporter abnormalities that can be revealed by 11C-
HED PET. Patients with congestive HF had reduced retention of 11C-HED globally in the 
heart which corresponded to blunted vascular sympathetic responses103. Diastolic 
dysfunction was shown to be associated with impaired sympathetic innervation in the heart 
using 11C-HED in patients with HF and preserved ejection fraction104. 11C-HED imaging 
may also be used as an alternative for myocardial blood flow imaging in ischemic 
cardiomyopathy105. Additionally, cardiac transplant patients can be imaged with 11C-HED 
to determine the extent of sympathetic reinnervation of the newly-implanted heart106. One 
study evaluated sympathetic activity in patients at different time points after transplant 
surgery, and healthy controls. In patients with recent surgery there was a 70% reduction in 
11C-HED uptake, which improved to a 59% reduction after 2 years. The authors found that 
after cardiac transplantation, the sympathetic activity in the heart improved from 30% to 
41% activity107. Regional and localized 11C-HED retention in the heart can show disease 
severity and dysfunction in arrhythmias108. Overall, 11C-HED can evaluate impairments in 




1.2.8 Emerging Cardiac PET Tracers 
In addition to these known tracers for cardiac PET imaging, many new tracers are being 
developed to specifically target aspects of cardiac pathology in HD. One new perfusion 
tracer that is not yet clinically available is 18F-flurpiridaz, a pyridazinone derivative, which 
gets metabolically trapped in the cardiomyocytes through the mitochondrial membrane 
complex-1 and reports cardiac blood flow. 18F-flurpiridaz was able to accurately detect 
reduction in myocardial blood flow in patients with coronary artery disease (sensitivity 
71.9%). 18F-flurpiridaz was superior to SPECT perfusion imaging in image quality, 
diagnostic certainty, and radiation exposure in human clinical trials109,110. Another tracer, 
11C-acetate, can indirectly estimate myocardial blood flow and oxygen metabolism where 
11C-acetate accumulation in cardiomyocytes refers to low oxygen consumption and blood 
flow111. In a rat model of congestive heart failure, 11C-acetate demonstrated decreased 
myocardial oxygen consumption with significant correlation to myocardial blood flow, 
therefore, 11C-acetate can be used as an estimate of cardiac perfusion112. Another target for 
perfusion imaging is the mitochondrial membrane potential which is higher in healthy 
cardiomyocytes and loss of this signal is associated with cell death. Ammonium and 
phosphonium cations accumulate in mitochondria and these compounds are targets for 
potential 18F imaging agents. Many 18F derivatives of tetraphenylphosphonium salt have 
been developed and tested for detection of cardiac perfusion in animal models78. In cardiac 
amyloidosis, many tracers have been developed to target amyloid depositions including 
11C-Pittsburgh B (PIB), 18Florbetapir, and 18Flutemetamol in detecting disease presence 
and severity113,114. In addition, 18F-sodium fluoride (18F-NaF) detects calcification and 
plaque formation in coronary artery disease and can determine plaque vulnerability along 
with future cardiac events115. An alternative to 18F-FDG for inflammation imaging is 68G-
DOTATATE which targets the somatostatin receptor type 2 that is overexpressed in 
inflammatory macrophages. 68G-DOTATATE can accurately detect inflammation after a 
myocardial infarction with minimal background uptake116 and can determine 
atherosclerotic disease severity by assessing high versus low risk lesions in the 
vasculature117. 68G-pentixafor, targeted to the chemokine receptor CXCR4, can also be 
used to image inflammation associated with atherosclerosis118. With cardiac neuronal 
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imaging, new 18F-labelled tracers are being developed to target the sympathetic nervous 
system in the cardiomyocytes. These tracers target the norepinephrine transporter uptake-
1 and accumulate in vesicles within the cells. These tracers have similar function to 11C-
HED although the longer half-life of 18F aids in the versatility in imaging119. In addition to 
the tracers described above, there are many other new tracers being developed to target 
specific molecular pathways of HD. These tracers have the potential to be used in an array 
of imaging profiles to help with diagnosis and targeted treatments of HD.  
 
1.2.9 Simultaneous PET/CT and PET/MR Imaging 
To better diagnose and predict adverse cardiac events, simultaneous imaging with PET and 
CT or MRI can be used to determine both molecular and functional abnormalities in HD. 
The main limitations with PET imaging alone are the low spatial resolution and lack of 
anatomical reference. Initially, sequential imaging sessions (PET followed by CT or MRI) 
were used with co-registration software to integrate the two sets of images. This posed a 
challenge due to the difference in scanner profiles, patient positioning and organ movement 
between scans120. To overcome these challenges, hybrid systems for both PET/CT and 
PET/MRI were developed to optimize scan overlay, to lower costs due to multiple scans, 
and to lower the burden on the patient. Simultaneous imaging poses significant advantages 
over sequential imaging as the scan duration is minimized and the patients do not have to 
move, allowing for improved co-registration of the PET images to anatomical imaging of 
MRI or CT. With PET/CT, an established x-ray (CT) based attenuation correction is used 
to quantify PET data. PET/MRI is more challenging due to the limited reliability of 
developed attenuation corrections for PET121. The advantages of using PET/CT are the 
high spatial resolution, shorter study times, can be used with patients with metal implants, 
and availability. Its disadvantages include extra radiation exposure, possible renal toxicity 
with large volume of iodine contrast agent (contrast induced nephropathy), limited use in 
patients with arrhythmias, and functional data acquired retrospectively. In contrast, 
PET/MRI poses many advantages including temporal resolution, superior soft-tissue 
contrast, and evaluation of both cardiac anatomy and function. The disadvantages include 
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inability to scan patients with certain implanted devices, possible renal failure with 
gadolinium contrast agent (nephrogenic systemic fibrosis), cost, and difficulties with scan 
duration with patients who have claustrophobia122. Overall, PET/MRI can provide more 
detailed anatomical information with less radiation over PET/CT, but availability is limited 
in the clinic and patient comfort level should be evaluated. 
When performing simultaneous imaging, one study evaluated information provided by 
PET when using either PET/MRI or PET/CT using the same patient cohort for both 
modalities. They found the same PET image results regardless of the imaging modality123. 
Therefore, when using simultaneous imaging modalities, the use of CT or MRI should be 
evaluated based on the choice of diagnostic parameters for the type of HF. In a patient 
sarcoidosis study with PET/MRI and PET/CT, overall 18F-FDG PET uptake using tissue to 
blood ratio (TBR) was comparable between imaging methods, although MRI data provided 
more detailed information in regional fibrotic deposition and edema124. Combined PET and 
MRI supplied complimentary information on disease pathology with both LV and RV 
abnormalities in cardiac sarcoidosis125. In myocarditis, cardiac MRI is widely used for 
diagnosis and 18F-FDG PET can add more information on the inflammation associated with 
myocarditis. PET/CT does not provide optimal anatomical information in this disease due 
to the lack of soft tissue contrast126. In patients with myocardial infarction and plaque 
formation, 18F-NaF PET/MRI and PET/CT were compared to find vulnerable plaques and 
scar tissue specifically in the myocardium where PET/MRI enabled structural myocardial 
information that CT was not able to provide. Overall PET/CT data was able to determine 
scar tissue and plaque presence and these results were comparable with PET/MRI results 
although anatomy was easier to identify with MRI127. Taken together, hybrid imaging with 
PET and either CT or MRI provides an exceptional amount of information that can improve 
diagnostic and prognostic accuracy. The choice of PET/CT versus PET/MRI relies on each 





1.3 Heart Failure and Heart Disease Biomarkers  
In addition to clinical examination and imaging, circulating cardiac biomarkers are used to 
evaluate heart disease. There is a need to develop methods to accurately predict which 
individuals will proceed to HF, particularly in the early stages when risk factors are present 
without any measurable deterioration in heart function. Circulating biomarkers can help 
augment the information provided by imaging and clinical examination.     
Circulating cardiac biomarkers are quantifiable biochemical indicators of alterations in 
cardiac function. Ideally, these biomarkers can be used to determine early molecular 
changes in the heart that precede the functional changes, as measured by imaging and 
clinical examination. Elucidating profiles for biomarkers of HD will help to guide therapies 
and help disease management. An ideal cardiac biomarker would be:  
• Quantifiable; able to be accurately and repeatably quantified with quick 
turnaround times  
• Specific; a marker native to cardiac tissue 
• Sensitive; shows changes that are scaled to disease severity  
• Stable; changes do not degrade prior to detection 
The most common clinical biomarkers used to detect damage in the heart are natriuretic 
peptides and cardiac troponins which measure cardiomyocyte stress and cardiac damage, 
respectively.  
 
1.3.1 Biomarkers of Cardiomyocyte Stress 
Cardiomyocyte stress occurs with extensive pressure and volume overload in the heart. 
This causes atrial and ventricular diastolic stretching which stimulates natriuresis and 
vasodilation, and LV relaxation128. Natriuretic peptide-B (BNP) is the gold standard 
biomarker for the diagnosis and prognosis of HF129, and is produced by primarily 
ventricular myocytes under conditions of stress. BNP is initially produced as the precursor 
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molecule pre-pro-BNP and cleaved to generate proBNP. The enzyme corin then cleaves 
proBNP to the active hormone BNP and the inactive form NT-proBNP (the N-terminal of 
pro-BNP)130. Both BNP and NT-proBNP are released into the blood stream from 
predominantly the left ventricle upon increased wall stress and neurohormonal activation. 
Physiologically, BNP promotes diuresis (sodium and water excretion), vasodilation, and 
attenuate the renin-angiotensin-aldosterone secretion (RAAS). In addition to BNP secreted 
from the ventricular myocytes, atrial natriuretic peptide (ANP) is produced primarily in the 
atrial myocytes and is secreted with hypertension and wall stress. The hormones ANP and 
BNP are eliminated from the body via two methods: receptor internalization, or proteolytic 
degradation in the excretion organs including kidneys and lungs130. The active form BNP 
has been evaluated in healthy individuals where circulating levels are extremely low. In 
one study, Tsutamoto et al. measured the circulating BNP levels in 85 patients with chronic 
HF where levels increased in proportion to disease severity. The plasma levels were 5-fold 
higher in patients who did not survive compared to survivors131. Other studies have also 
evaluated the measurement of plasma BNP in HF severity and found BNP to be an 
independent predictor of mortality132. BNP is also secreted under conditions of severe 
aortic regurgitation, mitral regurgitation, and aortic stenosis133. Another study compared 
BNP and NT-ANP to echocardiograms where BNP correctly identified HF with a positive 
predictive value of 84% while NT-ANP’s positive predictive value was only 78%. 
Therefore, BNP is an accurate diagnostic marker of HF134. BNP and NT-proBNP have the 
same cardiac actions which are released upon cardiac stress, although the half-life of NT-
proBNP is 5- to 10- fold higher (60-120 min) than BNP (23 min). The threshold values for 
HF diagnosis with BNP are: <100pg/ml – no HF; 100-400pg/ml – potential HF; >400pg/ml 
– HF; however, the diagnostic values for NT-proBNP differ significantly based on age: 
<300pg/ml – no HF; >450pg/ml – HF for patients under 50 years of age; >900pg/ml – HF 
for ages 50-75; >1800pg/ml – HF for ages over 75135. Therefore, due to the longer 
circulating half-life and age specificity of diagnostic thresholds, NT-proBNP is more 
commonly measured in a clinical setting.  
Although BNP and NT-proBNP are commonly used to diagnose clinical HF, it is important 
to note that BNP levels are increased or decreased with other comorbidities, most notably 
renal failure and sepsis, along with age, sex and obesity. BNP, along with all natriuretic 
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peptides, is elevated with renal failure even when no adverse cardiac events are present136. 
BNP is also elevated in sepsis and other non-cardiac disease states including atrial 
fibrillation, pulmonary embolism and amyloidosis137. BNP levels were significantly lower 
in obese patients which may be a contributing factor to the higher susceptibility of these 
individuals to adverse cardiac events138. BNP also increases with age139 and is higher in 
women compared men140. Different assay systems also have different thresholds and 
ranges which make having a universal threshold difficult140. With the multitude of variables 
present for the measurement of BNP, it is suggested that both BNP and NT-proBNP may 
not be the most suitable for detection of HF in the entire population.  
Suppression of tumorigenicity 2 (ST2) is another measure of mechanical stress in 
cardiomyocytes129. The ligand for the ST2 receptor is interleukin 33 (IL-33) which has 
anti-hypertrophic and anti-fibrotic benefits in the myocardium, partly due to inhibition of 
the pro-apoptotic pathway141. The soluble form of ST2 (sST2) is secreted from the 
myocardium and detectable in the circulation under conditions of cardiomyocyte stress. 
sST2 acts as a decoy receptor for IL-33 to suppress the natural IL-33 pathways which 
ultimately leads to increases in cardiac apoptosis and fibrosis. Therefore, increases in sST2 
indicate increased fibrosis, inflammation, and remodeling, reflecting many hallmarks of 
several cardiovascular diseases142. sST2 levels also appear to increase in acute HF, but 
unlike BNP, these values were not an independent predictor of mortality143. However, 
when measured with BNP, the prognostic accuracy for HF was greatly improved141. 
Therefore, it is evident that creating a panel of biomarkers to more accurately detect and 
predict HD is needed. 
 
1.3.2 Biomarkers of Cardiac Damage 
Cardiac troponins (cTn) are the leading candidate biomarkers in predicting myocardial 
damage. It is well established that cardiac troponins T and I levels are significantly elevated 
in myocardial injury, mainly ischemia144. In healthy cardiomyocytes, troponins are 
essential for regulation of muscle contraction through modulation of calcium-mediated 
actin and myosin interaction145. Cardiac troponin T, I, and C form the cTn complex where 
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troponin T (cTnT) and I (cTnI) are specific for mediating contractile function144. When the 
cardiomyocyte membrane is disrupted via ischemic (most common) or non-ischemic 
causes, the cTn complex disaggregates and enters the bloodstream, and therefore, increased 
levels of cTnI and cTnT correlate with the extent of cellular injury. Studies have observed 
increases of cTnT and cTnI in many forms of heart disease including coronary heart 
disease, heart failure, and atherosclerosis146,147. It is important to note that cTns are an acute 
marker of cardiac damage where their half lives in the blood range from 90-120 min with 
prolonged elevation (3-4 days) indicating severe and irreversible damage to the heart148. 
cTn measurements provided complimentary information to cardiac perfusion imaging to 
enhance diagnostic accuracy149. Some studies have also shown elevations of cTns in other 
disease states including stroke, pulmonary embolism, sepsis, perimyocarditis and 
tachycardia150,151. Therefore, measurement of cTn is usually evaluated along with clinical 
examination and imaging to form an accurate diagnosis of cardiac injury.  
In addition to troponins, heart-type fatty acid-binding protein (H-FABP) is another measure 
of cardiac damage. H-FABP is a cytoplasmic protein that transports long-chain fatty acids 
into the cardiomyocyte and is rapidly released into the bloodstream upon cardiomyocyte 
membrane damage129. Serum H-FABP levels were measured in chronic HF when patients 
were both admitted and released from the hospital where prolonged elevation at the time 
of release were associated with significantly higher future cardiac event rates152. When 
circulating levels of H-FABP were measured concurrently with cTn, testing sensitivity was 
improved in the first 4 hours after admission. However, at later timepoints H-FABP 
increased the false-positive rate of patients with acute MI153. Another study also evaluated 
H-FABP and cTn in acute coronary artery syndrome where early testing of H-FABP 
showed increased levels associated with cardiac events in all patients. In contrast to the last 
group, this group found H-FABP to have a greater predictive capacity for cardiac events 
within 6 months of initial admission154. Due to such differing findings with this biomarker 
at later stages, further analysis of the predicative value of H-FABP is needed. These studies 
have shown the importance of using an array of biomarkers in HD for improved prediction 




1.3.3 Inflammatory Biomarkers 
Inflammation is a key process that contributes to the progression of many forms of HD. 
Initially, acute inflammation is a necessary step in the process of healing. However, when 
the inflammation fails to resolve and becomes prolonged, further tissue damage may occur. 
Many cardiac biomarkers have been discovered to link to the overall cardiac inflammation 
in HF. Early studies focused on interleukin-6 (IL-6), tumour necrosis factor alpha (TNF-
α), C-reactive protein (CRP) and toll-like receptor 4 (TLR4) with their role in HF 
progression via adverse effects on vascular endothelium, cardiomyocyte apoptosis, 
induction of hypertrophy, and left ventricular dilatation155.  
Interleukin-6 (IL-6) is a common inflammatory cytokine that is secreted in response to 
infections and tissue injuries. It is produced by various cell types and exerts many 
biological responses through the IL-6 receptor. IL-6 has been reported to play a large role 
in the process of ischemic HD and HF156. In patients with chronic HF, plasma levels of IL-
6 increased with diseased severity and could provide prognostic information independent 
of left ventricular ejection fraction157. In a clinical trial from patients with acute coronary 
syndrome, increased IL-6 levels associated with adverse cardiac outcomes158 and increased 
risk of major cardiac events including possible HF159. Plasma levels of IL-6 are also 
elevated after trauma from acute myocardial infarction where prolonged elevation 
correlates with residual ischemia in the heart160. In addition to cardiac ischemia, IL-6 levels 
increase in dilated or hypertrophic cardiomyopathy and are associated with a higher risk of 
congestive HF161. In contrast to the findings that IL-6 further increases cardiac damage, 
some studies have shown that IL-6 may play a role in cardio-protection after ischemia/ 
reperfusion signalling162 and may even aid in tissue repair163. Therefore, IL-6 can be 
proposed to play a dual role in cardiovascular inflammation. Short term signalling of IL-6 
after ischemia can protect the heart from further damage while long term IL-6 elevation 
plays a role in the development and prediction of future cardiovascular diseases.   
Tumour necrosis-alpha (TNF-α) is an inflammatory protein produced primarily by 
macrophages and released into circulation to elicit an immune response. TNF-α binds to 2 
possible receptors, TNFR1 and TNFR2, with each producing divergent responses in HF. 
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TNFR1 functions through pathological pathways while activation of TNFR2 shows 
protective effects in the heart. In a mouse model of MI, knockout of TNFR1 indicated 
attenuated ventricular dysfunction and improved post-MI survival while knockout of 
TNFR2 exacerbated ventricular dysfunction and cardiac remodeling164. Therefore, TNF-α 
is expected to play a protective role in the heart via the TNFR2-mediated pathway. In the 
circulation, TNF-α levels have been found to increase in patients with heart disease and 
heart failure156. In patients with coronary artery disease (CAD), TNF-α increased according 
to disease severity165. When both TNF-α and IL-6 were measured in CAD, there was 
significant predictors of CAD severity while measured together they are an indicator of 
chronic inflammatory burden and increased atherosclerotic risk166. This pattern was also 
present in patients with LV diastolic dysfunction independent of other cardiac 
parameters167. In mechanistic studies utilizing transgenic mice, overexpression of cardiac 
TNF-α resulted in LV wall thinning and increased cardiomyocyte apoptosis via loss of 
cytoprotective factor Bcl-2 and activation of cell death pathways168. In isolated perfused 
rat hearts, TNF-α not only decreased heart rate and contractile force, but activated protein 
kinase C (PKC) which promotes the development of cardiac dysfunction169. High levels of 
TNF-α can also disrupt contractility through increases of intracellular calcium in 
cardiomyocytes170.  
The presence of C-reactive protein (CRP) in HF patients was first discovered back in 1956 
and since then there has been extensive work on the relationship between CRP and the 
inflammatory process in HF130. In the 1990s a more sensitive test was developed for CRP, 
namely high-sensitivity CRP (hs-CRP), as testing for this marker of cardiac inflammation 
became more prevalent171. hs-CRP is synthesized in the liver, and with increased vascular 
inflammatory cytokines in the circulation, hs-CRP is released into the bloodstream which 
can then be detected in inflammatory HF and atherosclerosis172. hs-CRP has a long half-
life of about 19 hours with its peak occurring at about 24-48 hours after initial inflammatory 
response173. A large meta-analyses evaluating the circulating levels of hs-CRP showed it 
to be a predictor of coronary heart disease and future coronary events174. Increased levels 
of this marker are also associated with many risk factors of heart disease including physical 
ability, smoking, cholesterol levels, body mass index (BMI), and blood pressure175.  
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The toll-like receptor (TLR) superfamily plays a crucial role in the innate immune system. 
Toll like receptor 4 (TLR4) is a membrane-bound receptor in cardiomyocytes and 
endothelial cells that is upregulated in HF where its activation leads to further inflammatory 
signalling. TLR4 can be activated by many ligands including endotoxins, heat shock 
protein 60 (HSP60), reactive oxygen species (ROS) and high mobility group box 1 
(HMGB1). Once TLR4 is activated, initiation of both My88-dependent and My88-
independent pathways activate many inflammatory transcription factors and 
proinflammatory cytokines, respectively176. Both pathways activate transcription of NF-
κB and activator protein-1 (AP-1) which regulate the expression of inflammatory cytokines 
IL-6 and TNF-α. Compared to all other toll-like receptors TLR4 has the highest expression 
in inflammatory HD including myocarditis, myocardial infarction, ischemia reperfusion 
(I/R) injury, HF, valve diseases, hypertension, and atherosclerosis177. In HF, many 
endogenous ligands of TLR4, such as HSP, ROS, and HMGB1, are elevated and mediate 
myocardial inflammation176. Studies in mice showed that TLR4 expression was increased 
in cardiomyocytes isolated after long-term myocardial infarction (MI)178, while mice with 
TLR4 deficiency showed reduced infarct sizes after I/R injury179. Cardiac TLR4 expression 
was also increased in patients with advanced HF180. Due to TLR4 overexpression in HD, 
this pathway has become a target of inhibition to reduce pro-inflammatory responses. 
Statins have been shown to inhibit TLR4 activity and reduce inflammation in the vascular 
system181. Eritoran is a TLR4 antagonist and has been shown to attenuate I/R injury182. 
Therefore, TLR4 may be a biomarker of myocardial inflammation in several types of HD 
and vascular diseases. 
 
1.3.4 Specificity of Cardiac Biomarkers 
Most of the cardiac biomarkers described above are secreted into the blood and can 
therefore be measured through a simple blood test. However, they can be associated with 
other comorbidities that can confound results. Some biomarkers are not even produced by 
the heart but are secreted by other tissues when cardiac injury or dysfunction occur. 
Therefore, circulating biomarker levels may not reflect actual cardiac tissue levels which 
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is a limitation to measuring circulation compared to tissue-specific biomarkers of HD. 
There is a clear need for the identification and development of ways to non-invasively 
detect tissue-localized biomarkers. In addition, there is evidence that no one single 
biomarker can accurately determine HD prognosis. In a study by Jungbauer et al. it was 
suggested that a panel of cardiac biomarkers should be used to more accurately diagnose 
and predict cardiac outcomes for patients183. As HD is a complex syndrome with diverse 
signs and symptoms, it is imperative to use a large panel of biomarkers to encompass all 
possible characteristics and aid in better diagnoses. One novel biomarker of interest that 
reflects cardiac tissue is the growth hormone secretagogue receptor (GHSR) and its 
endogenous ligand ghrelin. This cardiac system could be an important addition to the 
already established panel of biomarkers.  
 
 
1.4 Ghrelin-GHSR as a Novel Biomarker  
Upon cardiac biomarker discovery, a new hormone, ghrelin, and its receptor the growth 
hormone secretagogue receptor (GHSR) have been identified as potential target localized 
to cardiac tissue. The emerging discovery of this new biomarker has gained traction in HD 
with the identification of changes in this ghrelin-GHSR system in HF.  
1.4.1 GHSR and Ghrelin Discovery 
Ghrelin is a peptide hormone that modulates systemic metabolism through activation of 
orexigenic effects in the body184. Ghrelin is a 28-amino acid peptide that is encoded by the 
preproghrelin gene first discovered in the X/A like cells in the gastric oxyntic cells in the 
stomach185. It is first synthesized as a precursor, preproghrelin, which is cleaved to produce 
both ghrelin and obestatin. Obestatin has been thought to play a role in food intake and 
metabolism via the G protein-coupled receptor 39 (GPCR39) although these results have 
yet to be substantiated186. Ghrelin, however, has been extensively studied for its production 
and secretion in endocrine cells in the gastrointestinal mucosa. Ghrelin is present in cells 
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in two forms, acylated and un-acylated ghrelin. In the endoplasmic reticulum membrane, 
proghrelin is acylated on Ser-3 by ghrelin O-acyl transferase (GOAT) prior to its 
processing to mature ghrelin. Only the acylated form of ghrelin is the natural ligand to 
GHSR184. Although the un-acylated form of ghrelin (des-acyl ghrelin) does not bind 
GHSR, it also modulates energy metabolism, likely through an unknown receptor187. 
Structure-function studies have shown that the N-terminal 8 amino acids of ghrelin, 
including the octanoylated group, constitutes the receptor binding domain.  
The biologically active receptor for ghrelin is GHSR1a (here termed GHSR), a 366 amino 
acid, seven transmembrane G-protein coupled receptor that contains an extracellular 
binding region where active ghrelin binds specifically to transmembrane domains 3 and 6 
of GHSR. The splice variant GHSR1b contains only 298 amino acids and is truncated to 
only contain transmembrane sections 1-5188. GHSR1b has been shown to be expressed in 
the same tissues as GHSR1a as well as adipose tissue, breast, skeletal muscle and 
prostate188. GHSR1b is known to heterodimerize with other G-protein coupled receptors 
and functions in signalling. GHSR1b may form a heterodimer with GHSR1a in neurons 
and HEK293 cells where receptor internalization occurs with inhibition of GHSR1a 
signalling189,190. Although GHSR1b has been shown to dimerize with GPCRs, its biological 
function in the heart is not fully elucidated.  
While ghrelin was originally discovered in rat and human stomach191, it is now known that 
ghrelin and GHSR are expressed in many other organs; various brain regions; lung, liver, 
kidney; the epsilon cells of pancreatic islets; and, most importantly, cardiovascular tissues. 
The presence of GHSR has been demonstrated in human vascular tissues including the 
aorta, coronary and pulmonary arteries, as well as in the myocardium, indicating that 
GHSR is present throughout the heart192. Ghrelin has been thought to exert paracrine and 
autocrine effects in the heart where binding of ghrelin to GHSR elicits many 




1.4.2 GHSR Signalling in the Heart 
Activation of GHSR in the heart has been identified through both classical G-protein 
signaling and G-protein-independent pathways showing the complexity of GHSR 
activation194. Ghrelin activation of GHSR initiates many downstream signalling processes 
ranging from apoptosis and survival signaling, calcium regulation and contractility 
signaling, cellular metabolism, and inflammation.  
One of the main contributors to cardiac health is cardiomyocyte contractility and regulation 
of calcium influx/efflux. Calcium (Ca2+) signalling in the cardiomyocyte begins with an 
influx of calcium into the cell through the L-type calcium channel induced by excitation 
contraction coupling of the cardiomyocyte membrane. At the same time, Ca2+ is released 
from the sarcoplasmic reticulum (SR) through the ryanodine receptor 2 (RyR2). Increases 
in cytoplasmic Ca2+ bind to protein kinase C (PKC) and initiate phosphorylation of 
Ras/Raf, MEK1/2 and ERK1/2195. Intracellular Ca2+ induces cardiomyocyte contraction 
through binding to troponin (Tn) C within the actin filament in the sarcomere of the cell. 
Ca2+ is released from the Tn C and actin filament where a signal is sent to the cell to reduce 
intracellular levels. Stimulation of G-protein coupled receptors (GPCRs) initiate a 
signalling cascade starting with Gs activating cyclic adenosine monophosphate (cAMP), 
protein kinase A (PKA) which phosphorylates phospholambin B (PLB) and inhibits 
binding to sarcoplasmic reticulum calcium ATPase pump (SERCA2a) ultimately allowing 
for Ca2+ uptake into the SR. Furthermore, stimulation of GPCRs activates Gαq, 
phospholipase C β (PLCβ), inositol 3 phosphate (IP3) which binds to the IP3 receptor. This 
receptor is minimally active in healthy cells and becomes overactive in damaged or stressed 
cardiomyocytes196. Upon relaxation, Ca2+ is stored in the SR or removed from the cell 
through the sodium-calcium exchanger (NCX) on the cell membrane. This process is 







Figure 1.1 Calcium Regulation and Contractility Signaling in Cardiomyocytes. 
Calcium (Ca2+) into the cell through the L-type voltage gated calcium channel. Ca2+ 
induces the PKC → MEK → ERK1/2 pathway and stimulates both the opening of the 
ryonadine receptor 2 (RyR2) receptors to release stored Ca
2+ and activation of GPCRs. 
GPCRs activate Gs → cAMP → PKA → PLB to initiate influx into the sarcoplasmic 
reticulum along with Gαq → PLCβ → IP3 and binding to IP3 receptor (IP3R). Ca
2+
 is 
removed from the cytosol through storage in SR via SERCA2a and removed from the cell 
through the sodium-calcium exchanger (NCX). To induce contraction, Ca2+ binds to the 
troponin (Tn) C on the actin filament where myosin binds to contract the cell. Ca2+ and 
myosin are released from the actin upon relaxation of the cardiomyocyte. Figure was 





A number of studies using isolated cardiomyocytes have shown that the ghrelin-GHSR 
system in the myocardium plays a role in the regulation of Ca2+ homeostasis, which is 
associated with its action in cardioprotection and overall heart function. Treatment of 
mouse ischemic cardiomyocytes with ghrelin resulted in protection from ischemia/ 
reperfusion injury, likely from regulation of intracellular Ca2+ levels194. When ghrelin was 
administered to rat ventricular cardiomyocytes, a positive inotropic effect was seen through 
increased intracellular Ca2+ transients and increased L-type Ca2+ channel current, likely 
through GHSR-mediated signalling through PKC198. The same group evaluated the same 
parameters of intracellular Ca2+ flux on mouse cardiomyocytes with ischemia/ reperfusion 
(I/R) injury. Activation of GHSR with ghrelin produced a positive inotropic effect again 
with prevention of Ca2+ transient reduction and SR calcium reduction199. Therefore, GHSR 
is expected to protect the heart from I/R injury via the PLB pathway ultimately allowing 
for maintenance and recovery to normal contractility after cardiac injury199. Overall, GHSR 
is an important regulator of calcium signalling and ultimately contractility in the heart 
where activation of this system functions as a cardioprotective mechanism for HD. 
The inflammatory process plays an important role in the process of HD development. 
Ghrelin activation of GHSR is known to inhibit pro-inflammatory pathways and activate 
anti-inflammatory pathways to help protect the heart from further damage. Ghrelin has 
been shown to act on both immune and endothelial cells to inhibit the leptin- and 
endotoxin- induced production of pro-inflammatory cytokines, including interleukin 1-β 
(IL-1β), interleukin-6 (IL-6), and tumour necrosis factor alpha (TNF-α)200,201. Further 
studies evaluated the effect of ghrelin on the toll-like receptor 4 (TLR4)/ NF-κB 
inflammatory pathway. In the rat heart, ghrelin administration lessened pro-inflammatory 
signalling through the TLR4/ NF-κB pathway202. Additionally, in rats with induced 
ischemia/reperfusion injury, the increased expression of TLR4, IL-1β, and Caspase-1 were 
all reduced with the administration of ghrelin202. Endogenous ghrelin can also induce anti-
inflammation pathways; in ghrelin knockout mice with induced cardiac hypertrophy, the 
cholinergic anti-inflammatory pathway was suppressed and plasma inflammatory markers 
(IL-6, IL1-β) were high, compared with wild-type mice203. Ghrelin and GHSR also 
contribute to the inhibition of inflammation via activation of the Akt-activated anti-
inflammatory pathway202. Therefore, activation of GHSR with ghrelin both inhibits pro-
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inflammatory pathways and activates anti-inflammatory pathways to reduce the cardiac 
damage seen with excessive inflammatory response.  
GHSR signalling suppresses apoptosis and promotes survival. One study investigated 
GHSR signaling in rats with myocardial infarction (MI) and showed a decrease in both 
apoptosis (metalloproteinase 2 and 9) and inflammation (IL-1β and TNF-α)204. GHSR 
activation promotes pro-angiogenesis, pro-survival and proliferation through Akt and 
AMP-activated protein kinase (AMPK) in rat cardiomyocytes205, and extracellular 
signalling related kinase (ERK) phosphorylation in cardiomyocytes and endothelial 
cells206. Ghrelin has been shown to improve the integrity and decrease shrinkage of rat 
cardiomyocytes207. The ghrelin-GHSR system has been shown to inhibit apoptosis by 
decreasing pro-apoptotic signalling. In the rat left ventricle, administration of ghrelin 
decreased the pro-apoptotic factors Bax and Caspase-3 while increasing the anti-apoptotic 
factors Bcl-2 and Bcl-xL and prevented mitochondrial swelling208. In angiotensin II- (Ang 
II) and isoproterenol-induced HF in rats, activation of AMPK through ghrelin decreased 
overall apoptosis with decreases in apoptotic factors caspase-3 and caspase-12 208,209. 
GHSR activation has shown to be a cardioprotective marker as it activates many 
downstream signalling pathways for both decreasing apoptosis and promoting 
cardiomyocyte survival via a cardioprotective mechanism.   
Along with cellular survival, ghrelin acts through GHSR to regulate cellular metabolism, 
notably glucose metabolism and oxidative stress. In dogs with HF, ghrelin administration 
enhanced fatty acid oxidation and oxygen consumption and reduced glucose oxidation, 
thereby partially correcting the metabolic deficiencies from HF210. Ghrelin also attenuates 
the ER stress response to ischemia/reperfusion; in rat hearts with I/R, pre-administration 
of ghrelin reduced the IR-induced overexpression of mRNA and proteins of the ER stress 
(ERS) response, glucose-regulated protein78 (GRP78) and C/EBP homologous protein 
(CHOP)211. This group further evaluated the mechanism of ERS activation and determined 
that ghrelin activates GHSR through the calcium-calmodulin-dependent protein kinase 
kinase (CAMKK) and AMP-activated protein kinase (AMPK) to ultimately protect the 
heart from ERS-induced injury209. Additionally, ghrelin administration in the mouse heart 
using adeno-associated virus vectors sustained autophagy and minimized dysfunctional 
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mitochondria after MI212. Taken together, these studies demonstrate the multiple metabolic 
pathways through which ghrelin activation of GHSR operates to protect against cardiac 
damage and stress.  
Fibrotic deposition is commonly associated with extensive damage and disruption to the 
myocardium. Many studies have evaluated alterations in scar formation and size after 
GHSR activation to protect the heart from further injury. Ghrelin has been shown to reduce 
scar size and volume after MI in mice213, and ghrelin suppresses collagen I and III mRNA 
levels in rat cardiomyocytes214. In an Ang II-induced model of HF, ghrelin attenuated 
myocardial fibrosis and expression of fibrotic factors (collagen I, III, TGF-β1) through 
upregulation of PPAR-γ and inhibition TGF-β1 signalling215. The mechanism by which 
ghrelin inhibits fibrotic deposition was further evaluated in rat ventricular cardiomyocytes 
where activin A (Act A) levels were significantly increased after a MI. Ghrelin 
downregulated Act A back to basal levels, thus correcting this Act A imbalance during 
ventricular remodelling216. Therefore, GHSR activation with ghrelin attenuates fibrosis 
deposition and inhibits fibrotic protein formation to protect the heart from further damage.   
The ghrelin-GHSR system is proposed to initiate a cardioprotective mechanism when the 
myocardium is stressed or damaged. Therefore, studies evaluated cardiac function after 
activation of this system using ghrelin administration. In healthy humans, ghrelin was 
injected, and heart function was evaluated acutely after injection. Interestingly, ghrelin 
dose-dependently enhanced LVEF217 and vasodilation determined through forearm blood 
flow218. When ghrelin was repeatedly given to CHF patients, there was a drastic 
improvement in LVEF along with LV mass and end-systolic volume, oxygen capacity and 
muscle wasting219. In human studies, there has been clear evidence that the ghrelin-GHSR 
system functions to improve cardiac function after myocardial damage. Therefore, these 
studied have shown the clinical relevance of the ghrelin-GHSR system in HD models.  
Overall, these data depict a complex biochemical signalling network upon activation of 
myocardial GHSR. Cardio-protection via the ghrelin-GHSR system functions to regulate 
calcium homeostasis and, in turn, contractility; reduce inflammation; inhibit apoptosis and 
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cell death; regulate cellular metabolism; and reduce fibrosis deposition. These processes 




Figure 1.2 Proposed Biochemical Signalling Cascade of ghrelin-GHSR in 
Cardiomyocytes. 
Ghrelin activation of cardiac GHSR initiates downstream signalling pathways for 
contractility (cAMP → PKA → PLB → SERCA2a and calcium homeostasis); apoptosis/ 
hypertrophy (PKC → MEK → ERK1/2); cellular survival (PI3K → PDK1 → Akt); protein 
synthesis and cellular growth (Akt → mTOR); inflammation (TLR4 → MyD88 → NFκB 




1.4.3 Argument for GHSR as a Biomarker in Heart Disease and 
Heart Failure 
The biology of the myocardial ghrelin-GHSR system has been extensively studied and now 
the question remains, could this system act as a targeted biomarker for HD and a predictor 
of HF? Activation of the ghrelin-GHSR system improves overall heart function potentially 
acting through a cardioprotective mechanism to help mediate the negative effects of HD. 
The ghrelin-GHSR system dynamics are known to change for different forms of heart 
disease including diabetic cardiomyopathy, valvular disease, CHF, and MI.   
Changes in the ghrelin-GHSR system within the heart may provide clues to the 
development of HD and HF. The rodent MI model in which the left anterior descending 
coronary artery is ligated, has revealed some interesting dynamics. Following surgery, 
myocardial GHSR expression increased over time and ghrelin expression decreased220. 
Additionally, ghrelin serum levels correlated negatively with LV end-diastolic pressure 
and dimension indicating this ghrelin-GHSR system plays a role in LV function220. A rat 
model of MI was used to evaluate the effects of ghrelin administration on heart function. 
In rats that were ghrelin-treated post-MI, LV end-diastolic pressure and enlargement were 
reduced compared to saline controls214 and overall mortality rates were reduced221 while 
cardiac cachexia was reduced222. Similarly in a model of MI, isolated rat hearts were 
administered ghrelin during reperfusion where coronary flow, heart rate, contractility, and 
left ventricular end systolic and end-diastolic pressures were significantly improved223. 
Similar results were seen in another model of cardiac injury induced by isoproterenol in 
rats where GHSR and ghrelin mRNA expression increased with cardiac injury and were 
decreased back to normal levels with ghrelin treatment224. Interestingly, in a model of 
hypoxia/ reperfusion in isolated rat cardiomyocytes, GHSR expression was decreased 
acutely while ghrelin injection increased the expression of GHSR back to normal 
cardiomyocyte levels207. With Doxorubicin induced cardiotoxicity in mice, there was 
remarkable mortality and cardiac dysfunction which was ameliorated with ghrelin 
administration225. Our past work in a rodent model of diabetic cardiomyopathy (DCM) 
showed significant decreases in GHSR expression in acute severe and chronic mild DCM 
compared to control hearts. This is the first study showing GHSR expression changes in 
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DCM and significant decreases in GHSR expression in a model of HD. Together these 
results indicate significant regulation of cardiac function through the ghrelin-GHSR 
system. Threshold levels for GHSR expression decrease and increase based on the type 
and severity of heart disease.   
Is the ghrelin-GHSR system a clinically meaningful indicator of HD or HF? A few studies 
have evaluated the expression of both ghrelin and GHSR in human patients with heart 
disease. In a study by Beiras-Fernandex et al., myocardial tissue from patients with CHF 
was analyzed for expression of both GHSR and ghrelin and compared to control tissue. 
The authors found tissue ghrelin levels significantly decreased and levels of GHSR 
markedly increased in CHF226. This was the first study showing changes in both ghrelin 
and GHSR in the myocardium of patients with HF with association to cardiac function 
where these changes could reflect a compensatory mechanism. Another study evaluated 
GHSR density in cardiac vasculature using a labelled ghrelin probe, [125I-His9]-ghrelin, 
where GHSR density increased in atherosclerotic aorta, and coronary arteries and veins. 
These changes in GHSR density in atherosclerosis vasculature represent a potential 
therapeutic target in the treatment of cardiovascular disease227. Changes in GHSR are also 
associated with LV mass. GHSR gene variant analysis revealed one variant that was 
common in individuals with highly symptomatic LV hypertrophy. These data suggest that 
GHSR variants differ based on susceptibility to LVH228.  
Another indicator of cardiac damage is the circulating form of ghrelin where elevations can 
lead to poor outcomes for patients with cardiac conditions. Chen Y et al., demonstrated a 
decrease in plasma ghrelin levels in patients with CHF where survival analysis showed that 
a higher plasma ghrelin level (>85pmol/l) lead to increased 2-year survival rate229. 
Significant correlations were seen between circulating ghrelin levels and NT-proBNP 
indicating ghrelin could be a predictor of readmission in HF similar to NT-proBNP. 
Ghrelin also correlated to LVEF, another predictor of readmission, further suggesting 
lower circulating ghrelin levels could lead to patient readmission and a biomarker of HD 
and HF229. Another study in cardiac hypertrophy patients evaluated the relationship 
between plasma ghrelin levels and ventricular wall thickness. Higher plasma ghrelin levels 
correlated to increased wall thickness reflecting a possible compensatory mechanism to 
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up-regulate ghrelin concentrations and act through the cardiac ghrelin-GHSR system230. 
Plasma ghrelin levels were also correlated to atherosclerotic plaques in atherosclerosis 
where ghrelin was positively associated with mean artery plaque thickness231. Taken all 
together, these studies indicate that there are thresholds in serum ghrelin levels that are 
associated with disease severity in HD and HF. 
Overall, these data show a clear indication of the cardioprotective effects the ghrelin-GHSR 
system has on the myocardium and overall cardiac function. The expression of GHSR and 
ghrelin are altered depending on the type and severity of heart disease present while they 
ultimately act to improve the biochemical signalling in cardiomyocytes and enhance 
overall cardiac function. Therefore, the literature supports the use of GHSR as a cardiac 
localized biomarker of HD and HF and its potential predictive value as serum ghrelin levels 
and GHSR-associated biochemical signalling occurs early in the progression of cardiac 
dysfunction.   
 
1.4.4 Imaging Agents Targeting GHSR: Fluorescent Probes and 
PET Tracers  
With the relevance of the ghrelin-GHSR system to not only overall cardiac function but 
the multitude of biochemical signalling pathways involved in HD progression, this system 
is a promising target for evaluation of HD. Since ghrelin is produced and secreted from 
many tissues across the body the use of circulating ghrelin as a biomarker of HD may be 
confounded. Hence, GHSR may be an optimal target as it is localized to cardiac tissue and 
GHSR expression levels change significantly in the disease process. Therefore, imaging 
changes in myocardial GHSR may be an indicator of HD progression. 
The detection of GHSR and its associated signalling pathways in tissue has been 
problematic as antibodies targeting G-protein coupled receptors (GPCRs) are not 
specific232. To overcome this problem, transgenic mouse models of green fluorescent 
protein (GFP) tagged to GHSR were developed to specifically localize GHSR in vitro. In 
a mouse model of GHSR-GFP, GHSR was regionally localized in the anterior pituitary 
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with positive GFP fluorescent analysis233,234. Although this model accurately identifies 
GHSR positive cells, there is still the challenge of targeting GHSR in cells that are not 
transfected with a fluorescent reporter gene. To tackle this issue, fluorescent analogues 
have been developed targeting GHSR in any histological tissue. One study by Liu M et al., 
developed a fluorescent analogue of full-length human ghrelin where Alexa Fluor 568 was 
chemically bound to the C-terminal end of ghrelin. This analogue was found to bind GHSR 
in vitro with an IC50 of 11nM (comparable to native ghrelin at 3.3nM)
235. Another study 
evaluated an endogenous GHSR antagonist, liver-expressed antimicrobial peptide 2 
(LEAP2). This group developed a fluorescent LEAP2 analogue termed F-LEAP2 where 
the fluorescent moiety (F) was conjugated to the N-terminal end and specific binding to 
GHSR was observed in cells of mouse brain regions with a binding affinity of 3.9nM236. 
More recently, our team has developed fluorescent ghrelin analogues targeted to GHSR. 
The first fluorescent analogue developed was a truncated 18-amino acid analog of ghrelin 
tagged with fluorescein isothiocyanate (FITC). The analog was found to bind in mouse 
cardiac tissue. However, the FITC tag posed a problem as tissue autofluorescence occurs 
in this fluorescent wavelength in cardiomyocytes237. Therefore, we developed a far-red 
analogue to target GHSR to circumvent the autofluorescence issue. A far-red analogue of 
truncated ghrelin with a Cy5 fluorescent probe on the C-terminal end, Cy5-Ghrelin(1-19), 
was developed and tested in P19-derived cardiomyocytes to target GHSR. This analogue 
bound to GHSR specifically with a binding affinity of 26nM in cardiomyocytes with 
specificity validated in mouse cardiac tissue238. Since then we have developed a second 
generation of fluorescent peptides targeting GHSR239. These peptides have enhanced 
stability and affinity using a “stapling” method to bridge the peptide, ultimately preserving 
the cyclic α-helical structure essential for binding. Promising candidates from this array 
include Sulfo-Cy5-Ghrelin(1-20), Sulfo-Cy5-cyclo-12-Ghrelin(1-20), and Sulfo-Cy5-
cyclo-8-ghrelin(1-20) with binding affinities of 11nM, 1.0nM, and 6.2nM respectively239. 
With these new developments in fluorescent ghrelin-derived probes, there are many 
compounds available to specifically target GHSR in situ in cardiac cells and tissues. 
Additional to in situ imaging analogues, in vivo imaging agents have been developed to 
target GHSR in the body. Initial PET and SPECT imaging agents involved radio-labelling 
native ghrelin targeting GHSR through in situ studies. Studies have demonstrated that the 
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structure of ghrelin could be highly modified and the n-octanoylated group manipulated 
while preserving strong affinity to the receptor. This allowed for enhanced stability of the 
imaging agent to be used for in vivo studies240. The next stage in GHSR probe development 
was in 2009 where Rosita et al. reported new manipulation of ghrelin peptides including 
significant truncation and alterations in the octynol side chain of active ghrelin. The lead 
candidate for PET imaging was a fluorine-bearing 12 carbon aliphatic side chain of the 
ghrelin(1-14) compound with binding affinity of 28nM while the lead candidate for SPECT 
imaging was ghrelin(1-14) modified with a rhenium metal complex side chain with binding 
affinity of 35nM. These analogs show possibilities for future studies with 18F PET and 
99mTc SPECT imaging to noninvasively detect GHSR in vivo241. Additional SPECT 
imaging agents was reported by Koźmiński and Gniazdowska where 99mTc conjugated to 
CN-Lys-ghrelin was evaluated in situ in human prostate cells and in vivo in mice. Two 
promising candidates, 99mTc(CO)3Ls,o(CN-Lys-GHR) and 
99mTc(NS3)(CN-Lys-GHR), 
showed strong binding affinities to GHSR (54nM and 45nM respectively) with good 
stability and minimal tracer degradation in the human serum over time. Although these 
lead compounds showed promise in vivo, there was minimal uptake in the mouse heart242. 
Charron et al. developed a [68Ga]-ghrelin analogue, [Dpr3(octanoyl),Lys19(68Ga-
DOTA)]ghrelin(1-19), with a strong affinity to GHSR (5.9 nM) and strong serum stability. 
This analogue was tested in a xenograft mouse model where the tracer accumulated in the 
xenograft with excessive uptake in the kidney and minimal uptake in the heart243. Due to 
the limited uptake in the heart with these imaging agents, the labelled ghrelin-peptide may 
not be optimal for imaging in vivo changes in cardiac GHSR density.  
To overcome these issues, development of small molecule ligands of GHSR for in vivo 
imaging have been evaluated for increased affinity and serum stability. A study by Chollet 
et al. compared the binding of a 68Ga-NODAGA-ghrelin agonist peptide tracer to a 68Ga-
NODAGA-ghrelin small molecule inverse agonist tracer (binds to GHSR with opposite 
physiological responses). In vivo imaging experiments in rats showed increased stability in 
blood, reasonable clearance in kidneys and liver with both the peptide and small molecule, 
but higher uptake in the heart with the small molecule inverse agonist compared to the 
peptide tracer. The small molecule inverse agonist had unspecific diffusion and posed a 
challenge in understanding GHSR signalling244. Another study by Potter et al. evaluated a 
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(S)-stereoisomer of N-methyl piperidine-substituted quinazolinone small molecule 
derivative of ghrelin was developed to target GHSR with a binding affinity of 22nM. In 
vivo mouse studies demonstrated slight uptake in the heart, however blocking studies 
showed decreased tracer specificity (38%) and further enhancement of GHSR small 
molecules should be evaluated245. These initial results in ghrelin imaging agents have led 
to many developments in probes targeting GHSR in vivo. PET imaging probes have been 
developed and optimized by our research team. In a study by Charron et al., this group 
developed an array of ghrelin-derived peptides and small molecules labelled with 18F-
fluorine where the lead small molecule analogue, [Inp1,Dpr3(6-fluoro-2-naphthoate),1-
Nal4,Thr8]ghrelin(1−8), had a significantly stronger affinity (0.11nM) to GHSR compared 
to native ghrelin (3.3nM). This analogue incorporated a 6-fluoro-2-pentafluorophenyl 
naphthoate (PFPN) group to incorporate 18F and enhance in vivo stability246. In addition to 
these developed tracers, work by Abbas et al. evaluated a promising peptidomimetic 
candidate, [1-Nal4, Lys5(4-[18F]-FB)]G-7039, for in vivo PET imaging with binding 
affinity of 69nM. In healthy wild-type mice and mice lacking GHSR, there was no change 
in tracer uptake in the heart indicating mouse models may not be optimal for imaging 
GHSR in vivo247. Therefore, PET tracer development is an ongoing process to target GHSR 











1.5 Rationale and Aims of the Study  
With discovery and identification of the cardiac ghrelin-GHSR system there has been 
significant evidence of cardioprotective signalling through its activation. GHSR density in 
cardiac tissue may decrease and increase throughout the progression of HD. GHSR is 
elevated in end stage heart failure while circulating ghrelin may be a predictor of adverse 
cardiac events. GHSR activation after cardiac damage may increase pro-survival 
signalling, boost contractility and maintain calcium regulation, decrease harmful 
inflammatory effects, and enhance overall cardiac function. Many studies have evaluated 
the specific biochemical signalling pathways associated with GHSR activation although 
identification of GHSR density in situ and in vivo remain difficult. Conventional antibodies 
targeting GHSR lack specificity with in situ histological analysis and thus new targeted 
fluorescent imaging agents have been developed for GHSR binding and in vivo PET 
imaging agents have been optimized for GHSR detection. In this context, our team has 
developed and characterized imaging agents targeted to cardiac GHSR. These targeted 
imaging agents aid in revealing the dynamics of the ghrelin-GHSR system with associated 
biochemical signalling in HD and HF both in situ with quantitative fluorescence 
microscopy and in vivo with PET imaging. Elucidating the role of the ghrelin-GHSR 
system in the pathophysiological process of HD and HF may aid in clinical diagnosis and 
targeted therapies.    
The hypothesis of my thesis is: 
GHSR is a biomarker for the underlying biological mechanisms involved in heart disease 
and heart failure. 
The specific aims of my thesis are: 
1) To identify GHSR as a scalable biomarker in human heart failure and heart 
disease using quantitative fluorescence microscopy 
2) To develop and characterize a targeted PET imaging agent for cardiac GHSR 
in a large animal model of myocardial infarction 
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The peptide hormone ghrelin is well-known as a potent orexigenic hormone. It stimulates 
food intake by activating hypothalamic neurons that regulate normal feeding behaviour1. 
It is the natural ligand of the growth hormone secretagogue receptor (GHSR), a seven 
transmembrane, G protein-coupled receptor, which, in addition to the hypothalamus, is 
expressed in other brain regions as well as several endocrine organs, such as the anterior 
pituitary, pancreatic islets, the intestine, thyroid, and adipose tissue. In addition, ghrelin 
and GHSR are both expressed in cardiomyocytes where they function through a system 
that is independent of their role in regulating energy expenditure2. Activation of GHSR in 
cardiomyocytes promotes excitation-contraction coupling by increasing Ca2+ flux through 
both voltage-dependent Ca2+ channels3 and the sarcoplasmic reticulum Ca2+-ATPase pump 
(SERCA2a)4–6, and promotes cardiomyocyte growth and survival through extracellular 
signaling related kinase 1/2 (ERK1/2)4,5, and phosphatidylinositol-3-kinase / Akt 
(PI3K/AKT)5,7. We6, and others3, have recently shown that levels of GHSR are decreased 
in rodent models of diabetic cardiomyopathy, thus indicating that the dynamics of ghrelin 
and GHSR change even with mild impairments in left ventricular function.  
In contrast, levels of ghrelin and GHSR are dramatically increased throughout the heart in 
patients with severe heart failure8, indicating that myocardial GHSR is altered differently 
in heart failure compared with mild cardiomyopathy. The clinical syndrome of heart failure 
(HF) is most commonly associated with significant impairment of left ventricular (LV) 
contractility, leading to elevated intra-cardiac diastolic pressures and extravasation of fluid 
into the lung parenchyma and other tissues. The early detection and treatment of HF are 
limited by two issues: a) the specific series of molecular mechanisms leading to impaired 
contractility remain elusive in patients with idiopathic cardiomyopathies, and b) the 
responses to guideline-directed medical therapies remain highly variable, such that many 
patients continue to deteriorate, leading to either the need for cardiac transplantation or 
ultimately death. Clinically, there is a critical need to prospectively identify groups of 
patients who will ultimately be at higher risk, particularly in the early stages of left 
ventricular dysfunction, when the clinical status and ventricular function are not by 
themselves consistent reliable predictors of disease progression and clinical outcomes. 
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Circulating biomarkers, such as natriuretic peptide type-B (BNP), particularly the N-
terminal form (NT-proBNP), and troponins T and I9–11, provide some prediction of the 
progression of HF, by indicating changes within the cardiomyocyte that lead to stress, 
injury and apoptosis. However, they are produced whenever heart tissue is damaged by any 
direct or indirect injury to the myocardium, and there may be discordance between tissue 
and circulating levels of these biomarkers. Therefore, there is a need to identify biomarkers 
that are localized to the myocardium that reflect the cellular and molecular processes within 
the heart that underlie the progression of HF. 
In this study, we evaluated the role of tissue ghrelin-GHSR levels as a localized biomarker 
of cardiac dysfunction in a cohort of patients who underwent cardiac transplantation. We 
examined samples from the diseased explanted heart and biopsies from the same 
individual’s engrafted heart followed through to one-year post-transplantation. In addition, 
we aimed to determine the relationship between ghrelin-GHSR and BNP to biochemical 
signaling molecules in cardiac dysfunction. Given the importance of intracellular Ca2+ 
homeostasis in atrial and ventricular contractility and the role of phospho-ERK 1/2 in 
cardiomyocyte growth, we hypothesized that changes in the ghrelin-GHSR system in 
myocardial tissue could potentially reflect derangements in cardiomyocyte contractility 










2.2.1 Patient Cohort 
Tissue samples were harvested from 10 patients who underwent cardiac transplantation at 
the London Health Sciences Center (LHSC) between 2011 and 2013. The protocol for 
sample dissections was approved by Western University’s Health Sciences Research Ethics 
Board. Samples, roughly 0.5cm to 1.5cm in length, were collected from the right atrium 
(RA) and left ventricle (LV) of the explanted/diseased heart (DH) from each cardiac 
transplant patient. Endomyocardial biopsies, roughly 0.1 to 0.3cm in length, from the right 
ventricle (RV) of the newly grafted heart were also taken at various time-points post-
transplantation (PTx), generally weekly for the first 4 weeks, monthly for months 2-6 and 
then at 1 year PTx. Not all patients had biopsies at all time points listed post transplantation 
and therefore there are missing data points at some time points stated. Patient 
demographics, cardiac function (LVEF), and medications pre- and post-transplantation are 
shown in Tables 2 and 3, respectively. All patient samples and patient data were kept 












Table 2.1 Cardiac Transplant Recipient Patient Demographics 
 
Recipient Condition Number of Patients with Condition (n of 10) 
Male gender 6 
Mean recipient age (years) 54 
Coronary artery disease 5 
Hypertension 1 
High pulmonary artery pressure 10 
Diabetes 0 
Assist Device Pre-Transplant 3 
LVEF <30% Pre-Transplant  10 
LVEF >50% 1 month Post-
Transplant 
8 










Table 2.2 Patient Medications Pre- and Post-Cardiac Transplant 
*ACE: Angiotensin Converting Enzyme; ARB: Angiotensin receptor blocker   
Medications Pre-transplant 
(n of 10) 
Post-transplant 1 
month (n of 10) 
Post-transplant 6 
months (n of 10) 
Post-transplant 
1 year (n of 10) 
ACE Inhibitor * 8 2 2 8 
Anti-arrhythmic 5 2 0 0 
ARB  0 0 0 0 
Anti-platelet 5 7 7 8 
Coumadin 7 1 0 0 
Beta blocker 10 1 0 0 
Calcium channel 
blocker  
10 2 4 3 
Digoxin 8 0 0 0 
Diuretics 10 7 2 2 
Statins 5 5 6 6 
Nitrates 0 0 0 0 
Nitroglycerin  0 0 0 0 




1 0 0 0 
Tacrolimus 0 9 10 10 
Mycophenolate 
mofetil  
0 9 9 9 
Prednisone 0 7 9 6 
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2.2.2 Immunofluorescence Microscopy 
Samples from both the explanted (diseased) and grafted hearts were frozen and embedded 
in optimal cutting temperature compound (OCT), and subsequently sectioned at 7 μm 
thickness, as previously described4,12. Immunohistochemistry using primary and 
fluorophore-conjugated secondary antibodies was conducted as previously described4,12. 
In brief, tissue sections were incubated with primary polyclonal or monoclonal 
antibodies13–22 (Table 1) for 1h at room temperature in a humidified chamber. These 
antibodies were used to identify ghrelin (1:100), BNP (1:1000), pERK1/2 (1:250); 
SERCA2a (1:300), and collagen I (1:500). Samples were rinsed twice in phosphate 
buffered solution (PBS) and incubated for 2h at room temperature with secondary 
antibodies (1:500) (Table 1). To detect GHSR, we used the far-red ghrelin peptide analog, 
Ghrelin(1-18, Lys18(Cy5), as we have previously done to quantify GHSR in situ4. This 
analog binds with high specificity to GHSR in mouse cardiac tissue samples6.  Following 
incubation with secondary antibodies, this fluorescent peptide analog was added to tissue 
sections for 30 min. Sections were washed with PBS, incubated 8 min with DAPI nuclear 
stain (1:1000), and mounted with ProLong Gold antifade (Life Technologies) to prevent 
the tissues from photobleaching. Images were captured with a Nikon Eclipse TE2000-S 
fluorescent microscope. Five random fields of view were acquired for each of 4 tissue 
sections at 20X magnification (Nikon NIS Elements v. BR 4.50.00) and used for further 
image analysis. Higher-resolution images were captured using a Nikon A1R confocal 









Table 2.3 Antibody Table – Information on Antibodies Used. 
 
Antigen Catalog # Dilution Host Reference # 
Ghrelin sc-10359 1:100 Goat 13 
Serca2A ab3625 1:300 Rabbit 14 
pERK1/2 sc-377400 1:250 Mouse 15 
BNP ab19645 1:1000 Rabbit 16 
Collagen I ab34710 1:500 Rabbit 17 
DAPI 62247 1:1000 - 18 
Alexafluor 488 A11055 1:500 Donkey anti-goat 19 
Alexafluor 594 A21207 1:500 Donkey anti-rabbit 20 
Alexafluor 594 A21203 1:500 Donkey anti-mouse 21 







2.2.3 Fibrosis Imaging 
In order to assess fibrosis, heart tissue sections were stained with Masson’s Trichrome stain 
by the core Pathology laboratory at LHSC. Sections were acquired using bright field 
microscopy at 10X, 20X or 40X magnifications with a Zeiss Axioskop EL-Einsatz 
microscope and Northern Eclipse software. Fluorescence microscopy was also used to 
acquire collagen I images as described above.   
 
2.2.4 Data Analysis 
Images of GHSR, ghrelin, BNP, SERCA2a and pERK were analyzed with FIJI v. 1.49v, a 
distribution of ImageJ software (National Institutes of Health, Bethesda). Fluorescence 
intensities of each section were quantified using a custom FIJI script that integrates raw 
density images that represent protein expression levels, as we have previously 
reported4,6,12,23,24. Briefly, thresholding was conducted for each image to determine the 
fluorescence intensity (positive pixel count above threshold minus the background). 
Fibrosis was analyzed using an online script which quantified the percentage of fibrotic 
tissue in each sample by distinguishing fibrotic tissue from non-fibrotic tissue25. Statistical 
analyses were performed using GraphPad Prism version 7.02 or IBM SPSS statistics 25, 
as follows: unpaired student t test, a one-way ANOVA with analysis of variance using 
Tukey post-hoc test to compare differences between diseased hearts and biopsies of the 
grafted hearts; Pearson correlation and logistic linear regression for correlations between 
markers: and Spearman bivariate correlation for relationships between LVEF and the 
following markers: GHSR, ghrelin, BNP, pERK1/2 and SERCA2a, all with significance 






2.3.1 Cardiac Transplant Patient Cohort 
Six of the 10 patients who underwent cardiac transplantation were male, with an overall 
mean age of 54 years (Table 2.1). Five had significant coronary artery disease pre-
transplant, and none had diabetes. All patients had elevated pulmonary artery pressures 
pre-transplant, along with severely reduced left ventricular ejection fraction (LVEF <30%) 
by echocardiographic assessment. Serial echocardiographic assessment of LV function 
following cardiac transplant showed LV improvement to an LVEF > 50% in 8 of patients 
by 1 month PTx.  By 6 months PTx, all patients had normal LV function (Table 2.1). 
Although most patients were receiving HF medications, i.e., angiotensin converting 
enzyme (ACE) inhibitors/beta blockers/diuretics, prior to transplantation, only a small 
number continued to receive these medications following surgery. Table 2.2 contains a 
complete listing of medications pre- and post-Tx.   
2.3.2 GHSR and Ghrelin Expression in Cardiomyocytes 
In any given cardiac transplant patient, the expression of GHSR and ghrelin in both LV 
and RA appeared to be elevated in the explanted heart in comparison to their expression 
PTx in the grafted heart tissue biopsies over time (Figure 2.1 A-C). By logistic regression 
analysis of all patient specimens, both pre-and post-transplant, the level of GHSR 
expression demonstrated a strong and highly significant positive linear regression with the 
level of ghrelin expression (r = 0.7817, p<0.0001). To examine associations of ghrelin and 
GHSR with cardiac dysfunction, data were divided into 2 groups of LVEF < 30% (pre-
transplant) and LVEF > 50% (post-transplant), as there were no mid-range values of LVEF.  
In the pre-transplant hearts with LVEF < 30%, expression of GHSR and ghrelin clustered 
towards the higher end of the regression line, while in grafted heart biopsies at 1 and 6 
months (LVEF > 50%), expression of GHSR and ghrelin clustered towards the lower end 
of the regression line (Figure 2.1 D). To more closely examine correlations between 
ghrelin-GHSR and cardiac dysfunction, we used a Spearman bivariate correlation test, and 
showed significant negative correlations between GHSR and LVEF (p=0.018) and ghrelin 




Figure 2.1 Ghrelin and GHSR expression in patients pre- and post- cardiac 
transplant. 
A) Representative fluorescent images of GHSR (red), ghrelin (green), and DAPI (white) 
are shown in explanted heart tissue (left) and grafted heart biopsies (right) taken from the 
same patient. B) and C) Quantified fluorescence intensity of GHSR (red) and ghrelin 
(green) is shown from explanted heart tissue (LV and RA, black dots) and grafted heart 
biopsies (Bi 1-10, coloured dots). D) Positive linear regression of GHSR and ghrelin 
expression is shown in the entire cardiac transplant cohort with EF <30 in green and EF>50 
in red with white dots representing tissue samples without related EF values. Each dot 
represents one transplant patient sample. E) Negative correlation between LVEF and 
GHSR (red) and ghrelin (green). LV: Left Ventricle; RA: Right atrium; Bi 1 – Bi 10: 
Biopsy 1 – Biopsy 10; EF: ejection fraction.   
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2.3.3 Metabolic Markers in Cardiac Tissue 
The expression of metabolic markers in cardiac tissue that are associated with cardiac 
dysfunction were measured by immunofluorescence microscopy. We measured the 
following markers: a) SERCA2a, as an index of cardiomyocyte contractility, b) pERK1/2, 
as a marker of cardiomyocyte growth/hypertrophy, and c) BNP, as a validated clinical tool 
used to determine the presence and degree of HF.  Representative images of SERCA2a, 
pERK1/2 and BNP expression are shown in Figures 2.2A and 2.3A, respectively. The 
expression of SERCA2a was significantly elevated in cardiac tissue from the RA of the 
diseased heart (Figure 2.2 B) when compared to its expression in endomyocardial biopsies 
taken at weeks 1, 2, and 3 PTx by 3.2, 2.4, and 2.7 fold, respectively. However, there was 
no significant difference in SERCA2a expression in the RA after the first month PTx. There 
were also no significant differences in the expression of SERCA2a in the LV tissue of the 
diseased heart when compared to the PTx endomyocardial biopsies. pERK1/2 expression 
was significantly increased in the cardiac tissue of the diseased heart taken from the RA by 
1.8-3.1-fold and LV by 1.7-2.9-fold when compared to the grafted heart tissue biopsies 
taken at any time-point PTx (Figure 2.2 C). The degree of BNP expression (Figure 2.3B) 
showed similar trends as for GHSR and ghrelin. Logistic regression analyses were 
performed to determine the association between SERCA2a, pERK1/2, GHSR and ghrelin 
levels (Figure 2.2D-H). Highly significant and strong positive linear regressions were 
found between pERK1/2 and SERCA2a (r = 0.6867, p<0.0001), pERK1/2 and ghrelin (r = 
0.5719, p<0.0001), and SERCA2a and ghrelin (r = 0.7171, p<0.0001). By contrast, there 
was a much weaker linear regressions between SERCA2a and GHSR (r = 0.2320, 
p=0.0483), and there was no linear regression between pERK1/2 with GHSR. Logistic 
regression analyses were performed between all metabolic markers and BNP to determine 
any possible relationships (Figure 2.3 C-F). There was a positive linear regression between 
ghrelin and BNP (r = 0.6782, p<0.0001), and SERCA2a and BNP (r = 0.4838, p<0.0001). 
However, there were weak linear regressions between GHSR and BNP (r = 0.2423, 
p=0.0282), and pERK1/2 and BNP (r = 0.2745, p=0.0196). Spearman bivariate correlations 
(correlation coefficients, CorC) were calculated as above and indicated highly significant 
negative associations between LVEF and SERCA2a (p<0.001, CorC = -0.63), and pERK 




Figure 2.2 Cardiac metabolic markers in patients pre- and post-cardiac transplant in 
entire transplant patient cohort.  
A) Representative fluorescent images of pERK1/2 (green) and SERCA2a (red) are shown 
from explanted heart tissue (left) and grafted heart biopsies (right) samples taken from the 
same patient. B and C) Quantified fluorescence intensity of pERK1/2 (green) and 
SERCA2a (red) are shown for explanted heart tissue (LV and RA, black dots) and grafted 
heart biopsies (Bi 1-10, coloured dots). D-H) Positive linear regression is seen in the entire 
cardiac transplant cohort for pERK1/2 vs SERCA2a, pERK1/2 vs ghrelin, SERCA2a vs 
ghrelin, pERK1/2 vs GHSR, and SERCA2a vs GHSR. Each dot represents one transplant 
patient sample. LV: Left Ventricle; RA: Right atrium; Bi 1 – Bi 10: Biopsy 1 – Biopsy 10. 
*p<0.05 from RA; ** p<0.01 from RA; *** p<0.001 from RA; **** p<0.0001 from RA; 




Figure 2.3 BNP expression in patients pre- and post-cardiac transplant.  
A) Representative fluorescent images of BNP are shown from explanted heart tissue (left) 
and grafted heart biopsies (right) taken from the same patient. B) Quantified fluorescence 
intensity of BNP is shown in explanted heart tissue (LV and RA, black dots) and grafted 
heart biopsies (Bi 1-10, coloured dots). C-F) Positive linear regression is shown in the 
entire cardiac transplant cohort for ghrelin vs BNP, BNP vs GHSR, pERK1/2 vs BNP, and 
SERCA2a vs BNP. Each dot represents one transplant patient sample. LV: Left Ventricle; 
RA: Right atrium; Bi 1 – Bi 10: Biopsy 1 – Biopsy 10.    
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2.3.4 Cardiac Fibrosis 
Cardiac fibrosis was determined in all patient samples using Masson’s trichrome stain 
which measured the presence of collagen I and III (in blue) and compared that to the non-
fibrotic tissue (in red). Quantification of fibrosis is illustrated in Figure 2.4 A, and revealed 
a high degree of variability both between and within patients from one time point to another 
(Table 2.4). Representative images showing the high degree of variability between patients 
taken from a single time-point are shown in Figure 2.4 B where significant fibrosis was 
seen in one patient with large amounts of collagen I and II (blue) and minimal fibrosis was 
seen in another patient at the same time-point To determine whether GHSR tissue levels 
were contributed to by fibrosis, cardiac tissue was examined for colocalization between 
collagen I and GHSR by fluorescence microscopy (Figure 2.5 A and B). These analyses 
showed no colocalization between collagen I and GHSR in the human tissue samples 













Figure 2.4 Cardiac fibrosis in patients pre- and post-cardiac transplant.  
A) Quantified fibrotic data are shown for explanted heart tissue (LV and RA, black dots) 
and grafted heart biopsies (Bi 1-10, coloured dots). B) Representative images of the fibrotic 
variability between patients showing high levels of fibrosis (top) and low levels of fibrosis 
(bottom) where blue is fibrotic tissue (collagen I and III) and red is healthy cardiac tissue. 
Images of the RA, Bi 1, Bi 4, Bi 10 showing different patients at same time point pre- and 





Figure 2.5 Fibrosis and GHSR in human myocardial tissue.  
Representative images from grafted heart biopsy 1 showing the same patient sample in all 
images. A and B show no colocalization of GHSR (red) and collagen I (green) with DAPI 
showing nuclei (blue). C and D show Masson’s trichrome staining of same patient sample 
as in A and B where blue is fibrotic tissue (collagen I and III) and red is healthy tissue. A 







Table 2.4 Fibrosis Percentages of explanted hearts and healthy implanted heart 
biopsies.  
(RA and LV of explanted heart; Biopsy 1-10 of grafted heart). All values listed in 
percentages (%). 
 
 LV RA Bi 1 Bi 2 Bi 3 Bi 4 Bi 5 Bi 6 Bi 7 Bi 8 Bi 9 Bi 10 
Patient 1 26.1 10.6 1.3 2.9 5.4 1.5 15.8 2.2 1.3 - - - 
Patient 2 24.6 6.0 19.1 3.8 3.8 5.7 - - - - - - 
Patient 3 - 7.0 3.9 11.4 22.2 0.9 - - - 3.6 2.2 - 
Patient 4 2.6 32.5 1.2 0.3 - 3.9 4.6 - - 13.1 - - 
Patient 5 53.6 - 2.4 7.3 3.9 1.3 - - - - - - 
Patient 6 3.7 7.8 2.4 38.0 1.3 - - - 4.1 5.9 2.3 11.7 
Patient 7 5.5 - 39.4 2.9 2.7 3.1 17.4 3.5 1.8 6.1 6.4 0.3 
Patient 8 7.6 1.6 10.7 1.1 6.9 3.6 0.9 1.3 2.8 0.3 6.6 3.6 
Patient 9 - 21.9 8.9 6.1 3.5 - 1.2 2.3 - 17.3 - - 






This study is the first comprehensive and longitudinal study to examine tissue GHSR, 
ghrelin and subsequent downstream biochemical signaling molecules involved in 
cardiomyocyte contractility and growth, over time, in the same patients with two different 
hearts. Our findings have demonstrated a relationship between cardiac function, as 
measured by LVEF, and the expression of both ghrelin and GHSR, suggesting that the 
cardiac ghrelin-GHSR system may represent a new cardiac-localized biomarker in HF. Our 
findings further showed an association between some signaling proteins and their 
relationship to LVEF. Our results demonstrate relationships between GHSR, ghrelin, and 
biochemical signaling molecules in human cardiac tissues and their relationship to LV 
function, therefore providing substantial new findings related to this myocardial ghrelin-
GHSR system.  
Currently the “gold standard” cardiac biomarkers of heart failure are BNP and NT-proBNP, 
which are markers of myocardial stress. Historically, past studies using BNP have  focused 
on characterizing HF with reduced EF as associated with and directly linked to elevated 
circulating BNP levels11,26. More recent studies have also attempted to understand the 
mechanisms leading to HF in the setting of preserved EF. To explore this and other 
etiologies of HF, a variety of biomarkers including hormones (growth hormone)27,28, 
extracellular matrix proteins (matrix metalloproteinase, galectin-3); oxidative stress 
proteins (8-hydroxy-2,-deoxyguanosine, neopterin); and inflammatory molecules (c-
reactive protein, pentraxin 3)29 have been identified and their association with the presence 
and degree of heart failure investigated. Further, circulating biomarkers of HF continue to 
be discovered through proteomic and gene sequencing of blood serum analyses30–32. Many 
novel serum biomarkers are currently being identified33,34, and the ghrelin-GHSR system 
may provide a complementary cardiac tissue-localized indicator of LV function in HF. 
Certainly, biomarkers that are intimately involved in the different pathological processes 
in HF would help to both enhance diagnosis and might have the potential to optimize 
targeted therapies29,35. We propose that the ghrelin-GHSR system represents the first 
cardiac-localized indicator of HF.  
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A prior study has also shown that levels of myocardial GHSR are elevated in chronic heart 
failure in humans8. In contrast to our findings, where both GHSR and ghrelin were 
elevated, that study also reported a decrease in ghrelin expression in chronic heart failure. 
The difference in the degree of ghrelin expression between these two studies may be due 
to the different tissues being compared. Beiras-Fernandez et al8 compared tissue obtained 
from HF patients to those obtained from young adult subjects with no previous history of 
heart disease. In contrast, our study compared levels of GHSR and ghrelin at end stage HF 
with serial biopsies from the engrafted heart under the effects of immunosuppressive 
therapy taken up to a year after transplant surgery. Furthermore, there were significant 
relationships between LVEF and tissue ghrelin and GHSR levels in two hearts from the 
same patient. Similar to Beiras-Fernandez et al, our sample size is relatively small, and 
may provide challenges in making broad generalizations on increases or decreases in the 
cardiac ghrelin-GHSR system. Now that we have established that higher levels of GHSR 
and ghrelin associate with LVEF in the very low range, these results set the stage for a 
larger study examining changes in cardiac GHSR and ghrelin in patients with a range of 
LVEF values that reflect the evolution of heart failure.  
Strong positive linear regressions between GHSR and ghrelin were present in the entire 
patient cohort as shown in Fig 2.1D indicating the potential regulation of this ghrelin-
GHSR system in human HF. Additionally, we examined linear regressions between GHSR 
and ghrelin in both the end-stage HF and engrafted heart biopsies separately (Supplemental 
Fig 2.S1) where there are still highly significant positive linear regressions in both these 
individual cohorts. This may provide information about the engrafted heart as this ghrelin-
GHSR system is still increased up to 1 year after cardiac transplantation. Other cardiac 
markers, such as BNP, are known to be chronically elevated after transplantation which 
demonstrates ongoing active cardiac structural remodeling, vascular injury, and 
inflammation in the engrafted heart36. The correlation of the ghrelin-GHSR system in 
engrafted heart biopsies may provide more information on the biochemical processes that 
are activated in the engrafted heart after cardiac transplantation. 
Ghrelin is produced in a variety of cardiovascular cell types, including endothelial cells, 
inflammatory cells and cardiomyocytes37. Ghrelin down-regulates pro-inflammatory and 
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up-regulates anti-inflammatory signalling pathways in attenuating cardiac hypertrophy38, 
post-infarct cardiac remodeling39, and sepsis40. Although we did not study inflammatory 
signalling pathways, it is possible that the higher levels of ghrelin-GHSR in the diseased 
heart may indicate up-regulation in response to the inflammatory environment of heart 
failure. The post-transplant immunosuppressive regimen may also affect myocardial 
ghrelin levels and ghrelin-GHSR signalling, particularly through anti-inflammatory 
pathways. 
Circulating ghrelin may also be a potential single biomarker of HF, and from a prognostic 
perspective, a level of 85 pmol/l or higher was predictive of increased survival 41. However, 
circulating ghrelin levels are also elevated in the fasting state, and  are decreased in both 
the elderly population and with patients who have a higher BMI42, therefore skewing this 
prognostic cut-off level. While we did not obtain blood samples for measurement of 
circulating ghrelin, our data in cardiac tissue samples provide the first direct measure of 
the ghrelin-GHSR system being elevated in the human myocardium. These data further 
strengthen the case for the use of ghrelin-GHSR as a novel cardiac-localized biomarker of 
HF. However, how tissue levels of ghrelin-GHSR change with age or BMI in humans is 
not known. 
As mentioned above, circulating BNP and NT-pro BNP are the currently used clinical 
biomarkers of HF, as levels rise with decreasing LVEF43–45. Our results indicate that levels 
of BNP in human cardiac tissue trend towards an increase when LVEF is in the very low 
range and was more strongly correlated with LVEF than was ghrelin, suggesting that tissue 
levels of BNP could also be a sensitive biomarker for severe HF. Interestingly, in our study, 
levels of both GHSR and ghrelin were also associated with LVEF, indicating that the 
ghrelin-GHSR system may also be a good cardiac biomarker of LV function. As discussed 
below, ghrelin showed stronger correlations with biochemical signalling molecules, 
indicating that tissue ghrelin is more closely associated than is BNP with the biochemical 
mechanisms that underlie the development of HF. 
To better understand the potential mechanisms underlying HF, we examined the 
downstream signaling pathways that link the ghrelin-GHSR system to cardiomyocyte 
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contractility and growth. The significant elevation of pERK1/2 levels we observed in end-
stage HF is consistent with the reported elevations in pERK1/2 in cardiac tissue in mouse 
and rat models of HF46. Signalling through pERK1/2 is associated with pressure overload-
induced myocardial hypertrophy, and thus indicates maladaptive alterations under 
conditions of persistent myocardial stress. Interestingly, ghrelin and GHSR gene variants 
are also associated with LV hypertrophy47,48. Therefore, our data suggest a new upregulated 
ghrelin-GHSR-pERK1/2 pathway that may mediate HF in humans through myocardial 
hypertrophy. 
The strong positive correlation between ghrelin and SERCA2A is in accordance with the 
role of ghrelin in the improvement of Ca2+ dynamics in cardiomyocytes isolated from 
rodents with ischemia-reperfusion myocardial injury49. In this study, activation of GHSR 
by either ghrelin or hexarelin increased SERCA2a expression and activity through 
increased phosphorylation of its regulatory binding protein, phospholamban, thus 
replenishing Ca2+ stores in the sarcoplasmic reticulum. However, our results indicating that 
SERCA2a levels are actually elevated in end-stage HF are in sharp contrast to the literature 
documenting a decrease in SERCA2a expression and activity in the failing human 
myocardium50. In contrast to the literature, we compared SERCA2a expression between 
end-stage heart disease and engrafted hearts, and not to healthy controls. The relative 
decrease in SERCA2a expression in biopsies taken at earlier time points may reflect a 
subclinical immune response, as a recent study has suggested that decreases in tissue 
SERCA2a correlate with graft rejection51.  
Cardiac fibrosis due to a deposition of extracellular matrix proteins including fibroblasts 
and collagen, occurs in all etiologies of heart disease and heart failure and is a marker of 
increased heart failure severity52,53. Our results indicate increased collagen I and III 
deposition in the diseased hearts, although there was significant variability both between 
and within patients. The variability could be a consequence of sampling location; a high 
presence of fibrosis in the apparently healthy implanted hearts likely indicates a 
considerable degree of geographic heterogeneity within any given patient’s heart. 
Traditionally biopsies are acquired from the RV, as what was done here, although a recent 
study found LV biopsies to be not only possible with low risk via radial access, but 
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preferable for determination of heart function through immunohistochemistry and 
molecular analyses54. In our study, values of RV used a surrogate measure of LV 
dysfunction as RV failure is commonly associated with LV dysfunction and these biopsies 
were collected with preserved LV function (seen with preserved LVEF). Since there was 
such a large degree of variability in the amount of fibrotic tissue in both pre-transplant 
hearts and grafted heart tissue, there was a possibility that GHSR expression originated 
within the fibrotic tissue, thus potentially skewing our results. However, we have shown 
that GHSR was found only in non-fibrotic tissue; therefore, the variability in expression 
likely lies in HF type and severity, and not in sampling location. Since the diseased heart 
tends to have larger amounts of collagen deposition, the positive fluorescent signal is only 
originating from a limited, non-fibrotic component of the whole tissue section. Therefore, 
the measurement of GHSR which we used was affected by the extent of collagen deposition 
within any given sample, with samples with higher degrees of fibrosis having an artificially 
depressed measurement of “myocardial” levels.   
The present study characterized changes in myocardial GHSR and ghrelin before and after 
cardiac transplantation. The engrafted hearts were subjected to immunosuppressive 
therapy, and we did not measure the degree of inflammation or subclinical indicators of 
rejection in these biopsies. However, that four of these patients were followed up to a year 
after transplant, with normal EFs, and no dramatic changes in GHSR, ghrelin, SERCA2a, 
pERK1/2 and fibrosis from the first through to the last biopsy, suggests a normally 
functioning and stable engrafted heart during this time period. Our next step is to 
characterize the ghrelin-GHSR system in cardiac tissue obtained from human donors with 
no history of heart disease. 
Overall, we have identified the ghrelin-GHSR system as a cardiac-localized biomarker of 
cardiac dysfunction in human heart failure. This system was demonstrated to have a higher 
sensitivity to the downstream signaling molecules linked to cardiomyocyte contractility 
and hypertrophy when compared to BNP, the gold standard biomarker of HF used 
clinically. Cardiac fibrosis was highly variable both within and between patients and GHSR 
was not expressed in fibrotic tissue. We are currently examining the expression and 
relationship of ghrelin-GHSR signaling that contribute to defective cardiomyocyte 
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programming in other types of heart disease in humans, as well as in healthy human hearts. 
Our ongoing work will help to identify the role of myocardial ghrelin-GHSR as a 
biomarker that may be used to determine the progression of HF at earlier stages.     
    
 
 
2.5 Supplemental Figures 
 
Supplemental Figure  2.S1 Ghrelin and GHSR Correlation in End-Stage HF and 
Engrafted Heart Biopsies. 
Positive linear regression of GHSR and ghrelin expression is shown separated out into 
end-stage HF and in engrafted heart biopsies where string significance of p=0.0001 is 
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Ghrelin is a peptide hormone that has well-known orexigenic effects on the body. Ghrelin 
is an endogenous 28 amino acid peptide that is a natural ligand of the growth hormone 
secretagogue receptor (GHSR) 1a, a seven transmembrane G-protein coupled receptor. 
More recently, ghrelin has been studied for its effects and role in cardiac energetics through 
activation of myocardial GHSR. Specifically within cardiomyocytes, the binding of ghrelin 
to GHSR activates downstream signalling pathways that lead to cardioprotective effects, 
such as maintenance of contractility1,2, suppression of inflammation3,4, and promotion of  
growth and survival5. Cardiac GHSR activation promotes excitation-contraction coupling, 
increasing Ca2+ flux through the sarcoplasmic reticulum ATPase pump (SERCA2a) and 
the voltage gated Ca2+ channels, which produces a positive inotropic effect and protects 
against ischemia/reperfusion injury in cardiomyocytes2. Ghrelin also regulates 
inflammation in the heart through the protein kinase B (Akt) pathway, decreasing 
expression of the pro-inflammatory markers6 IL1-β, TNF-α, and IL-6, and upregulating the 
tumour necrosis factor α/ nuclear factor kappa-light-chain-enhancer of activated B cells 
(NFκB) pathways3. Ghrelin has been shown to protect the heart through the toll like 
receptor 4 pathway (TLR4)4. Apoptosis is decreased upon GHSR activation through 
extracellular signal-related kinases 1/2 (ERK1/2) and Akt serine kinases5,6 and inhibition 
of caspase-3 and 97. Fibrosis deposition is also minimized in the heart after ghrelin 
administration8,9. Therefore, the ghrelin-GHSR system within the myocardium plays a 
critical role in the maintenance of cardiomyocyte function and survival. 
The discovery of the myocardial ghrelin-GHSR system and its role in cardiomyocyte 
function and health has prompted studies on its dynamics in heart failure and 
cardiomyopathy. We and others have shown that myocardial GHSR is elevated in heart 
failure (HF)10,11. Additionally, we showed that the cardiac ghrelin-GHSR system was 
abnormally up-regulated in end-stage HF compared to endomyocardial biopsies from 
engrafted hearts11, thus suggesting that tissue levels of ghrelin and GSHR could be 
indicators of the health of transplanted hearts. In contrast, one study has reported decreased 
GHSR in tissue from patients with dilated cardiomyopathy, which negatively correlated 
with LVEF12. We13 and others14 have shown that tissue GHSR also decreased in mouse 
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models of diabetic cardiomyopathy, suggesting that the dynamics of the myocardial 
ghrelin-GHSR system may differ in earlier stages of myocardial decompensation as  
compared with end-stage heart failure.  
Some potential causes  of heart failure include coronary artery disease (an accumulation of 
cholesterol (plaques) in the vessel walls) or aortic stenosis (progressive restriction of the 
opening of the aortic valve)15, and there has been some clinical  investigation into 
correlations with serum ghrelin levels and the effects of ghrelin administration on heart 
function in these conditions. In humans with coronary artery disease and with diabetes-
associated coronary atherosclerosis, serum levels of ghrelin decreased significantly 
compared to healthy controls16,17. Another study also showed an inverse relationship 
between serum ghrelin and coronary artery disease (CAD) detected by angiography that 
was independent of other cardiovascular risk factors16, suggesting that a reduction in 
ghrelin-GHSR signalling may be correlated with progressively more severe CAD.  Ghrelin 
administration in rats with aortic stenosis reduced calcification buildup in the myocardium 
in a dose-dependent manner18, and attenuated aortic calcium deposition both in vivo and in 
vitro19. Therefore, investigating the dynamics of the ghrelin-GHSR system and signaling 
within cardiomyocytes may provide further insight into the potential use of ghrelin as a 
therapy for myocardial dysfunction (heart failure).   
In this study, towards the goal of determining the potential of ghrelin-GHSR as a biomarker 
of heart disease, we examined their levels in a cohort of patients who underwent elective 
cardiac valve replacement surgery and compared their expression levels to control heart 
tissues. We also determined the correlation of ghrelin-GHSR with an array of biomarkers 
including natriuretic peptide type-B (BNP), sarcoplasmic reticulum ATPase (SERCA2a), 
and toll-like receptor 4 (TLR4). With these data, we hope to obtain further insights into the 





3.2.1 Patient Cohort 
Tissue samples were harvested from 25 patients who underwent aortic valve replacement 
surgery for aortic stenosis at the London Health Sciences Center (LHSC) between 2013 
and 2014. Twenty-four of these patients had aortic stenosis and one had mitral valve 
impairment. Of these 25 patients, 11 concurrently had coronary artery disease and received 
coronary artery bypass grafts. Sixteen patients were male and nine were female, with an 
overall average age of 66 years. Twenty-three patients had normal ejection fractions 
(>45%) prior to surgery, and two patients had reduced ejection fractions (35-40%). The 
protocol for obtaining tissue samples was approved by Western University’s Health 
Sciences Research Ethics Board. Tissue samples, roughly 0.2cm to 0.5cm in length, were 
collected from the left atrium (LA) and left ventricular (LV) myocardium from each 
patient. The left atrial samples were obtained from the posterior left atrial wall just on the 
left atrial side of the inter-atrial septum (close to the right atrium but technically the left 
atrium). The left ventricular samples were taken from the posterior left ventricular wall, 
just below the mitral valve. Patient demographics, cardiac function (LVEF), and 
medications are shown in Tables 3.1 and 3.2. All patient samples and patient data were 
kept anonymous and all biomarker analyses were completed prior to receiving clinical data.   
In order to provide a reference non-diseased control, paraffin-embedded and sectioned 
samples of cardiac tissue (n=10) were obtained from the tissue archives of the Department 
of Pathology, London Health Sciences Centre. These tissue samples had been obtained 
from the LV of patients who had died from non-cardiac causes at the time of post-mortem, 
24-48 h after the patient was pronounced dead. Of these 10 patients, 5 were male and 5 
were female. The average age of all ten patients was approximately 59 years. Analysis of 
these tissues was compared to the analysis derived from the surgery patients for overall 






Table 3.1 Cardiac Surgery Patient Demographics. 
 
Patient Condition Number of Males with 
Condition (n of 16) 
Number of Females with 
Condition (n of 9) 
Age range (years) 49 – 84 45 – 77 
Mean age (years) 69 60 
Coronary artery disease 9 2 
Moderate – Severe Aortic 
Stenosis 
14 8 
Hypertension 8 2 
High pulmonary artery 
pressure 
10 7 
Diabetes 2 1 
LVEF <45%  2 0 
LVEF >45%  14 9 
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Table 3.2 Patient Medications Post-Heart Surgery. 
 
Patient Medication Number of Males with Use 
(n of 16) 
Number of Females with 
Use (n of 9) 
ACE Inhibitor 1 2 
Anti-arrhythmic 1 2 
Angiotensin receptor 
blocker (ARB)  
6 1 
Coumadin 4 2 
Beta blocker 5 5 
Calcium channel blocker  2 3 
Diuretics 8 3 






3.2.2 Quantitative Fluorescence Microscopy 
Samples were fixed, frozen and embedded in optimal cutting temperature compound 
(OCT), and subsequently sectioned at 6-7 μm thickness, as previously described20,21. 
Immunohistochemistry using primary and fluorophore-conjugated secondary antibodies 
was conducted as previously described20,21. In brief, tissue sections were incubated with 
blocking buffer in 10% serum for 30 minutes at room temperature followed by incubation 
with primary polyclonal or monoclonal antibodies (Table 3.3) for 1h at room temperature 
in a humidified chamber. These antibodies were used to identify ghrelin (1:100) [Santa 
Cruz Biotechnology], BNP (1:1000) [Abcam], SERCA2a (1:300) [Abcam], and TLR4 
(1:250) [Abcam]. Samples were rinsed twice in phosphate buffered saline (PBS) and 
incubated for 2h at room temperature with secondary antibodies (1:500) (Table 3.3). To 
detect GHSR, we used the far-red ghrelin peptide analog, [Dpr3(n-octanoyl),Lys19(sulfo-
Cy5)]ghrelin(1-19), referred to as Cy5-ghrelin(1-19), as we have previously done to 
quantify GHSR in situ21. This analog binds with high specificity to GHSR in mouse and 
human cardiac tissue samples11,13. After incubation with secondary antibodies, Cy5-
ghrelin(1-19) was added to tissue sections for 30 min. Sections were washed twice with 
PBS, incubated 8 min with DAPI nuclear stain (1:1000), and mounted with ProLong 
Diamond antifade (Life Technologies) to prevent the tissues from photobleaching. N 
numbers for each biochemical marker were different due to the limited amount of tissue 
available at the time of staining.  
For control cardiac tissue, all sections were deparaffinized with decreasing concentrations 
of alcohol solutions (95%-70%). Samples were then stained as previously stated for the 
following biomarkers: ghrelin (1:100) [Santa Cruz Biotechnology], BNP (1:1000) 







Table 3.3 Antibody Table – Information on Antibodies Used. 
 
Antigen Catalog Number Dilution Host 
Ghrelin sc-10359 1:100 Goat 
BNP ab19645 1:1000 Rabbit 
SERCA2a ab3265 1:300 Rabbit 
TLR4 ab22048 1:250 Mouse 
DAPI 62247 1:1000 
-  
Alexa Fluor 488 A11055 1:1000 Donkey anti-goat 
Alexa Fluor 594 A21207 1:1000 Donkey ant-rabbit 
Alexa Fluor 488 A21206 1:1000 Donkey anti-rabbit 






3.2.3 Background Subtraction for Fluorescence Microscopy 
Imaging  
To ensure specificity of the fluorescent signal for GHSR, background subtraction was 
performed, as GHSR has a diffuse staining pattern. To calculate the background signal, 
tissue sections were first incubated with 100µM hexarelin, a GHSR ligand22 known to 
competitively displace Cy5-ghrelin(1-19)21, for 1 hour at room temperature prior to 
incubation with 10µM Cy5-ghrelin(1-19) as described above. Tissues were then stained 
for DAPI (1:1000), washed and mounted with ProLong Diamond antifade as described 
above. For control tissue samples, background fluorescence intensity values were 
calculated in 5 separate control samples, and the average value of these intensities was 
subtracted from the total fluorescence intensities of GHSR in each of the 10 original tissue 
samples. For diseased tissue samples, background values were calculated from 5 fields of 
view in one slide from each patient, and the average value of this slide was calculated as 
the background fluorescence. These values were subtracted from the total fluorescence 
intensities of non-blocked tissue from that patient to obtain specific Cy5-ghrelin(1-19) 
signal in the diseased tissue.  
 
3.2.4 Image Acquisition and Analysis 
High resolution images of both the diseased and control tissues were captured with a Nikon 
A1R Confocal Microscope at 60x magnification using an oil immersion lens. Five random 
fields of view were acquired for each of 2 tissue sections per patient sample with the 
exposure time, gain and high/ow look up tables set the same for all tissue sections. 
Therefore, each patient sample (reported as data points in all graphs) reflects an average of 
2 technical replicates.  
Images of GHSR, ghrelin, BNP, SERCA2a, and TLR4 were analyzed with FIJI 1.49v, a 
distribution of ImageJ software (National Institutes of Health, Bethesda). Algorithms built 
into ImageJ were used to quantify different staining patterns in the tissue. Punctate staining 
patterns were quantified using the RenyiEntropy algorithm, an entropy-based approach that 
distinguishes the positive punctate signals within the cells from the background. The 
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integrated density represents the mean intensity of the positive signal above a certain 
threshold in scaled units divided by the area in pixels. The integrated density threshold was 
set such that the entropies of distributions above and below the set threshold are 
maximized. Therefore, this algorithm only captured the high intensity punctate staining 
patterns and did not calculate any background staining of these images. A representation 
of what the algorithm identified as positive versus background is shown in Supplemental 
Figure 3.S1.  
For diffuse staining patterns, the Li algorithm was used to quantify the specific 
fluorescence signal after background subtraction as described above. All images for diffuse 
staining were quantified using the built-in ImageJ Li algorithm with the integrated density 
(stated above) determined for each tissue.  
 
3.2.5 Fibrosis Imaging 
To assess fibrosis, heart tissue sections were stained with Masson’s Trichrome stain by the 
core Pathology Laboratory at LHSC. Sections of both the diseased and control tissue were 
acquired using bright field microscopy at 10X and 20X magnifications with a Zeiss 
Axioskop EL-Einsatz microscope and Northern Eclipse software as described 
previously11,13. Images were acquired for the entire tissue section and quantification was 
performed on the entire tissue.  
Fibrosis was analyzed using an online script in the program ImageJ Fiji which quantified 
the percentage of fibrotic tissue in each sample by distinguishing fibrotic tissue (blue) from 
non-fibrotic tissue (red), as previously described23. Briefly, this script divides the RBG 
image into each of its channels which thresholds the image for positive pixels in either the 
red or blue channels. All tissue sections were set at the same threshold for both the fibrotic 
and non-fibrotic tissue. The fibrosis was then quantified based on the fibrotic tissue 
compared to the total area of tissue to determine the average percentage of fibrosis in each 




3.2.6 Data Analysis 
Data from biomarkers (GHSR, ghrelin, BNP, SERCA2a, and TLR4) were disaggregated 
by cardiac region using a post-hoc analysis. Statistical analyses were performed using 
GraphPad Prism version 8. Unpaired student t-tests were used to compare overall 
biomarker expression differences between the diseased and control tissue. Within the 
diseased tissue cohort, a one-way analysis of variance (ANOVA) with analysis of variance 
using Tukey post-hoc test was used to determine regional differences. Linear regression 
was used to determine correlations between the following biomarkers: GHSR, ghrelin, 
BNP, SERCA2a and TLR4. Linear regression analysis was used to compare biomarker 
fluorescence intensities based on the following categories: entire patient cohort and 
regional differences (left atrium and left ventricle). Pearson correlation was used to 
determine colocalization between ghrelin and BNP in both diseased (LA and LV) and 
control tissue. All statistical analyses were completed with significance set at p<0.05.  
 
3.3 Results 
3.3.1 Cardiac Surgery Patient Cohort 
Of the twenty-five patients who underwent cardiac surgery, 16 were male and 9 were 
female with mean ages of 69 and 60 respectively (Table 3.1). The patients had a range of 
moderate to severe aortic stenosis while 11 also had coronary artery disease. In the patients 
with coronary artery disease, there were no linear regressions between any markers 
evaluated in this study (GHSR and ghrelin – r=0.3942 p=0.1826; GHSR and BNP – 
r=0.0596 p=0.8467; ghrelin and BNP – r=0.1769 p=0.8850; SERCA2a and GHSR – 
r=0.4132 p=0.2354; SERCA2a and ghrelin – r=0.5175 p=0.1256; SERCA2a and BNP – 
r=0.4315 p=0.2131). Sixteen patients had elevated estimated pulmonary artery pressures, 
based on their pre-operative echocardiograms and only two patients had a reduced ejection 
fraction prior to surgery (30-40%). After cardiac surgery, 10 patients were on beta blockers, 




3.3.2 Correlations Between GHSR and Ghrelin in Diseased 
Cardiac Tissue 
Fluorescence intensities of both GHSR and ghrelin were variable in any given cardiac 
tissue sample in both the diseased and control cohort (Fig 3.1A & C). Overall GHSR 
expression was not significantly different between the diseased and control groups (Fig 
3.1B) while tissue ghrelin was significantly lower (p<0.0001) in the diseased cohort in both 
the LA and the LV (Fig 3.2 D). Linear regression analysis of GHSR vs. ghrelin showed a 
positive relationship in the overall cardiac surgery cohort (r = 0.3995; p=0.0318) (Fig 3.2 
C). Regionally, this linear regression persisted only in the left atrium (r = 0.4859; 
p=0.0299) and not in the left ventricle (r = 0.01730; p=0.7562) (Fig 3.2D). There was no 
significant linear regression between GHSR and ghrelin in the control tissues (r = 0.1105; 





Figure 3.1 Representative confocal fluorescence images of all biomarkers. 
(A) [Dpr3(n-octanoyl),Lys19(sulfo-Cy5)]ghrelin(1-19): red, (C) ghrelin: green, (E) BNP: 
magenta, (G) SERCA2a: green, (I) toll-like receptor 4 [TLR4]; red) in the control tissue 
left ventricle (LV; left column) and diseased tissue LV (middle column) and LVA (right 
column). All images indicate DAPI nuclear stain in blue. Graphs represent quantification 
of fluorescent images as means  95% CI of integrated densities for each biomarker with 
each dot representing one patient sample. There were no significant differences in 
fluorescence intensities of (B) Cy5-ghrelin(1-19) [control LV n=10, LV n=9, LA=20], (F) 
BNP [control LV n=10, LV n=9, LA=20], (H) SERCA2a [control LV n=10, LV n=9, 
LA=17] or (J) TLR4 [control LV n=10, LV n=8, LA=12]. There was a significant decrease 
in the fluorescence intensities detecting (D) ghrelin (p<0.0001) [control LV n=10, LV n=9, 




Figure 3.2 GHSR and ghrelin fluorescence intensity in human cardiac tissue. 
(A) Representative confocal images of [Dpr3(n-octanoyl),Lys19(sulfo-Cy5)]ghrelin(1-19) 
(red), and ghrelin (green) in diseased control left ventricle (LV, top), diseased LV (middle) 
and diseased LA (bottom). DAPI (blue) indicates nuclear localization in cardiomyocytes. 
Graphs indicate quantification of integrated densities using linear regression between Cy5-
ghrelin(1-19) and ghrelin. In control tissue, there was no linear regression between Cy5-
ghrelin(1-19) and ghrelin (p=ns) [n=10] (B). Linear regression between Cy5-ghrelin(1-19) 
and ghrelin (r = 0.3995; p=0.0318) in the entire patient cohort [n=29] where each dot 
represents one patient sample (C). Regional analysis showed a significant linear regression 
of Cy5-ghrelin(1-19) and ghrelin in the LA (r = 0.4859; p=0.0299) [n=20] but not the LV 




3.3.3 Relationship of BNP to GHSR and Ghrelin in Diseased 
Cardiac Tissue 
Fluorescence images indicated the localization of BNP within the diseased and control 
heart tissue (Figure 3.1E). Analysis of these images indicated no significant difference in 
immunofluorescence (p=ns) in the disease cohort compared to the control tissues (Fig 
3.1F). Linear regression analysis indicated a strong and significant positive relationship 
between BNP and GHSR (r = 0.5633; p=0.0034); this relationship was strong within the 
LA (r = 0.6751; p=0.0029) but not the LV (r = 0.0127; p=0.9784) (Fig 3.3 C – D). There 
was also a significant positive relationship between BNP and ghrelin in the entire cohort (r 
= 0.5008; p=0.0108). This relationship, however, differed by region: LV (r = 0.9152; 
p=0.0014), LA (r = 0.394 p=0.1177) (Fig 3.3 E – F). Again, no relationship was seen 
between BNP and GHSR or ghrelin in the control cardiac tissue (r = 0.2465; p=0.4923 and 




Figure 3.3 BNP correlation to ghrelin-GHSR.  
Representative fluorescent confocal images of[Dpr3(n-octanoyl),Lys19(sulfo-
Cy5)]ghrelin(1-19) (red), ghrelin (green) and BNP (magenta) in human cardiac tissue in 
the LA and LV (A & B). Nuclei were visualized with DAPI (blue). Graphs show linear 
regression analysis of quantified integrated densities with each dot representing an 
individual patient sample. There was significant linear regression of Cy5-ghrelin(1-19) vs 
BNP (r = 0.5633; p=0.0034) in the entire patient cohort [n=25] (C). When data were 
disaggregated by region, a significant linear regression was found in the LA (r = 0.6751; 
p=0.0029) [n=17] but not the LV (p=ns) [n=8] (D). Ghrelin and BNP were correlated in 
the entire patient cohort (r = 0.5008; p=0.0108) [n=25] (E). Linear regression analysis 
between ghrelin and BNP indicate linear regressions in the LV (r = 0.9152; p=0.0014) 
[n=17] but not the LA (p=ns) [n=9] (F). LA, Left Atrium; LV, Left Ventricle. 
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3.3.4 Intracellular Colocalization of Ghrelin and BNP in 
Cardiomyocytes 
Ghrelin and BNP appeared to be spatially localized to the same intracellular compartment 
within cardiomyocytes. In the control tissue, ghrelin and BNP appeared as larger ordered 
punctate areas mainly surrounding the nucleus (Fig 3.4A) while in the diseased tissue these 
colocalized areas of ghrelin and BNP were smaller and scattered more diffusely throughout 
the cell, and are not focused primarily around the nucleus (Fig 3.4B – C). The Pearson 
Correlation Coefficient was strong for both diseased LA (PCC=0.76) and LV (PCC=0.83) 
and control (PCC=0.86) while there was a significantly higher correlation in the control 





Figure 3.4 Intracellular colocalization of ghrelin and BNP in control LV.  
(A) and diseased tissue LV (B) and LA (C). (A-C) Representative confocal fluorescent 
images of ghrelin (green) and BNP (red) in healthy and diseased tissue shows linear 
regression of ghrelin and BNP in the merged images. DAPI (blue) indicates nuclear 
staining. White arrows indicate areas of punctate staining and colocalization in the merged 
images. (D) Pearson Coefficient Correlation (PCC) values indicate a stronger correlation 
in the healthy tissue [n=10] compared to the diseased tissue in the left atrium (p=0.0040) 
[n=29] but not the left ventricle (p=ns) [n=29]. Values are means ± SD. 
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3.3.5 The Relationship of the Cardiac Contractility Biomarker 
SERCA2a to Ghrelin and GHSR in the diseased Heart 
Quantitative fluorescence microscopy was used to measure SERCA2a in the control and 
diseased cohorts with representative images shown in Fig 3.1G. No differences in overall 
expression were seen between the diseased and control cohorts (Fig 3.1H). Linear 
regression analysis showed that SERCA2a had a positive relationship to GHSR, ghrelin 
and BNP (Fig 3.5C – E) but only in the LV (r = 0.7893, p=0.0348; r = 0.7315, p=0.0392; r 
= 0.8401, p=0.0180 respectively) and not the LA. Quantification of overall expression of 
toll-like receptor 4 (TLR4) showed no differences between the diseased and control cohorts 
(Fig 3.1J). No relationships were present in the control group between SERCA2a and any 
other biomarker [GHSR (r = 0.0936; p=0.7970), ghrelin (r = 0.0089; p=0.9385), BNP (r = 












Figure 3.5 SERCA2a correlation to ghrelin-GHSR and BNP 
(A) Representative fluorescent confocal images of Cy5-ghrelin(1-19) (red), ghrelin 
(green), BNP (magenta), and SERCA2a (green) in cardiac tissue of the LA (A in top 
panels) and the LV (B middle panels). DAPI (blue) nuclear stain in all images. Graphs 
indicate fluorescence intensities represented by integrated densities where each dot 
represents one patient sample. A significant linear regression is present in only the LV 
between SERCA2a and (C) Cy5-ghrelin(1-19) (r = 0.7893; p=0.0348) [LA n=15, LV n=8], 
(D) ghrelin (r = 0.7315; p=0.0392) [LA n=15, LV n=8], and (E) BNP (r = 0.8401; 






3.3.6 Cardiac Fibrosis 
Masson’s trichrome staining was used to determine the extent of fibrosis in all cardiac 
tissue samples. There were highly variable amounts of fibrotic deposition (blue) in samples 
of diseased tissue compared to the non-fibrotic tissue (red) in any given cardiac surgery 
patient sample but not in the control tissue (Fig 3.6A – C). Quantification of fibrotic tissue 
showed a significantly higher amount of collagen deposition in diseased tissues of the LA 
(p=0.0034) but not of the LV (p=0.0509) compared to the control tissues (Fig 3.6D). 
 
Figure 3.6 Fibrosis deposition in healthy and diseased tissue.  
Representative images of fibrotic (blue) and non-fibrotic tissue (red) in control tissue LV 
(A) and diseased tissues of the LV (B) and the LA (C) show variability in fibrotic 
deposition in the diseased tissue while not in the control tissue. (D) Graph shows mean ± 
95% CI of percentage fibrotic tissue with significantly less fibrotic deposition in the control 





In this study, we used our fluorescent ghrelin analog, Cy5-ghrelin(1-19), to examine the 
expression of myocardial GHSR in relation to that of ghrelin and other known markers of 
downstream signaling pathways in tissue obtained from patients with valvular heart/ 
coronary artery disease but without reduced LVEF. We also measured these markers in 
control, non-diseased, cardiac tissue. In patients with valvular heart disease (±coronary 
artery disease), there were positive correlations between GHSR and ghrelin which were 
regionally constrained to the left atrium. Similarly, there were regionally divergent 
correlations between GHSR and BNP (the gold standard marker of HF) and ghrelin and 
BNP. The positive correlations with the contractility marker SERCA2a were specific to the 
left ventricle. In contrast, no correlations between GHSR and ghrelin, or any other 
biochemical marker were observed in the control tissue. Additionally, we found that both 
ghrelin and BNP localized to the same intracellular compartment within cardiomyocytes, 
and this colocalization was slightly disrupted in the left atrium in the heart disease (HD) 
cohort. Therefore, there was an emergence of region-specific patterns in the myocardial 
ghrelin-GHSR signalling system in patients with valvular disease despite the absence of 
measurable changes in heart function.  
We have previously shown that GHSR and ghrelin are positively correlated in tissue 
samples from patients with end-stage heart failure and are correlated negatively with 
LVEF11. Results from other studies also indicate changes in the dynamics of the ghrelin-
GHSR system in end-stage heart failure10 and dilated cardiomyopathy12, suggesting this 
cardioprotective ghrelin-GHSR system is abnormally up-regulated when there is injury or 
stress to the heart11. Our present results also show a positive correlation between ghrelin 
and GHSR in patients with heart disease, but this time in the absence of a decrease in 
LVEF. As this correlation was not observed in tissue samples from the control group, we 
suggest that changes in the myocardial ghrelin-GHSR system occur early in the progression 
of heart disease, (in this study, in hearts subject to increased LV systolic pressures 
secondary to aortic stenosis) prior to measurable changes in heart function, as defined by 
the global LVEF.   
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Post-hoc disaggregation of data by region showed that the positive correlation between 
ghrelin and GHSR was maintained in the left atrium (LA) but not the left ventricle (LV). 
Interpretation of these data is very limited as we did not collect data on the LA pressures 
which are commonly elevated in valvular diseases due to stretching of the atrial wall. We 
did, however, observe a very slight but significant negative correlation between GHSR in 
the left atrium and LV diastolic pressure (r = 0.6887, p = 0.0402). Left ventricular diastolic 
pressure is elevated in valve disease which is associated with increased LA pressure24. In 
one study by Schwarz et al., in patients with aortic valve disease, there was an elevation in 
end-diastolic left ventricular pressure and mean left atrial pressure along with significant 
correlations with myocardial cell diameter25. Therefore, in our study of patients with aortic 
stenosis, it is expected that with the increased LV diastolic pressure, left atrial pressures 
are also increased. The increased LA pressures may be related to the strong correlation 
between ghrelin and GHSR. The positive ghrelin-GHSR correlation in the LA but not the 
LV may also represent a compensatory up-regulation under conditions of mild stress and 
trauma of the LA without any measurable changes in the heart function as measured by the 
LVEF. An up-regulation may be increased through GHSR signalling in the LA, which 
promotes cardiomyocyte survival (through Akt and phosphorylated extracellular signal-
related kinase)5, contractility (through SERCA2a)26, and inhibits signalling through pro-
inflammatory proteins and apoptosis6,27. More robust data will be required to establish a 
concrete relationship between alterations in the ghrelin-GHSR system and onset of LA 
dysfunction.    
In addition to the myocardium, ghrelin and GHSR are also present in the endothelial cells 
of the aorta, coronary arteries, and pulmonary arteries and veins28. Ghrelin is known to 
have vasoconstrictive effects in the coronary arteries and dose-dependently increases 
coronary perfusion pressure in a calcium-dependent manner thereby enhancing arteriole 
contractility29. The density of GHSR is increased in the atherosclerotic coronary artery and 
the saphenous vein compared to the corresponding non-diseased artery and vein30, 
indicating that up-regulation of ghrelin-GHSR signalling may occur within the diseased 
vasculature. In the same study, no differences in GHSR density were observed in the LA 
or the LV between the ischemic heart disease or dilated cardiomyopathy to the control 
tissues30. Our findings also showed no changes in myocardial GHSR as measured by Cy5-
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ghrelin(1-19), and a relatively weak correlation with ghrelin, suggesting that more dramatic 
changes in GHSR may occur at the site of vascular tissue injury or dysfunction.   
The secretion of both natriuretic peptide type-B (BNP) and its N-terminal form (NT-
proBNP), the current “gold standard” clinical heart failure (HF) biomarkers, are increased 
under conditions of cardiomyocyte stress and pressure overload. Circulating BNP levels 
are also increased in patients with aortic stenosis and mitral regurgitation, and can be used 
as a potential indication for valve replacement in patients with normal ejection fraction31. 
However, myocardial BNP mRNA does not change in patients who had aortic valve 
stenosis32. In our current study in patients with valvular disease, we also did not find a 
change in the tissue expression of BNP in either the LA or the LV. If tissue levels of BNP 
do not change, but levels of circulating BNP increase in valvular disease, it may suggest 
that the rate of post-translational processing of pro-BNP, rather than transcription or 
translation, increases in cardiomyocytes.   
Interestingly, we found that BNP and ghrelin correlated in the left ventricle, and 
furthermore, strongly co-localized to the same intracellular compartment within ventricular 
cardiomyocytes. In healthy individuals, BNP is predominantly localized in the atrium; in 
heart failure, BNP appears to localize primarily in the ventricles33. In aortic stenosis, the 
endocrine profile of aortic valves, which includes natriuretic peptides, their receptors and 
processing enzymes, is altered 32; taken together with our results, we suggest that a regional 
shift in myocardial endocrine programming may be part of the progression of heart disease 
to heart failure. This regional shift may extend to other genetic programs as well; in dogs 
exposed to prolonged rapid ventricular pacing, there were drastic changes in genes 
expressing apoptosis, cell structure and mobility, and inflammation in the left atrium, while 
genes involved in metabolism and Ca2+ signalling changed only in the left ventricle34,35. 
Therefore, there are clear regional differences in the genetic programs that underlie 
cardiomyocyte function in heart disease. Further studies will determine the intracellular 
dynamics of ghrelin and BNP during the progression of heart disease.  
We also evaluated GHSR signalling pathways involving contractility and inflammation. 
We were particularly interested in correlations with SERCA2a, a common marker of 
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contractility, as it has been shown to be activated through the GHSR signalling pathway, 
reducing intracellular Ca2+ levels and improving LVEF after myocardial infarction2. 
Additionally, we have previously found strong relationships between ghrelin and 
SERCA2a in both a mouse model of cardiomyopathy13 and human heart failure11. In the 
present study, we observed a positive correlation between SERCA2a and ghrelin-GHSR 
only in the left ventricle, which may indicate the importance of contractility signalling in 
the left ventricle, as it is the predominant chamber for contractile force. Activation of 
GHSR is known to regulate calcium handling and cardiomyocyte relaxation. This positive 
correlation in the LV may indicate the promotion of contractile function in the heart 
through GHSR by enhancing SERCA2a function. GHSR activation causes Gαq11 to 
activate the protein kinase A/calmodulin-dependent phosphokinases pathway through 
phosphorylation of phospholamban (PLB) from SERCA2a on the sarcoplasmic reticulum 
(SR) membrane thereby eliminating the inhibitory effect of PLB on SERCA2a uptake26. 
Removal of this inhibition increases the calcium flux in the SR thereby decreasing 
intracellular calcium and promoting contractility2,26. Additionally, SERCA2a and BNP 
were also correlated only in the left ventricle. Through binding natriuretic peptide receptor-
A, BNP activates cyclic guanosine mono phosphate (cGMP) signalling, which is coupled 
to L-type calcium channels and intracellular calcium levels through SERCA2a in 
ventricular cardiomyocytes36. As LVEF was unchanged in most of the patients, it is likely 
that alterations in the relationships between SERCA2a, ghrelin-GHSR, and BNP within 
left ventricular cardiomyocytes occurs prior to any overt functional changes as detected by 
echocardiography.  
Toll-like receptor 4 (TLR4) is a marker of inflammation elevated in the myocardium in 
end stage heart failure37,38, and ghrelin has been shown to attenuate the pro-inflammatory 
effects of TLR4 in HF4,39. In this study, we did not find any significant correlations between 
TLR4 and GHSR or ghrelin or other biomarkers, which may indicate the TLR4-mediated 
pro-inflammatory system is not co-regulated with the ghrelin-GHSR system at this point 
in valvular heart disease.    
Another measure of cardiac damage is the presence of fibrosis (collagen and fibroblast 
deposition) in the myocardium, which increases with HD severity40,41. Our results indicate 
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a significant increase in the fibrotic deposition in only the left atrium of HD patients when 
compared to the control heart tissues. The apparent lack of left ventricular fibrosis is 
consistent with the preserved LVEF of this cohort42. This accumulation of fibrosis present 
in the left atrium may be associated to the downstream signalling pathway changes seen in 
ghrelin-GHSR in this cohort as increased fibrosis deposition is common in the heart during 
the later stages of heart failure and is a sign of cardiomyocyte damage. However, these 
results are a bit difficult to interpret due to the large degree of variability in fibrosis in the 
patient cohort. This result is not surprising due to the heterogenous nature of fibrosis 
deposition in the myocardium and the subsequent difficulty in obtaining representative 
biopsy specimens43.   
There are a few limitations to our study to note. Our study was conducted with a small 
sample size that limited effective disaggregation of the data by region. It is important to 
note that the control and diseased tissues were embedded differently (paraffin wax vs fixed 
frozen respectively), although all samples were stained with the same protocols for each 
marker tested. Quantification of both paraffin and frozen healthy heart tissue is shown in 
Supplemental Figure 3.S2 where there was no difference in the quantification between 
either tissue storage method. In addition, control LV tissue was obtained up to 1-3 days 
post-mortem which could allow for potential protein degradation between time of death 
and when the tissue samples were put in fixative during autopsy. Finally, we did not obtain 
blood samples from the patients, which would have provided useful insight into the 
relationship between myocardial and circulating levels of ghrelin and BNP. 
To conclude, we have identified changes in the myocardial ghrelin-GHSR system in human 
valvular heart disease as compared to control cardiac tissues. The correlation between 
ghrelin and BNP and the colocalization in the myocardium of these peptides may suggest 
a regional shift in myocardial endocrine programming of cardiac cells in valvular heart 
disease. We have shown that the contractility marker SERCA2a was selectively correlated 
in the left ventricle, potentially as a cardioprotective mechanism prior to decreased LVEF. 
Our ongoing work will help to characterize GHSR-associated biochemical changes present 
in early stages of heart disease.  
130 
 
3.5 Supplemental Figures 
 
Supplemental Figure 3.S1 Punctate staining with RenyiEntropy algorithm. 
Top panel shows representative fluorescent staining of healthy, diseased left atrium (LA) 
and diseased left ventricle (LV) tissue. Bottom panels show what the RenyiEntrophy 
algorithm considers positive staining (green) and what is background staining (black) for 










Supplemental Figure 3.S2 Comparison between paraffin embedded control human 
tissue and frozen healthy heart biopsy samples. 
Marker comparison between GHSR (A), Ghrelin (B), and BNP (C) indicated no significant 
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4.1 Introduction  
Detection of heart disease (HD) is limited by the current clinically used imaging modalities 
and circulating cardiac biomarkers. Echocardiography is commonly used to evaluate heart 
structure and function1,2 while cardiac magnetic resonance imaging (cMRI) evaluates the 
heart anatomy, edema, and fibrosis deposition3. These modalities can provide information 
on structural and functional changes when the disease has advanced to a level to become 
clinically manifest, by which time, prevention and therapy are difficult. Circulating 
biomarkers may be used as an adjunct to imaging to determine the state of cardiac distress 
via a blood test. The gold standard biomarkers are natriuretic peptide type-B (BNP)4,5, 
secreted from the myocardium upon pressure and volume overload in cardiac tissue, and 
troponin T and I6, released into the circulation when the myocardium is damaged. 
However, limitations of the use of these circulating biomarkers include normal variations 
due to age, sex, and weight; their association with other comorbidities; and their short half 
lives in the blood. Therefore, there is a need for the use of in vivo molecular imaging 
techniques to detect HD earlier, when structural changes are not yet prominent, perhaps 
even prior to clinical symptoms, using a biomarker localized and specific to the cardiac 
tissue.  
One particular marker of interest is the growth hormone secretagogue receptor (GHSR) 
and its ligand ghrelin. Ghrelin and GHSR form an independent system in the myocardium, 
and GHSR signalling is associated with cardioprotection through anti-apoptosis7, anti-
inflammation8,9, contractility10,11 and cell growth12. Their expression levels and associated 
downstream signalling events are altered in both HD (initial or acute structural and 
functional changes in cardiac output), and HF (severe function and structural damage to 
the heart). Myocardial tissue expression of GHSR in patients is elevated in end stage heart 
failure 13 and cardiac transplantation14. In patients with valvular disease there was a 
decrease in myocardial ghrelin expression with minimal changes in GHSR expression15. In 
rat myocardium after myocardial infarction (MI) the expression of GHSR increased over 
time as an expected compensatory mechanism for the heart16. Therefore, GHSR may be a 
potential molecular imaging target for detecting molecular changes in the HD process.  
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Positron emission tomography (PET) imaging is a highly sensitive imaging modality that 
can be potentially be used to image changes in GHSR in vivo. Radiolabelled PET tracers 
based on the structure of ghrelin have been developed to target GHSR in tissues17. More 
recently, 18F-labelled peptidomimetic and small molecule GHSR agonists have been 
developed18,19 with the overall purpose of imaging the dynamics of GHSR expression as a 
clinically relevant means of detecting disease.  
In this study, we characterized a new 18F-tracer targeting GHSR for its ability to evaluate 
regional dynamics of GHSR over time in a canine model of moderately extensive anterior 
MI. Using simultaneous multi-tracer PET/MRI, we were able to determine the relationships 
between GHSR, perfusion and heart function before and after myocardial infarction. Our 
18F-tracer was found to bind sensitively and specifically in the left ventricle of the heart, 
independent of perfusion tracer distributions and global cardiac function.  
 
4.2 Methods 
4.2.1 Production of 18F and Synthesis of 18F-LCE470 
The [18F-]anion was produced by the PET cyclotron (St. Joseph’s Health Care London 
Ontario, Canada) as a result of the 18O(p,n)18F reaction involving proton bombardment of 
[18O]H2O. A Waters Sep-Pak
® Accell™ PlusLight (46 mg) QMA Carbonate cartridge was 
pre-activated by slowly treating with EtOH (10 ml) and Milli-Q® water (10 ml) and then 
flushing with air. The radioactive [18F-] anion was then trapped by drawing up the [18O]H2O 
solution containing it through the Sep-Pak. 
To potassium carbonate (3.0 mg) and Kryptofix 222 (10.0 mg) was added water (200 μl) 
and MeCN (800 μl) and the resulting solution used to elute the Sep-Pak® containing 
[18F]fluoride into a glass vial. The mixture was dried azeotropically (120 °C). The drying 
step was repeated twice more after the drop-wise addition of anhydrous MeCN (1 ml). The 
precursor with tosylate (2.0 mg in 0.5 mL of MeCN) was added to the aforementioned 
mixture, and the mixture was heated at 100oC for 10 min under sealed conditions. 0.5ml of 
water containing 0.1% TFA as added. The radiolabelled compound LCE470 was purified 
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by semi-prep HPLC using 40-80% MeCN in Water (0.1% TFA, flow rate: 4.5ml/min, 
15min run, 2min wash). 
 
Radioligand [18F] LCE470 
Radiochemical Yield (%) 42±10 
Radiochemical Purity (%) ≥99 
Total Synthesis Time (mins) 71±1 
  
 
Figure 4.1 Stacked HPLC chromatograms.   




















4.2.2 Animal Use and Surgical Preparation 
All animals used in this study were treated in accordance with ethical guidelines of the 
Canadian Council on Animal Care (CCAC). Animal protocol #2017-006 was approved by 
the Animal Use Subcommittee at Western University for the experiments described herein.  
Four bred-for-research female hounds (19-22kg) were obtained at 10-11 months of age. 
Anesthesia for surgery was induced using Propofol and maintained with 1.5 – 2.0% 
isoflurane. The heart was exposed through a left thoracotomy where the mid portion of the 
left anterior descending coronary artery (LAD) was isolated and occluded for two hours by 
a snare ligature, a type of ligature to allow for release externally, to induce a myocardial 
infarction (MI). After the 2-hour occlusion, the ligature was released causing reperfusion 
in the infarcted area. After MI surgery all animals were allowed to recover for 24 hours 
before next imaging session and simultaneous PET/MR imaging was performed at multiple 
time-points over a period of 1.5 years along with one timepoint one week prior to surgery 
to establish a baseline. All dogs were administered an oral iron chelator (to reduce iron 
deposition from blood and hemorrhaging in the heart) twice daily for 30 days after MI 
starting on the day of surgery.  
 
4.2.3 Positron Emission Tomography/ Magnetic Resonance 
Imaging  
Hounds were anesthetized as described above (induced with Propofol and maintained at 
1.5 – 2.0% isoflurane) and placed onto the bed of a 3T Biograph mMR (Siemens Medical 
Solutions, Erlangen, Germany). A hind leg catheter was inserted prior to imaging to allow 
for injection of tracers and contrast agents. All hounds were imaged with simultaneous 
PET/MRI for either 18F-LCE470 or 13N-NH3 at specified time points pre-post and surgery 
(illustrated in Fig 4.2). Due to technical difficulties, not all tracers were imaged on all days. 
Technical difficulties include: data corruption of either the PET or cMRI sequences, tracers 






Figure 4.2 PET/MR Imaging Schematic. 
Injection of 13N-NH3 tracer followed by 30 min scan and 50 min after injection the 
18F-
LCE470 tracer was injected and scanned for 60 min. Simultaneous MRI sequences 
acquired include: MR attenuation correction (MRAC), TrueFISP cine images to determine 
heart function and T1 images and 3D T1 weighted images to determine anatomy of the 
heart. Gadolinium DTPA contrast was injected during the 18F-LCE470 scan to determine 







4.2.3.1 Imaging Perfusion with 13N-NH3  
The PET-MR imaging protocol is illustrated in Figure 4.2. Hounds were imaged at the 
following time points post-surgery: Day 21 (n=3), Week 16 (n=4), Month 11(n=3).  A 30-
minute dynamic list-mode PET acquisition was initiated simultaneously with a bolus 
injection of 6.5 – 7 MBq/kg of 13N-NH3 (produced in-house at the Lawson Cyclotron 
Facility). PET data was reconstructed using a 3D Ordered Subset Expectation 
Maximization reconstruction (3 iterations, 21 subsets, 172 x 172 x 127 matrix size, zoom 
of 2, and 4 mm Gaussian filter) in the following segments: 12 frames x 10 seconds, 2 frames 
x 30 seconds, 1 frame x 60 seconds, 1 frame x 360 seconds. An MR-based attenuation 
correction was used from a two-point Dixon MRI sequence that was segmented into water, 
fat, lung, and air with constant attenuation coefficients for each tissue listed. PET voxel 
size was 2.09 x 2.09 x 2.03mm. 
 
4.2.3.2 Imaging GHSR with the Novel PET tracer 18F-LCE470 
Fifty minutes following 13N-NH3 imaging, hounds were imaged with 
18F-LCE470 at the 
following time points: baseline (n=3), day 3 (n=4), Day 21 (n=3), Week 16 (n=4), Month 
11(n=3). A 60-minute dynamic list mode PET acquisition was started simultaneously with 
injection of 6.5 – 7 MBq/kg of 18F-LCE470 in the hind leg catheter. PET data was 
reconstructed using OSEM as above in the following segments for a dynamic scan: 12 
frames x 10 seconds, 6 frames x 30 seconds, 5 frames x 60 seconds, 10 frames x 300 
seconds. PET data was also reconstructed using the last 15 minutes to generate a static scan 
for additional analysis. An MR-based attenuation correction was used as stated above. PET 
voxel size was 2.09 x 2.09 x 2.03mm.    
 
4.2.3.3 Cardiac MR Imaging 
MR imaging was initiated at the beginning of the first PET scan (13N-NH3 or 
18F-LCE470) 
and continued throughout the full imaging session. MR sequences included short axis cine 
stacks of the left ventricle synchronized to the Echo signal (true fast imaging with steady-
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state free precession (TrueFISP), slice thickness of 6 mm, 356 x 216 voxels with voxel size 
of 1.09 x 1.09 mm, 10-12 second acquisition time, based in heart rate) with each slice 
acquired during a breath hold where the ventilator was manually turned off for 10 seconds 
to allow for image acquisition. To determine the scar formation in the left ventricle, 
gadolinium diethylenetriamine penta-acetic acid (Gd-DTPA) contrast agent was injected 
(44 mmol/kg, Gadovist, Bayer) as a bolus at the 30-min time point of the 18F-LCE470 scan. 
A 3D T1 weighted image was used with LGE to create scar images (Echo triggered 
inversion recovery sequence with respiratory gating, 256 x 200 x 112 voxels, voxel size 
0.625 x 0.625 x 0.99 mm, 4-minute acquisition time, based on heart and respiratory rate). 
T1 maps (Echo triggered modified Lock-Locker inversion recovery sequence, slice 
thickness 6 mm, 256 x 144 voxels, voxel size 1.09 x 1.09, 12 second acquisition time, 
based on heart rate) were generated in a single breath hold to acquire 2- and 4- chamber 
views (Siemens Work In Progress).  
 
4.2.3.4 TBR Analysis 
Static acquisitions were used for the assessment of tracer uptake via calculation of 
standardized uptake values (SUV) and tissue to blood ratios (TBR) of both 18F-LCE470 
and 13N-NH3, using the online software 3D Slicer 4.8.1 (https://www.slicer.org/). To obtain 
the TBR for each tracer, the PET and gadolinium-enhanced T1 MR images were uploaded 
and regions of interest (ROIs) were manually drawn onto the MR images. The regions 
specified were the infarct region, the left circumflex region, remote tissue of the septal 
wall, and blood pool. The 2D ROIs were then transferred to the corresponding PET slices. 
The SUVs were determined where the tissue activity (MBq/ml) was divided by the injected 
dose (MBq) all multiplied by the body weight (g). To determine the TBR, the SUV of each 
tissue region (infarct, remote, left circumflex) were divided by the SUV of the blood pool. 

















4.2.3.5 Compartmental Modelling of PET Data 
Compartmental modelling of both tracers was done by uploading the dynamic list mode 
scan data to the online software package Carimas 2.10.0.0 (Turku Pet Center, Hospital 
District of Southwest Finland, https://turkupetcentre.fi/carimas/). For 18F-LCE470, the 
reconstructed dynamic data from the left ventricle was used to segment the area of the LV 
automatically (Fig 4.3). Manual corrections were made based on tissue localization in each 
axis (coronal short axis, vertical long axis, horizontal long axis) and slice. 
 
Figure 4.3 Representative images of LV segmentation. 
Manual corrections were performed to delineate LV tissue, right ventricle, base and apex 




An image-derived arterial input function was extracted from the time-activity curve 
measured in the blood pool of the left ventricle. This input function, along with the tissue 
time-activity curves, was used to solve for the kinetics of the tracer uptake in heart tissue 
using a two-compartment Logan model that accounts for free and bound components of 
18F-LCE47020, as we expect a receptor-ligand reversible interaction based on the natural 
ghrelin-GHSR system present in the heart. From the Logan analysis, we calculated the 
distribution volume of 8F-LCE470, and a full tracer kinetic analysis can determine the 
binding potential and receptor density.  
The following equation (2) illustrates the formula of Logan analysis where Ctissue represents 
the pixel-wise time activity curves of the target tissue tracer concentration measured by 
PET, Cplamsa is the tracer concentration in plasma, DVt is the slope of the resulting line, V 
is the y-intercept or initial concentration ratio at time 0 of the graph. The distribution 
volume (DV), total distribution for 18F-LCE470 in the tissue, is calculated using a 2-tissue 
reversible compartmental model shown in the equation (2 – 3) where Cplasma is the 
concentration is tracer in the blood plasma, Cfree is the concentration of unbound tracer in 
the tissue, and Cbound is the concentration of specifically bound tracer to the receptor. The 
distribution volume using the kinetic rate constants in equation 3 is represented by equation 
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The Logan analysis generates a polar map of the left ventricle partitioned into 17 individual 
segments where the outer part of polar map represents the base of the heart and the center 
is the apex. These segments were manually grouped into three regions: infarct, left 
circumflex tissue, and remote non-infarcted tissue. The distribution volume (ml plasma/ml 
tissue) was determined for each of these three regions to calculate the overall tracer 
distribution in the LV. The segments assigned to each of the three regions was variable for 
each dog due to differences in infarct size. Within each individual dog, grouped segments 
were maintained for all timepoints to maintain consistency for all regions. Fig 4.4 shows 










Figure 4.4 Polar map segmentation with manual grouping of segments into 3 regions. 
Left circumflex region (in light blue), infarct region (in pink), and remote tissue (all other 








For more precise mapping of tracer movement over time of the dynamic scan, the three 
regions (infarct, remote, left circumflex, blood pool) were manually delineated using 
Matlab R2020a software with custom scripts, and separate time-activity curves were 
generated for the blood pool in the left ventricle and the 3 tissue regions (Supplemental Fig 
4.S1). 
 
For 13N-NH3 the 30-minute data was segmented automatically in the left ventricle and 
manual correction was performed as stated for 18F-LCE470. Compartmental modelling for 
13N-NH3 used a 1-tissue compartment model (5) as demonstrated by Degrado et al
21 where 
a polar map was generated and the left ventricle was segmented into 17 individual segments 
as was done for 18F-LCE470. The rate of tracer movement into the tissue is defined by K1 
and is represented as the flow of tracer in the heart. The equation used to generate this 
compartmental model is illustrated in the following equation (6). Ctissue is the concentration 
in the myocardial tissue, Cplasma is the concentration in the blood plasma, FBV is the 




6) 𝐶𝑡𝑖𝑠𝑠𝑢𝑒(𝑡) = (𝐹𝐵𝑉) (𝐶𝑝𝑙𝑎𝑠𝑚𝑎(𝑡)) + (1 − 𝐹𝐵𝑉)𝐾1𝐶𝑝𝑙𝑎𝑠𝑚𝑎(𝑡) ⊗ 𝑒
−𝐾2𝑡 
 
The K1 (ml/g*min)) and K2 (min-1) values were generated for each segment and segments 
were grouped into 3 regions in the left ventricle as stated above. These grouped segments 
were maintained for all timepoints and for each hound to maintain consistency for all 
regions amongst time.  
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4.2.3.6 Correlation of 18F-LCE470 and 13N-NH3 Uptake 
In order to determine the relationship between 18F-LCE470 uptake and myocardial 
perfusion, linear regressions were performed between TBRs of 18F-LCE470 and 13N-NH3 
and between 18F-LCE470 distribution volumes and K1 values of 13N-NH3. Values from 
remote and left circumflex areas were selected for analysis; values from the infarct region 
were not used as tracer uptake in this area was significantly decreased and would therefore 
skew the regression analysis. Data from day 21, week 16 and month 11 were selected, as 
these were the time points at which both tracers were injected.   
 
4.2.3.7 MRI Data Analysis 
A commercial cardiovascular image analysis software Circle CVI42 (Circle cardiovascular 
Imaging Inc, Calgary) was used to calculate the following parameters of heart function: 
left ventricular ejection fraction, stroke volume, end systolic and diastolic volume, and end 
systolic and diastolic mass. Short axis TrueFISP image series were uploaded and automated 
segmentation for systole and diastole were generated. Manual adjustments were made 
when needed to correct for LV segmentation and to select slices in the series at systole and 
diastole for calculating functional parameters. Slices in the series were excluded due to 
poor image quality, if the aorta or left atrium were visible, or if they were past the apex. 
Based on proper segmentation of the series, all cardiac function values were calculated 
automatically in the online software.  
 
4.2.3.8 Statistical Analyses of PET and MR Imaging Data 
Statistical analysis was performed with GraphPad Prism Version 8.2.0 (GraphPad 
Software, San Diego, California USA, www.graphpad.com). For TBR and compartmental 
modelling analysis, a repeated measures analysis of variance (ANOVA) for both 18F-
LCE470 and 13N-NH3 were used to determine regional differences at any given time point 
pre- and post- myocardial infarction. Corrections for multiple comparisons were performed 
using Tukey’s post-hoc test. Statistical analysis of functional MR data was calculated using 
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an ANOVA with Tukey’s post-hoc test for multiple comparisons based on each imaging 
time point. All statistical analyses were completed with significance set at p<0.05. PET 
and MR Images were generated using 3D Slicer software where MR and PET images were 
optimized with individual window/levelling for each individual dog at each time point.  
 
4.2.4 Tissue Harvesting and Imaging Acquisition 
At 1.5 years after MI, animals were sacrificed, and tissue was obtained for histological 
analysis. Immediately after sacrifice the chest was opened and the entire heart was 
removed. Myocardial tissue samples (roughly 1 cm3) were collected in duplicate from areas 
within the left ventricle including center of infarct, remote (non-infarcted) tissue, and the 
territory served by the left circumflex artery. Tissue was immediately snap frozen in liquid 
nitrogen and kept at -80°C until use. Frozen tissue blocks were embedded in optical cutting 
temperature medium (OCT) and left to freeze at -80°C overnight. Tissue was cryosectioned 
at 5-6 µm and adhered to positively charged microscope slides. All tissue sections were 
stored at -80°C until use. Tissue sections were subsequently fixed using ice cold acetone 
for 15 minutes at room temperature (RT). All tissues were then stained for GHSR using 
our custom-made far-red ghrelin analogue (cyclo 12,16)-
[Dpr3(octanoyl),Lys20(SulfoCy5)] ghrelin(1-20)
22, termed Cy5-cyclo-ghrelin(1-20), at a 20 
µM concentration for 1 hour at RT. We have previously used [Dpr3(n-
octanoyl),Lys19(sulfo-Cy5)]ghrelin(1-19) to detect GHSR in human14 and mouse cardiac 
tissue23. Cy5-cyclo-ghrelin (1-20) has a greatly improved affinity towards GHSR (1.0 nM). 
Samples were then stained with 4’,6-diamidino-2-phenulindole (DAPI) at a concentration 
of 300 nM for 6 minutes at RT followed by mounting with ProLong Diamond Antifade 
(Life Technologies) to prevent photobleaching. 
High resolution images were captured with a Nikon A1R Confocal Microscope at 60x 
magnification using an oil immersion lens. For each tissue location in the heart (technical 
replicate of 2), five random fields of view were captured with microscope parameters 
(exposure time, gain and LUT) set the same for all tissue sections.  
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In addition, we evaluated regional fibrosis deposition using Masson’s Trichrome and tissue 
morphology using hematoxylin and eosin (H&E). Adjacent sections were stained with 
Masson’s Trichrome and H&E by the Molecular Pathology Department at Robarts 
Research Institute. Images of all cardiac tissue (infarct, edge of infarct, remote, left 
circumflex) were acquired using bright field microscopy at 10X, 20X and 40X 
magnifications with a Zeiss Axioskope EL-Einsatz microscope and Northern Eclipse 
software as described previously14,15.  
Blood plasma was obtained at all time points prior to imaging to evaluate circulating levels 
of ghrelin. Samples of whole blood were added to tubes containing a complete mini 
protease inhibitor (Sigma Aldrich) to inhibit degradation of active circulating biomarkers. 
The blood was centrifuged at 3000rpm for 10 min at 4°C to separate red blood cells from 
plasma. The plasma was kept at -80°C until end of the study for analysis. Levels of canine 
ghrelin (CGTMAG-98K-02 - Millipore Sigma) were measured using multiplexed 
immunoassay kits according to manufacturers’ instructions (R&D Systems, Minneapolis, 
MN). A Bio-Plex 200 readout system was used (Bio-Rad), which utilizes Luminex® 
xMAP fluorescent bead-based technology (Luminex Corporation, Austin, TX). Levels 
were automatically calculated from standard curves using Bio-Plex Manager software (v. 
6.1, Bio-Rad). 
 
4.2.4.1 Tissue Image Analysis 
Images of tissue GHSR were analyzed with FIJI v. 1.49v, a distribution of ImageJ software 
(National Institutes of Health). An algorithm built into ImageJ, Percentile24, was used to 
quantify regional distribution of GHSR in cardiac tissue. The value assumes the threshold 
of all foreground pixels is 0.5 and therefore quantifies the integrated density of the 
positively stained tissue. The integrated density represents the mean intensity of the 
positive signal above the threshold in scaled units divided by the area in pixels. Therefore, 
this algorithm only captured foreground images and calculated the intensity values based 
on a percentile value of 0.5.  
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4.2.4.2 Correlation of 18F-LCE470 Uptake and Distribution Volume 
to Tissue GHSR and Plasma Ghrelin  
In order to determine the sensitivity of the GHSR-targeted PET tracer 18F-LCE470 to 
GHSR tissue levels, both TBR and distribution volumes obtained at the final imaging 
session (18 months) were correlated with fluorescence intensities of Cy5-cyclo-ghrelin(1-
20). Values from all tissue regions were pooled to obtain a robust sample size.  
To determine the impact of circulating ghrelin on LCE470 tracer binding in the heart, 
plasma ghrelin levels were compared to LCE470 distribution volume at all time points 
from baseline to 12 months post MI. Linear regression of plasma ghrelin and 18F-LCE470 
distribution volume were compared based on region (infarct, remote, circumflex). 
 
4.2.4.3 Statistical Analyses 
Statistical analysis was performed with GraphPad Prism Version 8.2.0 (GraphPad 
Software, San Diego, California USA, www.graphpad.com). Unpaired student t-tests and 
a one-way ANOVA analyses were used to compare overall GHSR expression in tissue 
based on region in the left ventricle. Correlation analyses of tissue and PET values were 
performed using linear regression analysis. All statistical analyses were completed with 









4.3.1 18F-LCE470 Tracer Uptake in the Left Ventricle 
Standardized uptake value ratios (TBR) for 18F-LCE470 were calculated at baseline, day 
3, day 21, week 16 and month 11 post-MI overall for all dogs (n=4). TBR was significantly 
elevated in the left circumflex region compared to both the remote (p=0.0348) and infarct 
(p=0.0003) regions over time (Fig 4.5a). TBR in the infarct region was significantly 
decreased over time compared to the remote tissue (p=0.0365). Representative PET/MR 
images from one dog are shown in Fig 4.5b at all time points analyzed in TBR analysis. 
The PET signal in the LV at baseline shows a uniform distribution of tracer binding. After 
MI, the tracer uptake decreases in the infarct area compared to the remote and circumflex 






Figure 4.5 In vivo 18F-LCE470 in canine model of myocardial infarction (n=4). 
A) Tissue to Blood Ratio (TBR) for tracer 18F-LCE470 over time in the left ventricle from 
baseline to 330 days post-myocardial infarction. Values calculated from static scan at 45-
60 min post-injection where three regions were delineated: infarct, remote non-infarcted 
tissue, left circumflex tissue. For overall canine TBR values there was a significant 
difference between infarct and remote regions (*p=0.0365); remote and circumflex regions 
(*p=0.0348); infarct and circumflex regions (***p=0.0003). B) Representative images of 
the four-chamber view of the left ventricle from one dog depicting the PET, MRI, and 
fused PET/MR images for all timepoints shown in the graph above. Arrows point to the 3 
regions of interest including: Infarct (blue), Remote (green), Circumflex (red). After MI 
there is minimal uptake of tracer in the infarct while remote and circumflex increase. This 
pattern is present at both acute and chronic time points.   
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The regional dynamics of GHSR is represented by the distribution volume of 18F-LCE470 
and is presented at all time points for each individual dog to show regional patterns in tracer 
uptake in the LV (Fig 4.6a). Similar to the TBR analysis, 18F-LCE470 distribution volume 
in the area of infarct was significantly decreased compared to the left circumflex area at 
any given time point post-MI in all dogs (p<0.001). There was a slight decrease in tracer 
uptake in the infarct region in dogs 2 and 4 only. One pattern that emerged in dogs 1, 2 and 
3 was a significant increase (p<0.05) in 18F-LCE470 distribution volumes in the left 
circumflex region compared to the remote tissue at week 16 and month 11 post-MI, a 
difference that was not present at baseline. Interestingly, this pattern was also observed in 
dogs 2 and 3 at acute time point day 3. Polar maps (Fig 4.6b) were generated for a visual 
representation of how the LV volume was segmented for the calculation of distribution 
volume in the different regions of the left ventricle. Distribution volume in polar maps 
indicated a lower uptake in the center of infarct (shown in green) while there is increased 
tracer binding in the remote area (yellow to orange colour) and left circumflex tissue 
increased in uptake even further (dark orange to red colours).   
Dynamic 18F-LCE470 tracer uptake over time was evaluated based on region (infarct, 
remote, left circumflex area, blood pool) at all time points including baseline, day 3, day 
21, week 16, and month 11 (Supplemental Fig 4.S1). Tracer uptake in the infarct slightly 
decreased after Mi compared to baseline while both remote and left circumflex regions 
increased in tracer uptake after MI. Tracer in the blood showed quick washout with rapid 










Figure 4.6 Compartmental modelling of 18F-LCE470 in the left ventricle of canine 
hearts (n=4). 
A reversible receptor-ligand interaction (Logan analysis) was used for compartmental 
modelling of this novel tracer. A) The distribution volume was calculated for all dogs 
shown in each graph. The left ventricle was segmented into 3 regions for each timepoint: 
infarct, remote non-infarcted region, left circumflex region. [Black – Baseline; Red – Day 
3; Blue – Day 21; Green – Week 16; White – Month 11] Significant differences were seen 
between all regions at most timepoints, particularly between infarct and remote and infarct 
and circumflex while these differences were not seen at baseline. (*p<0.05; **p<0.01; 
***p<0.001; ****p<0.0001) B) Representative polar maps of the left ventricle for one dog 
at all time points imaged with the 18F-LCE470 tracer. All images are scaled the same with 
maximum DV of 7.45 and minimum DV 0. Images depict the binding pattern of the tracer 
in the left ventricle showing the lower uptake in the apex/infarct of the heart at the center 
of the map (green colour), with moderate uptake in the remote tissue (yellow - orange 
colour), and increased uptake in the left circumflex area at the right middle to bottom (red). 




4.3.2 Perfusion Throughout the Left Ventricle 
13N-NH3 was used to determine changes in regional perfusion in the LV using TBR at day 
21, week 16 and month 11 post-MI overall for all dogs (n=4) (scans at baseline and day 3 
post-MI were not obtained). As expected, TBR was significantly decreased in the area of 
infarct (p<0.0001) at all time points compared to the remote and left circumflex regions; 
however, there were no differences in TBR between the remote and left circumflex tissue 
at any time point (Fig 4.7a). Representative PET/MR images from one dog are shown in 
Fig 4.7b. The PET signal in the LV after MI shows decreased tracer uptake in the infarct 
area compared to the remote and circumflex regions. This pattern is present at acute and 






Figure 4.7 Analysis of perfusion imaging tracer in dogs (n=4). 
Due to technical difficulties perfusion imaging was only initiated at day 21. A) Tissue to 
Blood Ratio (TBR) for tracer 13N-NH3 over time in the left ventricle from day 21 to 330 
days post-myocardial infarction. Values calculated from static scan of 9-15 min where 
three regions were delineated: infarct, remote non-infarcted tissue, left circumflex tissue. 
For overall canine TBR values there was a significant difference between infarct and 
remote regions (****p<0.0001); infarct and circumflex regions (****p<0.0001); but no 
significant difference between remote and circumflex regions. B) Representative images 
of the for-chamber view of the left ventricle from one dog depicting the PET, MRI, and 
fused PET/MR images for all timepoints shown in the graph above.  Regions are delineated 
by coloured arrows including infarct (blue), remote tissue (green), left circumflex tissue 
(red). The PET images have decreased distribution of ammonia in the infarct region 
compared to the remote and circumflex regions at all time points.  
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The rate of 13N-NH3 uptake (K1) into the tissue was determined at all timepoints for each 
individual dog to allow for visualization of perfusion patterns (Fig 4.8a). There were 
significant differences in the rate of tracer perfusion pattern between the infarct and both 
the remote (p<0.05) and left circumflex (p<0.05) tissues at week 16 and month 11 in dogs 
2 and 3, and at day 21 and week 16 in dog 1. There were no significant differences in K1 
in dog 4. There was also no difference in K1 between the remote and left circumflex regions 
at any time points in any dog. A visual representation of the regional rate of tracer perfusion 
pattern in the LV is shown in polar maps representative of one dog (Fig 4.8b). These polar 
maps demonstrate the 3 regions evaluated (left circumflex region, remote tissue, infarct) 
where there was a decreased perfusion pattern in infarct (green to yellow) and an increased 
perfusion pattern in the remote and circumflex regions (orange to red). There appeared to 






Figure 4.8 Compartmental Modelling of Perfusion Tracer 13N-NH3 in the left 
ventricle of canine hearts (n=4). 
A 1-Tissue compartment model was used for this tracer in the canine heart. A) The K1 
values were calculated for all dogs shown in each graph. The left ventricle was segmented 
into 3 regions for each timepoint: infarct, remote non-infarcted region, left circumflex 
region. [Blue – Day 21; Green – Week 16; White – Month 11] Significant differences were 
seen at some time points between infarct and remote and infarct and circumflex while no 
differences were seen between remote and circumflex at any timepoint. (*p<0.05; 
**p<0.01; ***p<0.001; ****p<0.0001) B) Representative polar maps of the left ventricle 
for one dog at all time points imaged with the 13N-NH3 tracer. All images were normalized 
for maximum flow (0.625) to the minimum flow (0). Images depict the rate of tracer 
movement in the left ventricle showing the lower perfusion in the apex/infarct of the heart 
at the center of the map (green colour), with moderate perfusion in the remote tissue 
(orange - red colour), and no differences in colour perfusion of the left circumflex area 
right middle to bottom (orange - red). [LCX – left circumflex tissue; Rem – remote tissue; 




4.3.3 18F-LCE470 Uptake Does Not Correlate with Perfusion in 
Remote or Left Circumflex Regions 
To assess whether the regional flux of 18F-LCE470 could be accounted for by perfusion 
alone, linear regression analysis was applied for TBR values of both tracers (Figure 4.9A), 
and to the distribution volumes of 18F-LCE470 (representing GHSR density) and adjusted 
K1 values for 13N-NH3 (representing the rate of perfusion (Figure 4.9B). Linear regressions 
were separated by day of scanning and were limited to the time points at which 13N-NH3 
scans were acquired (Day 21, Week 16 and Month 11 post-infarct), and to the remote and 
left circumflex regions. There were no significant linear regressions at any time point 
between TBR values of the tracers (Fig 4.9a). There were also no significant linear 









Figure 4.9 Correlation of 18F-LCE470 and 13N-NH3. 
Data derived from the remote and left circumflex tissues from all dogs were pooled. A) 
Linear regression analysis of TBR values showed no correlation at any given time point. 
B) Linear regression analysis showed no correlation between tracer patterns in the remote 
and circumflex areas at any time point.  
 
4.3.4 Specificity of 18F-LCE470 Binding in Cardiac Tissue 
Tissue quantification of GHSR was determined with quantitative fluorescence microscopy 
using the fluorescent ghrelin analogue Cy5-cyclo-ghrelin(1-20)22.  Representative images 
of the infarct, remote and left circumflex regions are shown in Fig 4.10a, and quantification 
of fluorescence in each region for each individual dog (n=3) is shown in Fig 4.10b. In all 
dogs, Cy5 fluorescence in the left circumflex region was significantly increased compared 
to the infarct region (p<0.0001). Interestingly, there was a significant increase in 
fluorescence in the left circumflex region compared to the remote region in two of three 
dogs (p<0.001). Tissue specificity was demonstrated through a blocking study with 
hexarelin (GHSR blocking agent) shown in Fig 4.11 where blocking showed a drastic 





Figure 4.10 Tissue Characterization of GHSR in Canine Heart. 
A) Representative fluorescent images of GHSR in the canine heart with the novel imaging 
agent Cy5-ghrelin stapled peptide. Tissue gathered from 3 regions of the heart at sacrifice: 
infarct, remote non-infarcted tissue, left circumflex tissue with red stain showing diffuse 
staining of GHSR in the heart and DAPI nuclear stain in blue. B) Quantification of 
fluorescent images for each dog (n=3) at end point. Significant differences seen between 





Figure 4.11 Cy5-cyclo-ghrelin(1-20) specificity in canine tissue. 
Tissue shown without blocking agent on left and with blocking agent (hexarelin) on right. 





We then determined the sensitivity of the GHSR-targeted PET tracer 18F-LCE470 by linear 
regression to Cy5-cyclo-ghrelin(1-20)22 fluorescence in the left ventricle by pooling data 
from the infarct, remote and left circumflex regions (Fig 4.12). There was a significant 
positive linear regression between tissue Cy5-cyclo-ghrelin(1-20) fluorescence and 18F-
LCE470 TBR values (p=0.0070, r=0.8185). Tissue Cy5-cyclo-ghrelin(1-20) fluorescence 
was also positively and significantly correlated to 18F-LCE470 distribution volume (p-





Figure 4.12 Correlation of GHSR tissue analysis to 18F-LCE470 TBR and 
distribution volume at end point. 
A) Linear regression of tissue GHSR values and PET TBR for all dogs (n=3) at endpoint. 
There was a significant linear regression between tissue and PET with r = 0.8185 and 
p=0.0070. B) Tissue GHSR linear regression with 18F-LCE470 distribution volume (DV) 





4.3.5 Fibrotic Deposition and Circulating Ghrelin 
Fibrotic deposition was determined regionally in the left ventricle using Masson’s 
trichrome stain (Fig 4.13a). Qualitative images show a large amount of fibrosis (blue) in 
the infarct while the remote and left circumflex areas were predominantly non-infarcted 
areas (red). Hematoxylin and eosin (H&E) stain also qualitatively showed the distinct 
changes in tissue morphology and type between in the infarct and both remote and left 
circumflex areas. These images clearly show the extensive fibrotic deposition in the infarct.  
Circulating ghrelin levels were evaluated at all time points and correlated to the LCE470 
distribution volume tracer binding (Fig 4.13b). There were no significant linear regressions 
in any region evaluated (infarct, remote, circumflex) where changes in circulating ghrelin 













Figure 4.13 Representative qualitative images of fibrosis and hematoxylin and eosin 
(H&E) are shown in each region. 
A) Masson’s trichrome (MT) stained for fibrosis (blue) and non-fibrotic tissue (red) where 
there were significant amounts of fibrosis in the infarct compared to the remote and 
circumflex tissue regions (A top). H&E stain confirmed differences in tissue distribution 
and type as seen in fibrosis (A bottom). B) Linear regression between LCE470 distribution 
volume and circulating plasma ghrelin levels based on region (infarct, remote, circumflex). 
There were no significant linear regressions in any region where circulating ghrelin did not 
alter the binding of LCE470 regionally in the heart.  
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4.3.6 Heart Function Before and After MI 
Parameters of heart function were determined from the cardiac MRI sequence short axis 
TrueFISP series (10-11 slices through the LV) and generates a 3D representation of the left 
ventricle. The short axis TrueFISP sequences were acquired at all time points, from 
baseline to 11 months post-infarct. Heart function parameters evaluated were left 
ventricular ejection fraction, stroke volume, diastolic and systolic volume, and end 
diastolic and end systolic mass. There were no significant differences in any measured 




Figure 4.14 Heart Function Analysis (n=4). 
Calculation of MR images of Echo triggered short axis TrueFISP image series was used to 
calculate heart function parameters including left ventricular ejection fraction (LVEF) and 
stroke volume. No significant differences were seen in overall heart function at any given 






In this study, we characterized a new PET tracer, 18F-labelled small molecule GHSR ligand 
termed 18F-LCE470 to examine GHSR density in the heart in vivo with simultaneous 
PET/MR imaging in a canine model of MI. We used TBR to calculate tracer uptake and 
quantitative PET to determine the distribution volume of 8F-LCE470, which is a measure 
of GHSR in three regions of the LV: area of infarct, the territory of the left circumflex 
artery, and remote myocardium, where we revealed a unique pattern of uptake of 18F-
LCE470 in the left ventricle that persisted over time. This work is extremely novel as it 
follows tracer distribution out for 18 months after MI including timepoints before and both 
acutely and chronically after MI. The regional distribution of 18F-LCE470 in the LCX 
territory and remote myocardium differed from that of the perfusion tracer, 13N-NH3, 
suggesting potential specificity to binding GHSR. As well, both TBR and distribution 
volume of 18F-LCE470 significantly correlated with levels of tissue GHSR as determined 
by Cy5-cyclo-ghrelin(1-20)22 fluorescence in tissue obtained at the end of the study. Heart 
function (global LVEF and stroke volume) as determined by cMRI did not change 
significantly over the one-year period of the study, although regional changes may have 
occurred but were not formally assessed in this study. Therefore, we have characterized the 
specificity and sensitivity of 18F-LCE470 in detecting myocardial GHSR and shown that 
regional GHSR distribution is altered after MI independently of changes in perfusion and 
global LV function.  
Specifically, for the entity of heart failure (HF) diagnosis, there is a need for the 
development of new targets for in vivo imaging that are specific for cardiac tissue and can 
directly detect molecular changes in disease pathophysiology. Such imaging may allow 
early detection of altered disease patterns, and the fashioning of targeted interventions that 
may improve patient outcomes. The current promising cardiac PET tracers have been 
developed for the purpose of tracking the biological processes that underlie HD. In 
particular 13N-ammonia (13N-NH3) is commonly used after a MI to determine the extent of 
diminished cardiac perfusion and damaged myocardium21. 13N-NH3 freely diffuses across 
the cell membrane and is utilized in glutamine synthesis via glutamate synthase. 13N-NH3 
only enters viable cells and therefore regional perfusion patterns in the myocardium 
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directly detects blood flow and tissue viability. Another common clinically used PET tracer 
is a glucose analogue, 18F-fluorodeoxy glucose (18F-FDG) which primarily measures the 
rate of glucose metabolism in cells. 18F-FDG enters cells through glucose transporters, gets 
phosphorylated by hexokinase and is trapped in the cell. Changes in 18F-FDG uptake are 
primarily related to the upregulation or downregulation of glucose transporters on cellular 
membranes. With an appropriate protocol that suppresses normal myocardial glucose 
uptake, 18F-FDG can be used to detect inflammation, mediated by primarily pro-
inflammatory macrophages25. Glucose transporters are upregulated in pro-inflammatory 
macrophages; therefore, increased 18F-FDG signal can be used to detect the extent of 
inflammation in HD26,27. In addition, 18F-FDG can measure changes in myocardial 
substrate metabolism from predominantly fatty acid metabolism to glucose metabolism as 
seen in congestive HF28. 11C-meta-hydroxyephedrine (HED) is a norepinephrine (NE) 
analogue that targets the NE receptor to evaluate regional changes in cardiac neuronal 
activity which can help assess HF presence and reinnervation commonly present in 
arrythmias29. In addition to these common cardiac PET tracers used in research, there have 
been many recent discoveries in developing PET tracers targeting cardiac transporters, 
receptors, and proteases that change in HD30,31. An emerging perfusion tracer is 18F-
flurpiridaz, a pyridazinone derivative, which gets metabolically trapped in cardiomyocytes 
through the mitochondrial membrane complex-1 and determines cardiac blood flow. 18F-
flurpiridaz was able to accurately detect coronary artery disease using cardiac perfusion 
PET imaging32,33. When detecting cardiac inflammation, 68G-DOTATATE targets the 
somatostatin receptor 2 that is overexpressed in inflammatory macrophages. It can 
accurately detect inflammation after a myocardial infarction with minimal background 
uptake34 and can determine atherosclerotic disease severity35. Lastly, there is emergence of 
68Ga labelled fatty acid analogues (68Ga–NOTA–undecanoic acid) that target fatty acid 
transporters and can detect abnormalities of fatty-acid oxidation in myocardial disease36. 
Therefore, there are several ongoing efforts at generating novel molecular imaging agents 
that target a number of cardiac biomarkers of heart disease.  
To optimize new targeted PET tracer development, there are many important factors to 
consider. First, for improved plasma stability, small molecule ligands are preferable to 
peptide analogues or natural ligands. Second, binding affinity that is improved from that 
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of the natural ligand would be ideal for in vivo studies specifically. Finally, labelling with 
a clinically used radioisotope, such as 18F can allow for easy clinical translation. These 
considerations have led our team to develop small molecule PET probes targeting GHSR, 
specifically 18F-CE470, with strong binding affinities to the receptor (0.11nM). We have 
developed an 18F-labelled ghrelin octapeptide analogue from N-terminal 8 amino acids of 
native ghrelin, [Inp1,Dpr3(6-fluoro-2-naphthoate),1-Nal4,Thr8]ghrelin(1−8), termed 18F-
LCE470, which had a significantly stronger affinity (0.11nM) to GHSR compared to native 
ghrelin (3.3nM) with in vitro studies37. The next step for this analogue is to evaluate in vivo 
binding. We also characterized the efficacy of 18F-G-7039, a ghrelin peptidomimetic 
(binding affinity 69nM), in healthy mice where minimal tracer uptake was present in the 
heart18. Therefore, we concluded mouse models may not be optimal for imaging GHSR in 
vivo. We also determined that small molecules (low molecular weight organic compound 
with minimal resemblance to the ligand) are optimal for tracer binding compared to both 
peptidomimetics (combination of amino acids to resemble ligand which have been 
manipulated for better binding) and analogues (truncated versions of natural ligands).  
We then evaluated our new PET tracer, 18F-LCE470, using both a semi-quantitative TBR 
method to determine regional tracer uptake and quantitative kinetic modelling reflecting 
GHSR distribution. It is important to note here that one limitation with our kinetic 
modelling is the lack of plasma metabolite analysis that corrects the image-derived arterial 
input function for metabolic degradation of the tracer over the image acquisition period. 
Initial results in one dog showed that 18F-LCE470 was fairly stable, with the parent 
compound decreasing at a linear rate by approximately 40% 60 minute after injection 
(Supplemental Fig 4.S2). While this result may indicate relative stability of 18F-LCE470 in 
canine plasma over time, we need more robust data in canine plasma to accurately 
determine the metabolite correction for this tracer and thus did not use metabolite 
correction for this study38.  
Typically, in humans, after a MI occurs, there are significant remodeling changes in the 
left ventricle that result from both the acute and chronic phases of remodeling. This pattern 
of remodeling also occurs in the canine heart after MI39. After the initial infarct, the acute 
remodeling phase involves the myocardium surrounding the infarct, termed border 
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myocardium, with infarct expansion and the initiation of adaptive biochemical processes 
to preserve LVEF and stroke volume40. One such adaptive process is the upregulation of 
the Gqα/Phospholipase C β (PLCβ) pathway which play a role in cardio-protection,  cardiac 
hypertrophy and fibrosis deposition41. This pathway is also known to be activated by 
GHSR in cardiomyocytes in the regulation of calcium homeostasis and contractility10,42. 
Therefore, the border myocardium may be essential in cardiac remodeling after injury. In 
late stage remodeling, the LV is globally involved in progressive dilatation and scar 
enlargement, along with distortion of shape and contractile function43. Importantly, in later 
stages of remodeling, the border myocardium plays a large role in cardio-protection to 
minimize the scar enlargement and reduce damage to heart structure and function44. In our 
study, the border myocardium is represented by the left circumflex (LCX) tissue which 
surrounds the edge of the infarct.  
We evaluated uptake of 18F-LCE470 in the LV semi-quantitatively through TBR values. 
There were some significant regional changes in TBR of 18F-LCE470 post-MI compared 
with pre-MI. The sustained post-MI decrease in 18F-LCE470 uptake in the infarct area 
compared to the remote and LCX tissue likely suggests a significant and sustained decrease 
in GHSR expression over time after MI. Similarly, the slight decrease of 18F-LCE470 in 
the remote tissue could also be due to a slight decrease in receptor density, and the sustained 
uptake in the LCX region suggests that GHSR expression is maintained in this region. 
Interestingly, the decrease in 18F-LCE470 TBR specifically in the infarct region could also 
be due to a lack of perfusion not allowing the tracer to enter this area. To better determine 
the actual dynamics of GHSR distribution after MI, we used kinetic modelling to examine 
changes in distribution volume. 
Kinetic modelling revealed highly individual responses to MI regarding GHSR 
distribution. One pattern that emerged was increased distribution volume in the LCX 
border region compared to the remote and infarcted tissue, similar to the pattern of TBR.  
These results suggest that one mechanism by which the border myocardium is 
cardioprotective is through GHSR signalling. Activation of GHSR in the myocardium is 
known to function through the Gαq/PLCβ pathway to regulate contractility through calcium 
homeostasis11 along with decreasing inflammatory and fibrotic signalling45, reducing 
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apoptosis12, and promoting cellular metabolism46. This pathway is likely upregulated to 
compensate for the reduced contractile stress of this area acutely after MI47. Such a 
mechanism may also operate to a lesser extent in the remote myocardium, as suggested by 
the elevated distribution volumes compared to the area of infarct. In one study evaluating 
the strain and stiffness of tissue from baseline to day 28 post MI, increased diastolic 
stiffness was initially observed in the infarct and border myocardium at day 3 post MI but 
not until day 14 post MI in remote tissue44. In addition apoptosis after MI is increased 
extensively in border myocardium and to a lesser extent in remote tissue which is sustained 
for 4 weeks48. This provides evidence that there is milder dysregulation of processes in the 
remote tissue compared to border tissue. In a proteomic and histological analysis of 
signalling in a porcine MI model, 4 weeks after I/R injury the border myocardium had 
decreases in proteins for energy metabolism and mitochondrial dysfunction, while proteins 
for endothelial growth and apoptosis increased. These results may provide a mechanism 
for increased angiogenesis seen in LV remodeling after MI and for increased apoptosis in 
the expansion of the infarct when the compensatory mechanisms fail48. Acutely after an 
infarct necrosis of cardiomyocytes initiate an intense inflammatory and immune response 
where monocytes, neutrophils, and leukocytes clear dead cells out of the infarcted area. An 
anti-inflammatory response is then initiated at about 3-4 weeks post MI where fibroblasts 
deposit extracellular matrix proteins and cross-linked collagen while granulation tissue 
becomes apoptotic49. We have previously shown that GHSR is not expressed in fibrotic 
deposition, specifically collagen I and III14. However, GHSR expression is present in 
fibroblasts50,51 which may explain the lower 18F-LCE470 distribution in the infarct region 
since as the scar matures, the density of cardiac fibroblasts is greatly reduced52. GHSR and 
ghrelin are also expressed in macrophages53 which are chronically present in the infarct 
and border myocardium at lower levels48, again attributing to part of the weakened 18F-
LCE470 signal in the infarct. It is important to note that a lack of perfusion in the infarct 
area can be physiology linked to the changes in receptor availability. The calculations 
derived from kinetic modeling are not biased due to this as changes in perfusion are 
reflected in the plasma-to-tissue influx and efflux. The binding potential of the tracer is not 
dependent on these rate constants, rather to the tracer binding and disassociating to the 
receptor. The concept of tracer binding to receptors independently of altered delivery 
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(perfusion), have been validated in multiple PET studies. These overall changes in GHSR 
binding and activation in the border myocardium to infarct region may prove optimal 
targets for increasing angiogenesis and decreasing apoptosis/ scar expansion chronically.  
To better evaluate if these changes in infarct and border myocardium are attributed to actual 
changes in distribution volume or cardiac perfusion, we determined regional cardiac 
perfusion post-MI. Perfusion in the LV was measured using 13N-NH3
21,54,55
 which functions 
through entering the cardiomyocytes by diffusion and incorporation into the glutamine 
synthesis pathway56, and is thus metabolically trapped within the cardiomyocyte. This 
pathway of uptake and retention does not operate if the cell membrane is damaged, and 
therefore 13N-NH3 detects only viable myocardium
21,54. In our study, the pattern of 13N-
NH3 TBR indicated persistently lower perfusion in the area of infarct for the duration of 
the study compared with the remote and LCX myocardium. Interpretation of this difference 
is limited by the lack of perfusion data before MI and immediately after. However, it is 
known that, in this particular model, perfusion of the infarct area significantly decreases 
immediately after MI57,58. The MI biology changes dramatically acutely (up to 4 weeks 
post-MI) versus chronically (4 weeks onwards). In the acute phase post-MI, the 
inflammatory and immune response initiate the removal of dead tissue and begin formation 
of new vasculature to restore blood flow to this area. Until this revascularization occurs, 
blood flow to the infarcted area is highly limited49. Once fibrotic tissue is deposited and 
angiogenesis is present in the infarct area, perfusion is restored while 13N-NH3 binding 
remains minimal. Therefore, the decreased 13N-NH3 binding in infarct area shows a lack 
of tracer access to infarcted area acutely, while chronically it represents scar formation. 
When analyzing trends in perfusion imaging after MI, decreased perfusion with 13N-NH3 
in patients with HD symptoms were predictive of adverse cardiac outcomes59,60. Therefore, 
these acute immune and inflammatory processes may prove to be ideal therapeutic targets 
for HD patients.   
There is a notable divergence in the perfusion pattern of 13N-NH3 in the remote and LCX 
areas when compared with uptake of 18F-LCE470, in that 13N-NH3 TBR was the same in 
these two regions, whereas 18F-LCE470 TBR were different. These results suggest that 
uptake of 18F-LCE470 is independent of perfusion in the remote myocardium. This is 
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further supported by the lack of correlation of both TBRs and that of the distribution 
volume of 18F-LCE470 and K1 of 13N-NH3 in these two areas. Therefore, uptake and 
distribution volume of 18F-LCE470 is likely due to binding to GHSR, and not due to 
changes in perfusion. In lieu of a blocking study we compared the TBRs and distribution 
volumes of 18F-LCE470 to the kinetics of perfusion (blood flow) to determine tracer 
specificity.  
We acknowledge that the specificity of LCE towards cardiac GHSR would be further 
confirmed through a blocking study, in which an excess of unlabeled ghrelin would be 
administered before or during tracer injection. To date, there has been no GHSR 
antagonists administered to humans. The most commonly used GHSR antagonists are [D-
Lys-3]-GHRP-6 and YIL781 which have primarily been used in energy metabolism studies 
in rodents61. However, there is evidence that increased concentrations of [D-Lys-3]-GHRP-
6 injected in rats show adverse cardiac events including elevated mean atrial pressure and 
heart rate62. There has also not been any toxicity study performed for these antagonists in 
canines and administering large doses is likely to cause significant adverse cardiac events, 
similar to what was seen in rats. Therefore, with these important considerations, we did not 
use a bocking study to determine tracer specificity.   
To validate our in vivo findings, and to further demonstrate that 18F-LCE470 yields a 
readout of GHSR, we measured GHSR expression in all three LV regions using Cy5-cyclo-
ghrelin(1-20)22. Fluorescent signal intensity was significantly increased in tissue from the 
LCX area compared to the infarct region, and in most dogs, the LCX tissue had higher 
fluorescence intensity compared to the remote. These results indicate the relative 
differences in the presence of GHSR in LCX, remote and infarct areas, and mirror the 
distribution of 18F-LCE470 in each of these regions. In the chronic stages after MI, late-
stage remodeling occurs in both the remote and border myocardium which encompasses 
decreased LV function and global apoptosis. As discussed above, activation of GHSR in 
the border myocardium could contribute to enhanced cardioprotective signalling in the 
failing cardiac muscle41,63. There is also a significant amount of fibrosis (collagen 
deposition) in the infarct area, which may explain the low GHSR signal in this region, as  
we have previously shown that GHSR is not expressed in the collagen deposition of fibrotic 
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tissue14. GHSR is also known to have increased expression in HF13,14 and after MI16 which 
reflects the pattern of GHSR expression present here in cardiac tissue at 18 months post-
MI. In addition, the lack of GHSR in infarct tissue provides further evidence that the 
decreased 18F-LCE470 distribution in the infarct is due to a lack of GHSR uptake and not 
solely due to decreased perfusion in that area.   
In order to examine the sensitivity of 18F-LCE470 in binding GHSR, we determined the 
relationship between TBR and DV values obtained during the final imaging session and 
tissue fluorescence intensities. The strong significant positive correlations between TBR 
and fluorescence intensity, and between distribution volume and fluorescence intensity, 
demonstrates high tracer sensitivity targeting GHSR density in the heart. One limitation to 
note is that tissue was only collected upon sacrifice, and thus tissue GHSR expression could 
only be compared to in vivo image analysis at 11 months. Other 18F PET tracers have been 
validated for diagnostic accuracy using histological analysis with known positive and 
negative samples64–66. The histological analysis in our study used a custom Cy5-cyclo-
ghrelin(1-20)22 to accurately determine GHSR presence in the tissue. This method is 
superior as we measured GHSR protein in the tissue and we used a fluorescent analogue 
instead of antibodies. Traditional GPCR antibodies have shown to have low specificity 
whereas our fluorescent analogue demonstrated a high specificity to the receptor as shown 
through significant decreases in fluorescence after added blocking agent (supplemental Fig 
4.11). Nonetheless, the strong correlation between tissue fluorescence of GHSR and 18F-
LCE470 uptake indicates the high specificity of 18F-LCE470 binding to GHSR in the LV. 
Surprisingly, heart function as determined by MR did not significantly change over time 
between baseline and both acute and chronic time points after MI. There was a slight but 
not significant decrease in both LVEF and stroke volume observed at day 3 post-MI in the 
overall cohort. Normally after a MI, heart function is significantly reduced at acute time 
points and can either return to normal, pre-MI levels of heart function, or continue to 
decrease and proceed to HF67. The main explanation for no significant functional changes 
over time is due to the use of global function rather than regional function. Global heart 
function can be an insensitive marker as hypercontractility in non-infarcted tissue will 
compensate for the hypocontractility in the infarct. Another possibility for why we are not 
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seeing significant changes could be due to the small cohort of dogs used in this study. In 
addition, an iron chelator was given to these dogs twice a day from days 1-30 post MI. Iron 
chelation has shown to reduce the amount of iron deposition in hemorrhages after acute 
MI68 and reduce adverse remodeling such as ventricular enlargement and myocardial 
hypertrophy69. The iron chelation agent used in this study could have had similar effects 
on LVEF. Even with these variables present, we were still able to demonstrate clear 
significant regional changes in both in vivo PET imaging with 18F-LCE470 and tissue 
GHSR fluorescence in the absence of any functional changes seen in the heart.   
The main limitation to this study is the lack of metabolite-corrected arterial input function 
for compartmental modelling of our new 18F-LCE470 tracer. Metabolite corrections are 
used to determine the rate of tracer decay over time70. Our initial results indicate that the 
tracer appears to be relatively stable in the blood over the image acquisition time 
(supplemental Fig 4.S2), and more studies need to be completed to show reproducibility. 
Other forms of metabolite correction include a mathematical model of correction and 
population-based correction. To use the mathematical model, an optimal model must be 
selected based on the quality of data and reliability of results. In studies with unknown or 
too many parameters, the fitting may be poor71. Metabolite correction based on population 
can only be used with a large number of available samples and the population used to 
correct must be diverse. This method is rarely possible due to the extensive testing and 
validation required for each individual tracer71. Alternatively, a tissue reference region that 
does not contain the receptor could be used to generate ratios of tracer uptake with 
distribution volume for accurate analysis70. This option is difficult for our particular tracer, 
since GHSR is present in both atrial and ventricular myocytes, and vascular endothelial 
cells of the aorta, coronary, pulmonary, and arcuate arteries in human tissue72. If we assume 
the binding patterns in canine cardiovascular tissue follow those of humans and rats, there 
is no appropriate reference region in the heart. There is also evidence that GHSR expression 
is present in lung tissue, thereby excluding them as a suitable reference region73. Therefore, 
as of now, there is no accurate tissue reference region in the heart with this canine model.  
To conclude, we have characterized a novel PET tracer, 18F-LCE470, to sensitively and 
specifically target GHSR in vivo. 18F-LCE470 had a unique, specific binding pattern in the 
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canine heart after MI, which did not fully reflect changes in cardiac perfusion. Tissue 
GHSR showed a strong correlation to 18F-LCE470 in vivo PET imaging, further supporting 
the sensitivity of our tracer to GHSR density. While changes in 18F-LCE470 tracer uptake 
were present in the LV, there were no significant changes to the overall heart function 
indicating 18F-LCE470 may reflect the molecular and biochemical changes that occur in 
the absence of functional changes after MI. Our ongoing work will help to further 
characterize the in vivo changes to the ghrelin-GHSR system throughout the progression 











4.5 Supplemental Figures 
 
Supplemental Figure 4.S1 Time-activity curves showing regional uptake of 18F-
LCE470 in infarct, remote, left circumflex area, and blood pool. 
A) Baseline; B) Day 3; C) Day 21; D) Week 16; E) Month 11. Regional uptake decreased 
slightly in the infarct after MI compared to baseline while both remote and left circumflex 






























Supplemental Figure 4.S2 Metabolite Analysis. 
Preliminary metabolite analysis on one dog where parent tracer compound decreases 40% 
by 60 minutes after injection. Metabolite analysis indicates the tracer degrades 40% over 
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Chapter 4  
5 Discussion, Future Studies, and Clinical Significance  
 
5.1 Cardiac Ghrelin-GHSR System is a Scalable Marker for 
Heart Disease 
To optimize diagnosis for heart disease (HD) and prediction towards the development of 
heart failure (HF), a better understanding of the underlying biological mechanisms through 
the evolution of HF is needed. My work has revealed some dynamics of ghrelin and GHSR 
in the human myocardium that may be a key factor in this understanding. GHSR expression 
is abnormally elevated in end-stage heart failure1 and activation of this system elicits many 
cardioprotective mechanisms, including preservation of calcium homeostasis/ 
contractiliy2, decreasing inflammatory and fibrotic signalling3, reducing apoptosis4, and 
promoting cellular metabolism5. Because many of these effects occur before the onset of 
structural changes that define HD, myocardial GHSR may be an optimal target for HD 
diagnosis in its earlier stages. In Chapter 2, I used a novel far-red fluorescently labelled 
ligand of GHSR to examine the dynamics of the ghrelin-GHSR system. It is important to 
note that the expression of GHSR shown with this fluorescent ligand is not necessarily a 
demonstration of biological activity in the myocardium. It is better demonstrated by an 
increase in production of the receptor that is expressed both on the membrane and within 
the cardiomyocytes. This is the first study that evaluated GHSR and ghrelin expression in 
human cardiac tissue in patients before and up to 1 year after cardiac transplantation. I 
demonstrated that both GHSR and ghrelin were slightly elevated in end-stage HF compared 
to serial biopsies of the newly transplanted heart, and both ghrelin and GHSR were 
correlated negatively with LVEF. Changes in the ghrelin-GHSR system were associated 
with cardioprotective mechanisms as reflected by significant correlations to biochemical 
markers of contractility and cell survival/ hypertrophy. My work suggested that ghrelin-
GHSR may be a more sensitive indicator of alterations in these signalling pathways of 
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contractility and hypertrophy than BNP, the gold standard HF biomarker6. Additionally, 
GHSR was not expressed in fibrotic tissue, specifically within areas of collagen deposition, 
which can provide more information on the exact types of tissues express GHSR and the 
biological composition of damaged tissue in this area. Therefore, ghrelin-GHSR can 
provide significant information about HF biology.  
To further understand the dynamics of how ghrelin-GHSR changes in the heart, this system 
was measured in tissue obtained from patients with valvular heart disease with preserved 
ejection fraction. These patients had not been diagnosed with HF, but had some significant 
risk factors, such as valvular impairments, hypertension, coronary artery disease, and 
medications including diuretics and ACE/ARB inhibitors. In Chapter 3, I evaluated the 
expression and biology of the ghrelin-GHSR system using our fluorescently labelled 
ghrelin ligand in control non-diseased cardiac tissue and in tissue obtained from different 
regions of the heart from patients undergoing valve replacement surgery. A positive 
correlation between ghrelin and GHSR was present in tissue from the left atrium but not 
the left ventricle. In contrast, no correlations were present in the control tissue, which was 
sampled from the left ventricle. Taken together with the correlations in end-stage HF, the 
weak regional correlation of ghrelin and GHSR in the absence of measurable changes in 
LVEF could indicate the scalability of this marker from control → HD → HF. Further 
assessment of biochemical changes associated with GHSR activation in valvular disease 
indicated a significant positive correlation with SERCA2a, a marker of Ca2+-dependent 
contractility, only in the LV. That this relationship was also present in the absence of 
measurable changes in LVEF suggests subclinical alterations in GHSR-associated 
signalling in the LV. Therefore, I have demonstrated specific, regional changes in the 
ghrelin-GHSR system and associated biochemical signalling pathways at different stages 
in the progression of HD. The scalability of this system can help provide clues to 




5.2 Is the Ghrelin-GHSR System a Clinical Diagnostic 
Biomarker?  
Heart disease (HD) is a diverse clinical syndrome with no one specific path of progression. 
This makes diagnosis extremely difficult in the evolution of HD as current biomarkers can 
only detect at late stages. Here, we suggest the ghrelin-GHSR system as a potential new 
cardiac-localized biomarker of cardiac dysfunction. My work has demonstrated a 
significant relationship between ghrelin-GHSR and overall heart function indicating 
increases in this system in late stages of HF. This system clearly shows its scalability with 
disease severity progressing from no correlations in healthy tissue, to weak correlations in 
HD with preserved ejection fraction, to strong correlations in end stage HF. This scalability 
also translates with GHSR-associated biochemical signalling as there is no correlation of 
GHSR with markers of signalling pathways in control tissue, weak correlations in the HD 
cohort, and strong correlations in HF. That these specific alterations in GHSR-associated 
signalling occur in both the presence and absence of reduced LVEF indicates subclinical 
changes in contractile function may occur prior to overt derangements in cardiac function 
and structure. This work is unique in its development and use of a novel fluorescent optical 
imaging tool to specifically target expression of GHSR as conventional antibodies lack 
specificity. This imaging tool was evaluated in human cardiac tissue, demonstrating the 
clinical relevance of ghrelin-GHSR in cardiovascular disease and heart failure. The next 
step was to develop a novel in vivo imaging tool to target and track changes in GHSR in 
the heart. We then developed a targeted PET tracer for GHSR that can track changes in 
tracer distribution in HD and HF. 
 
5.3 In Vivo GHSR PET Tracer Optimization 
In the past decade there have been developments for targeting GHSR in vivo with PET 
imaging. The first study in designing GHSR-targeted probes was in 2009 by Rosita et al. 
where the structure of the ghrelin peptide was significantly modified to carry SPECT and 
PET radioisotopes, while maintaining binding to GHSR. They determined that ghrelin 
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could be truncated to ghrelin(1-14) and modified on the Ser-3 side chain to carry SPECT 
and PET isotopes and still maintain GHSR binding similar to that of native ghrelin.  The 
lead PET analog, ghrelin(1-14)-12C-F, had a fluorine addition with a strong binding 
affinity to GHSR of 28nM. They showed that binding to GHSR could be preserved even 
though the octanoyl side chain on Ser3, which comprises the receptor binding domain of 
ghrelin, had been altered. In another study by Charron et al., a [68Ga]-ghrelin analogue 
([Dpr3(octanoyl),Lys19(Ga-DOTA)]ghrelin(1- 19)) showed strong affinity to GHSR 
(5.9nM) in a xenograft mouse model. This analogue was tested in vivo where there was 
significant uptake in the xenograft although no uptake was seen in the cardiovascular 
system7. This study confirmed the manipulation and radiolabeling of ghrelin to target 
GHSR in vivo with motivation to further optimize tracers for GHSR PET imaging. Up until 
this point, peptide derivates of ghrelin had been used to target GHSR in vivo but peptides 
are inherently unstable in circulation. To generate tracers with improved plasma stability, 
small molecule ligands to GHSR have been developed. A small molecule developed by 
Chollet et al8, Nα-NODAGA(68Ga)-KwFwLL-CONH2, was evaluated in vivo in rats. This 
compound exhibited high stability in the blood, good clearance in kidneys and liver, and 
detectable but minimal uptake in the heart. Therefore, the tracer profile should be further 
developed for optimal detection of cardiac GHSR8. Another study by Potter et al. evaluated 
a small molecule labelled with 11C, (S)- 6-(4-fluorophenoxy)-3-((1-[11C]methylpiperidin-
3-yl)methyl)-2-o-tolylquinazolin-4(3H)-one, targeted to GHSR where there was increased 
stability and clearance with significant uptake in the brain region but minimal uptake in the 
mouse heart9. With these improvements in ghrelin analogues, our team developed targeted 
analogues for GHSR. Previously, we developed and tested a peptidomimetic, [1-
Nal4,Lys5(4-[18F]-FB)]G-7039, for GHSR binding (69nM) in wildtype mice and mice 
lacking GHSR. There was no significant difference in tracer accumulation in the heart 
between mouse models indicating mouse models may not be optimal for imaging cardiac 
GHSR in vivo10. The next generation of tracer development incorporated small molecules 
where the lead candidate, 18F-LCE470, showed improved binding affinity to GHSR of 
0.11nM when compared to native ghrelin (3.3nM) with in vitro studies11.  
For my project, I evaluated the sensitivity and specificity of this new small molecule tracer, 
18F-LCE470, in targeting cardiac GHSR in vivo. In chapter 4, I used 18F-LCE470 to 
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measure the regional distribution of GHSR density before and after a myocardial infarction 
(MI) using simultaneous PET/MRI. My work suggested that the uptake and distribution of 
18F-LCE470 are altered immediately (3 days) after a MI, with increases in uptake in the 
left circumflex region and significant decreases in the infarct region, and this pattern 
persisted for 11 months. The increased tracer uptake in the circumflex tissue surrounding 
the infarct suggests that GHSR activation may play a role in the mechanism of 
cardioprotection within the border myocardium in the weakening heart. To evaluate tracer 
specificity, patterns of cardiac perfusion measured through 13N-NH3 were compared to 
binding patterns in 18F-LCE470. There was a unique binding pattern of 18F-LCE470 in the 
LV of the canine heart when compared to cardiac perfusion (blood flow) as demonstrated 
by 13N-NH3. I then evaluated tracer sensitivity by correlating 
18F-LCE470 to tissue GHSR 
expression at end point (1.5 years after MI) using a custom far-red ghrelin analog, Cy5-
cyclo-ghrelin(1-20), in infarct, remote, and LCX regions. The overall tissue GHSR 
expression strongly correlated to GHSR density as measured by 18F-LCE470, showing the 
sensitivity of tracer binding in the canine heart. These specific regional changes in GHSR 
density show molecular alterations in the heart independently of changes in perfusion and 
overall LV function. Therefore, I have characterized a novel PET tracer, 18F-LCE470, to 
sensitively and specifically detect molecular GHSR changes the heart in the absence of 
overall cardiac dysfunction. 
 
5.4 Can GHSR Imaging be Used for Clinical Diagnosis for 
Cardiac Impairment?  
Diagnosis of HD remain difficult as pathogenesis occurs in a variety of forms. The current 
diagnostic tests commonly encompass cardiac biomarkers and cardiac imaging. 
Conventional cardiac imaging, in the form of echocardiography, CT and MRI, detects 
functional and structural changes that are characteristic of the later stages of HD 
development while molecular imaging can target specific receptors or signalling pathways 
to measure the subclinical changes in the heart. My work suggests that a novel molecular 
PET imaging agent, 18F-LCE470, may report increases in GHSR density in vivo in regions 
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surrounding a MI in the canine heart in the absence of overt global cardiac dysfunction. 
The increase in GHSR density may indicate GHSR-associated subclinical biochemical 
changes, as my results in human tissue biopsies showed that upregulation of GHSR is 
correlated with specific signalling pathways that induce cardioprotective responses through 
enhancing contractility, hypertrophy, and cell survival6,12. Alterations in cardiomyocyte 
biochemical signalling are known to occur early in the progression of HD and therefore 
early detection of these changes can provide significant advancements in diagnosis13. 
Additionally, we have demonstrated the scalability of the ghrelin-GHSR system in HD and 
hence, 18F-LCE470 has the potential to track specific regional changes in GHSR density in 
the evolution of HD and HF. With the development of this novel PET imaging tool, we can 
detect molecular changes of GHSR through imaging which can be a useful tool in early 
diagnosis of clinical HD. 
 
5.5 Elucidation of the Relationship Between GHSR and 
Inflammation 
Now that we have validated 18F-LCE470 sensitivity and specificity to GHSR in vivo in the 
canine model of MI, we want to evaluate the biochemical mechanisms associated with 
GHSR in vivo. One important process of interest is the relationship between GHSR and 
inflammation in the injured and failing heart. After cardiac injury, an intense acute immune 
and pro-inflammatory process is activated where monocytes, neutrophils, and leukocytes 
migrate to the site of injury to remove dead and damaged cells. This process specifically 
includes high numbers of pro-inflammatory macrophages in which glucose transporters 
have been upregulated due to their high energy demand14. About 3-4 weeks after injury, 
the pro-inflammatory response subsides, and the anti-inflammatory response is initiated. 
During this process, fibroblasts deposit extracellular matrix proteins and cross-linked 
collagen while granulation tissue becomes apoptotic and is cleared15. As discussed in the 
Introduction, GHSR functions through both an inhibitory effect of the pro-inflammatory 
response16,17 and activation of the anti-inflammatory response18,19 to protect the heart from 
further injury and adverse cardiac events induced by a prolonged inflammatory response. 
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We can measure potential in vivo relationships between GHSR and inflammation using 
PET imaging techniques.  
Many PET tracers have been developed to target different aspects of the cardiac 
inflammatory process20. 68Ga-[1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic 
acid]-d- Phe1,Tyr3-octreotate (DOTATATE) is a common PET tracer that targets the 
somatostatin receptor 2 which is overexpressed in inflammatory macrophages. 68G-
DOTATATE can accurately detect inflammation after a myocardial infarction with 
minimal background uptake21 and can determine atherosclerotic disease severity by 
differentiating high versus low risk lesions in the vasculature22. Another target for 
inflammation is the receptor C-X-C motif chemokine receptor 4 (CXCR4) which is 
upregulated on macrophage and T-cells associated with the pro-inflammatory process. 68G-
pentixafor, targeted to CXCR4, has been used to detect the increase in pro-inflammatory 
cells and vasculature lesions associated with atherosclerosis23. Another emerging target is 
the mitochondrial translocator protein TSPO, which is upregulated in most macrophages 
and lymphocytes; however, all cells express TSPO on the mitochondrial membrane, 
thereby creating background uptake in the myocardium24. Many tracers have been 
developed to target TSPO, and tracers that target TSPO specifically in cardiac 
inflammation include 18F-flutriciclamide (18F-GE180)25, 11C-PK1119526, and 18F-
FEDAA110627. 18F-GE180 has been shown to be elevated globally in inflammatory 
macrophages acutely after an MI25, and 11C-PK11195 was elevated in inflammation 
associated with vulnerable/ symptomatic plaques in atherosclerosis28. Therefore, increased 
uptake of tracers that target TSPO measures increases in activated inflammatory cells and 
mitochondrial dysfunction in failing cardiomyocytes24. 
The most common clinically used tracer to detect inflammation in the heart is 18F-
fluorodeoxyglucose (18F-FDG). Proinflammatory macrophages have significant 
overexpression of glucose transporters resulting in increased 18F-FDG uptake14. One 
important thing to note when using 18F-FDG in studies of inflammation is that normal 
myocardial glucose uptake needs to be suppressed to minimize background signal. This is 
usually done with an Intralipid™ infusion in animal studies, or by requiring human subjects 
to fast or have a high fat meal prior to imaging to reduce glucose metabolism and increase 
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the lipid metabolism in the normal myocardium29. It is uncommon for suppression to be 
ineffective; however, there may be variability in effectiveness. An example of such 
variability shown in Figure 5.1 where suppression was effective at the day 28 and week 8 
time points after MI. However, suppression did not work effectively at month 6, as there 
is a significant amount of PET signal throughout the entire heart without any discernable 
cardiac region. Regardless, 18F-FDG is clinically used to determine inflammation 
associated with HD such as endocarditis, sarcoidosis, and atherosclerosis. Additionally, 
18F-FDG is currently the clinical gold standard for determination of viable tissue in patients 
after myocardial infarction and in cardiac dysfunction with accurate assessment of scar 
presence30,31. Therefore, 18F-FDG is an optimal tracer to evaluate the relationship between 
inflammation and GHSR in vivo in the heart.  
 
 
Figure 5.1 18F-FDG imaging in the canine heart after MI.   
Canine heart after MI using Intralipid™ suppression to reduce background myocardial 
glucose uptake with PET imaging. Day 28 and week 8 demonstrate effective Intralipid™ 
suppression while month 6 indicates ineffective suppression with no clear discernible 




We have performed preliminary analysis of 18F-FDG uptake in the same dogs described in 
Chapter 4 with Intralipid™ suppression from day 1 to 1-year post-MI to evaluate the 
temporal dynamics of glucose metabolism in inflammation. We used kinetic modeling with 
Patlak analysis, an established method to quantify glucose metabolism32,33, to determine 
the regional Ki values (net influx rate of the tracer). The Ki values of 18F-FDG were 
determined for three different regions including the remote, infarct and left circumflex at 
days 1,7, 28, week 8, months 6 and 12 (Fig 5.2a). There was a significant increase in  Ki 
values in the area of infarct compared to both the remote and circumflex tissue during the 
acute inflammatory phase of macrophage infiltration at days 1 and 7. We observed 
increased inflammation in the infarct region acutely and there is evidence in the literature 
of abundant macrophage, monocyte, and leukocyte infiltration in acute myocardial damage 
that can account for this increased signal we observed15. There was no significant 
inflammatory process in the remote or circumflex tissues acutely (days 1 and 7 post MI) as 
there was minimal 18F-FDG uptake in these areas. The minimal 18F-FDG uptake persisted 
around the same level through the chronic phase of MI (day 28 - 1 year post MI) which 
may be indicative of the lack of inflammatory processes in these areas chronically. 
However, there was a significant reduction of 18F-FDG uptake in the infarct region in the 
chronic phase of MI (day 28 - 1 year post MI). It is known that the chronic phase of 
inflammation encompasses fibroblasts deposition of extracellular matrix proteins and 
cross-linked collagen with minimal macrophage presence15 which likely accounts for the 
chronic decreased 18F-FDG uptake in the infarct region. Therefore, changes in 18F-FDG 
uptake help to provide a better understanding of the biology of the infarct region acutely 
and chronically.  
We also measured levels of circulating cardiac inflammatory marker C-reactive protein 
(CRP), which is an indicator of inflammation associated with stressed and damaged 
myocardium, at the same time points as 18F-FDG imaging sessions. CRP is released from 
the liver upon activation by a pro-inflammatory IL-6 specific response to cardiac stress and 
injury34. In cardiac inflammation, CRP exacerbates the pro-inflammatory response by 
binding to damaged cell membranes to enhance macrophage recruitment and 
phagocytosis35. In our study, there was a significant increase in plasma CRP in the pro-
inflammatory phase (days 1, 3, and 7) after cardiac injury followed by reduced 
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inflammation back to baseline levels by day 21 (Fig 5.2b). That the peak of circulating 
CRP coincides with the peak of 18F-FDG uptake suggests there is a significant increase in 
macrophage presence in the infarct at these time points, as 18F-FDG is known to have 
significant uptake in macrophages while CRP recruits them to the site of cardiac 
inflammation. The enhancement of both 18F-FDG and CRP acutely after MI provides a 
better understanding of the pro-inflammatory temporal timeline and the cell types present 
in the infarct region. Further elucidating the regional inflammatory biology composition 
and biochemical activation will help with understanding the evolution of HD.  
To evaluate the relationship between inflammation and GHSR in the heart, we conducted 
linear regression analysis with 18F-FDG Ki values and 18F-LCE470 DV values in both the 
acute and chronic phases after MI (Fig 5.3). There was no correlation between GHSR 
density and glucose metabolism in the acute phase; however, there was a significant 
positive correlation in the chronic phase. GHSR is shown to have increased expression in 
tissue that is stressed1, such as the region surrounding the infarct, no expression in dead 
and fibrotic tissue6, and low expression in macrophages36. GHSR signalling is also known 
to activate cardioprotective responses, including anti-inflammatory responses, in cardiac 
tissue18,19. The lack of correlation between GHSR density and glucose metabolism acutely 
could be due to significant increases in macrophages where GHSR density is known to be 
low but 18F-FDG uptake is increased. This lack of correlation acutely supports no 
significant relationship between GHSR and pro-inflammatory signaling in this model of 
MI. In contrast in the chronic phase (day 28 – 1 year post MI), macrophage presence is 
known to be decreased which is supported by decreased 18F-FDG uptake in the area of 
infarct in our study. The positive correlation of 18F-FDG and GHSR density chronically 
could be due to a cardioprotective response through GHSR in non-infarcted tissue. After 
MI, increases in inflammation in the heart are commonly associated with increase LV wall 
stress especially in the border myocardium37. The LV dilates as a compensatory mechanism 
to improve overall cardiac output38. GHSR is expected to be activated in the border 
myocardium after MI and induce cardioprotective mechanisms and help improve cardiac 
function39,40. Therefore, increased GHSR expression chronically after MI is likely due to 
cardioprotective mechanisms, partly due to inflammation associated to LV wall stress and 
dilation. To fully evaluate the relationship between GHSR and inflammation, in vivo PET 
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results should be compared to circulating inflammatory markers and histological samples 
of cardiac tissue.  
 
Figure 5.2 Quantification of glucose metabolism with 18F-FDG in canine heart after 
MI. 
A) Ki values increased in acute pro-inflammatory phase in the infarct at days 1 and 7. In 
the chronic anti-inflammatory phase, there was no significant differences between regions. 
B) Circulating CRP (cardiac specific inflammatory marker) levels which increased acutely 




Figure 5.3 Correlation between inflammation (18F-FDG) and GHSR (18F-LCE470) 
over time. 
A) Acute (days 1 and 7 post MI) inflammatory response shows no linear regression with 
GHSR in vivo. B) Chronic (day 28, week 8, month 6, and 1-year post MI) inflammatory 
response indicates a positive linear regression with GHSR in vivo in the canine heart after 
MI.  
 
Our preliminary results outline a potential relationship between GHSR and inflammation 
after MI, and this process should be investigated in subsequent studies. To further 
determine the connections between cardiac inflammation and the regional distribution of 
GHSR, baseline 18F-FDG imaging, before MI, is needed for accurate comparison of 
changes to both the acute and chronic inflammatory processes. The baseline images will 
help determine the extent of the pro- and anti-inflammatory phases and how long each 
phase persists. The change in 18F-FDG uptake from baseline can then be correlated to the 
change in 18F-LCE470 uptake at the same time points. To better compare GHSR to 
inflammation signalling, 18F-LCE470 could be further characterized for quantitative PET 
imaging. A complete metabolite analysis should be conducted to generate a metabolite-
corrected image-derived input function for precision quantitative imaging of GHSR 
dynamics. Although the quantitative values may change with metabolite correction, the 
pattern of tracer uptake should remain consistent. In addition to the GHSR-inflammation 
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relationship with PET imaging, circulating levels of inflammatory markers CRP and IL-6 
along with HF markers BNP/NT-proBNP and high sensitive-Troponin T and I, should be 
correlated to circulating ghrelin levels to show the temporal relationships in the blood 
between ghrelin and both inflammation and HF. Furthermore, to accurately examine the 
regional and temporal relationship between GHSR and inflammation, endomyocardial 
biopsies of cardiac tissue, from baseline up to 1 year, should be analyzed for tissue markers 
of pro- and anti- inflammation along with GHSR expression. Additionally, changes in 
signalling pathways associated with contractility, metabolism, survival, and apoptosis 
should be measured in these tissue samples. These analyses will provide a more complete 
picture of the biology underlying the progression of cardiac dysfunction after MI.  
In summary, my project successfully identified GHSR as a scalable biomarker in human 
heart failure and heart disease using quantitative fluorescence microscopy. I demonstrated 
specific regional changes in both the ghrelin-GHSR system and GHSR-associated 
signalling. These molecular and biochemical changes were present prior to the 
development of overt cardiac dysfunction. I then developed and characterized a targeted 
PET imaging agent for cardiac GHSR in a large animal model of myocardial infarction. I 
determined this PET tracer to sensitively and specifically bind to GHSR before and up to 
one year post-MI. This work not only demonstrated significant advancement in elucidating 
the biology of the myocardial ghrelin-GHSR system, but I have identified a novel in vivo 
imaging tool to accurately identify specific regional changes in cardiac tissue. The 
myocardial ghrelin-GHSR system can be a unique tool to non-invasively determine 
alterations in the molecular and biochemical processes associated with early stages of HD.  
My project focused on three specific types of HD including end-stage HF, aortic stenosis, 
healthy heart, and cardiac remodeling after MI. In these specific models the ghrelin-GHSR 
system correlated in a scalable manner. It is still unknown how the ghrelin-GHSR system 
changes in all types of HD and therefore this system must be explored in all disease states. 
There is currently no universal biomarker of HD or HF and ghrelin-GHSR must be 
explored to determine which disease states have increased or decreased GHSR expression 
in the myocardium. In vivo imaging has allowed for detection of GHSR changes in the 
heart which can be quantified with compartmental modelling. The next step for this system 
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is to determine a quantitative threshold where GHSR is elevated, likely at earlier stages 
when HF is still treatable with medications or surgery. This biomarker, GHSR, can be used 
in conjunction with a panel of biomarkers to help predict which patients may proceed to 
HF. This system may ultimately help to diagnose HD earlier in its progression, resulting in 
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